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Abstract 
Sphingolipids play critical roles in signal transduction, intercellular membrane 
trafficking and cell growth. As bioactive sphingolipids, ceramide and sphingosine have 
been implicated in activating anti-proliferative and apoptotic responses in various cancer 
cells. Conversely, metabolic conversion of ceramide into sphingosine 1-phosphate, 
ceramide 1-phosphate and glucosylceramide regulates cell proliferation and suppresses 
programmed cell death. Many anticancer drugs and stress-induced agonists have been 
developed to increase endogenous ceramide levels. Sphingosine/ceramide analogues 
reportedly enhance antitumor activity and have been proposed as a potential new class of 
chemotherapeutic agents. Among these, sphingosines with aromatic substituents in the 
side chain often exhibit stronger biological activity compared to natural sphingosines. 
While a large number of synthetic pathways to sphingosine analogues have been 
described in the literature, very few pathways provide analogues with high 
stereospecificity. This dissertation describes a novel synthetic pathway to aromatic 
sphingosines which is highly stereospecific, provides good yields, uses commonly 
available reagents, and is versatile in terms of its potential to provide a large family of 
sphingosine analogues for future research.     
    The entry into the synthetic pathway toward sphingosine analogues involves first the 
enantiospecific synthesis of trans-γ, δ-unsaturated β-hydroxyesters using biocatalytic 
reduction of trans-γ, δ-unsaturated-β-ketoesters with commercially available 
ketoreductases. With the advantages of compatibility with carbon-carbon double bonds, 
vi 
 
high enantioselectivity, broader substrate acceptance, mild environmentally-friendly 
reaction conditions and easy separation, the biocatalytic reduction was found to be 
superior compared to other more traditional chemical methods. Indeed, both (R) and (S)-
enantiomers of trans-γ, δ-unsaturated β-hydroxyesters are synthesized by one or more 
ketoreductases in excellent stereochemical purity and high yield.  The enantiopure trans-γ, 
δ-unsaturated β-hydroxyesters were used to prepare erthyro-sphingosine analogues with 
aromatic substituents in the side chain. The strategy is based on the diastereospecific 
amination of trans-γ, δ-unsaturated β-hydroxyesters to introduce the amino group and 
establish anti N-Boc-α-hydrazino-β-hydroxyesters. Proper E1cB non-reductive 
elimination is essential for the successful cleavage of N-N bond of the hydrazino group. 
No racemization is detected during the entire course of the synthetic pathway. A total 
novel synthetic route of sphingosine analogues was thus accomplished with 
stereochemically pure intermediates and products.    
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Chapter 1 
Introduction 
 
1.1. Biological significance of ceramide, sphingosine and sphingosine 1-phosphate 
As the fourth largest class of membrane lipids, sphingolipids (SP) play critical roles in 
signal transduction, intercellular membrane trafficking and cell growth and survival 
(Hannun, Luberto et al. 2001, van Meer and Lisman 2002, Sigal, McDermott et al. 2005). 
Sphingolipids are found in essentially all animals, plants, and fungi, as well as some 
prokaryotic organisms and viruses. They are mostly located in membranes, and are also 
major constituents of lipoproteins (Merrill, Wang et al. 2007). Sphingolipids, as shown in 
Figure 1.1, have one polar head group and two nonpolar tails including one molecule of 
the long-chain amino sphingoid base (such as sphingosine or its derivatives) and one 
molecule of a long-chain fatty acid (Hannun and Obeid 2008).  
2
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3O
HN
OH
O
X
Sphingosine
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Head Group
Figure 1.1. General structure of sphingolipids. 
 
Sphingolipids metabolism, as shown in Scheme 1.1, involves several intermediate 
metabolites, many of which have distinctive biological activities (Pyne and Pyne 2000, 
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Merrill 2002, Spiegel and Milstien 2003, Ogretmen and Hannun 2004, Hannun and 
Obeid 2008, Wymann and Schneiter 2008). The reviews typically describe the de 
novo biosynthesis of SP beginning with condensation of L-serine and palmitoyl-CoA by 
serine palmitoyltransferase at the cytoplasmic face of the endoplasmic reticulum (ER). 
After formation in ER, ceramide (Cer) is translocated into Golgi apparatus, where it is 
converted to sphingomyelin (SM) by sphingomyelin synthase on the lumen side of the 
Golgi. Cer is also converted to glucosylceramide (GlcCer) mediated by glucosylceramide 
synthase (GCS) on the cytosolic surface of the Golgi. Cer can also be phosphorylated by 
ceramide kinase (CerK) into ceramide-1-phosphate (C1P). After formation, SM is 
translocated into the plasma membrane, where it can be hydrolyzed back into Cer, and 
then catalyzed by acid and neutral sphingomyelinase (SMase). Cer can be broken down 
by one of many ceramidases (CDase), leading to the formation of SP in endosome. SP is 
then phosphorylated to sphingosine 1-phosphate (S1P) by one of two sphingosine kinases 
(SK1 and SK2), or acylated back to pro-apoptotic C16-ceramide (R is C14H29 in Scheme 
1.1) via ceramide synthase (CS) in the mitochondria to lead to downstream activation of 
caspases and apoptosis (Pyne and Pyne 2000, Kroesen, Pettus et al. 2001, Spiegel and 
Milstien 2003). 
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Scheme 1.1. Pathway of sphingolipid metabolism. 
 
Cer has been involved in regulation of anti-proliferative and apoptotic responses in 
various cancer cells, and proposed as a potential new class of chemotherapeutic agent 
(Hannun and Obeid 2002, Ogretmen and Hannun 2004, Reynolds, Maurer et al. 2004). 
However, its metabolites GlcCer, C1P and S1P promote cell proliferation, as opposed to 
apoptosis, which result in the development of a multidrug resistance in many cancer cells 
(Ogretmen and Hannun 2004, Reynolds, Maurer et al. 2004). Approaches to elevate 
tumor Cer levels have been reviewed by Radin (Radin 2003). This includes (1) 
introducing exogenous Cer or analogues to mimic Cer and produce apoptosis; (2) 
accelerating de novo synthesis of Cer; (3) stimulating the hydrolysis of SM and GlcCer 
back into Cer; (4) inhibiting the conversion of Cer to GlcCer, C1P, SM and S1P by 
blocking relevant enzymes; and (5) elevating Cer level in tumor by radiation. The 
interrelated network of Cer and its metabolites suggest that blocking or stimulating one or 
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two of the pathways in Cer metabolism is very likely to fail in anti-tumor treatment. 
Because, although elevated Cer levels produce apoptosis, the conversion of Cer to other 
metabolites leads to cell proliferation. While some tumor cells will undergo apoptosis, 
other tumor cells will adapt and find alternative pathways and ultimately proliferate 
(Radin 2003). Thus multiple pathways will need to be controlled using many different 
agents. 
Sphingosine, the backbone of sphingolipids, has also been indicated to have significant 
biological activity. For example, sphingosine is an inhibitor of extracellular signal-
regulated kinase signaling in airway smooth muscle cells (Tolan, Conway et al. 1996) 
and it may also inhibit protein kinase C to suppress the insulin-like effects of growth 
hormone in rat adipocytes (Smal and Demeyts 1989).  
      S1P has been reported to act as an extracellular mediator and intercellular second 
messenger, and therefore has become a target in drug development (Pyne and Pyne 2000, 
Spiegel and Milstien 2002, Huwiler and Pfeischifter 2008, Pyne and Pyne 2010). S1P 
formed intracellularly from SP by SK is implicated in various stages of cancer 
pathogenesis, including an anti-apoptotic phenotype, metastasis and escape from 
senescence (Ogretmen and Hannun 2004). Therefore, SK inhibitors have been proposed 
as potential anti-cancer agents (Watson, Tonelli et al. 2013). For example, a selective 
SK1 inhibitor BLM-258 reported by Paugh et al. could integrate multiple molecular 
therapeutic targets in human leukemia (Paugh, Paugh et al. 2008). Also, inhibition of 
SK1 has been reported to reduce gastric and mammary adenocarcinoma tumor growth in 
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mice (French, Schrecengost et al. 2003). Sphingosine analogues such as DMS (N, N-
dimethylsphingosine) (Yatomi, Ruan et al. 1996, Edsall, Van Brocklyn et al. 1998) and 
sphingamine (D, L-threo-dihydrosphingosine) (Ahn, Chang et al. 2006, Ahn and 
Schroeder 2010) have been developed to serve as pharmalogical inhibitors of SK. 
FTY720 (fingolimod) directly inhibits SK1 activity and is reported to decrease metastasis 
in a breast cancer mouse model (Pyne, Bittman et al. 2011). Antoon et al. reported a 
selective SK2 inhibitor ABC294640 which has therapeutic potential in the treatment of 
chemo and endocrine therapy resistant human breast cancer (Antoon, White et al. 2011).  
S1P could also be translocated into the extracellular side of the cell, where it functions 
as a ligand and binds to five S1P specific G-protein-coupled receptors (GPCRs) S1PR1-5 
of the endothelial differentiation gene (EDG) family (Rosen and Goetzl 2005, Kim, 
Takabe et al. 2009, Pyne and Pyne 2010). The binding of S1P with its receptors could 
promote downstream regulation and activation of SK to synthesize more S1P in 
intracellular side of the cell (Taha, Hannun et al. 2006). S1P- S1PR1-5 regulatory systems 
could therefore be novel targets for cancer research (Rosen and Goetzl 2005, Rivera, 
Proia et al. 2008). Many synthetic chemical modulators of S1P receptors have been 
reported by Marsolais and Rosen (Marsolais and Rosen 2009, Marsolais, Yagi et al. 
2009). 
The Cer-SP-S1P rheostat model was  first proposed by Cuvillier (Cuvillier, Pirianov et 
al. 1996), which is based on the fact that ceramide/SP and S1P elicit opposing cellular 
responses. For example, ceramide and sphingosine are involved in the regulation of anti-
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proliferative and apoptotic responses in various cancer cells (Hannun and Obeid 2002, 
Ogretmen and Hannun 2004), while S1P leads to cell proliferation, inflammation and is 
referred to as a tumor-promoting lipid (Spiegel and Milstien 2003, Milstien and Spiegel 
2006, Wymann and Schneiter 2008, Pyne and Pyne 2010). The Cer-SP-S1P rheostat 
model predicts that the balance between ceramide and S1P may determine the 
physiological fate of the cell. The key evidence thereof is that ceramide induced cell 
apoptosis is suppressed by exogenous increase of S1P or sphingosine kinase activated 
endogenous increase of S1P (Cuvillier, Pirianov et al. 1996, Pyne and Pyne 2000). 
Current articles should be consulted for more details related to sphingolipids 
metabolism (Divecha and Irvine 1995, Kolesnick, Goni et al. 2000, Pyne and Pyne 2000, 
Shayman 2000, Hannun and Obeid 2002, Merrill 2002, van Meer and Lisman 2002, 
Spiegel and Milstien 2003, Ogretmen and Hannun 2004, Rosen and Goetzl 2005, Taha, 
Hannun et al. 2006, Rivera, Proia et al. 2008, Ader, Malavaud et al. 2009, Fyrst and Saba 
2010, Pyne and Pyne 2010). 
 
1.2. Structure-activity relationship between sphingolipid metabolites and enzymes 
 
The structure-activity relationship (SAR) relates the effect of the functional groups and 
their structural modification in the drug to its biological activity. SAR is a widely 
employed approach in both pharmaceutical research and the drug design (McKinney, 
Richard et al. 2000, Hajduk, Huth et al. 2005). SAR of sphingosine analogues on 
ceramidase and S1P analogues on sphingosine 1-phosphate receptor have been 
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investigated, respectively, by Usta et al. and Lim et al. (Usta, Bawab et al. 2001, Lim, 
Park et al. 2004). The critical SARs of analogues with enzymes are described below. 
1.2.1. C3-Hydroxyl group  
The C3 hydroxyl group plays a very important role in the interaction and recognition 
of sphingosine analogues with ceramidase. When C3-hydroxyl group was methylated, the 
potency of D-erythro-sphingosine as an inhibitor decreased severely. Moreover, (2S)-3-
keto-sphingosine showed significant loss of inhibition to ceramidase in comparison to D-
erthyro-sphingosine. These findings suggest the C3-hydroxyl group plays a critical role 
in the specific binding of sphingosine analogues to ceramidase (Usta, Bawab et al. 2001).    
 
1.2.2. C2-Amino group 
N-methylation of the C2-NH of D-erythro-ceramide caused loss of interaction of 
ceramide with ceramidase. Also, N-methylation of sphingosine attenuated inhibition by 
sphingosine, and N,N-dimethylation of sphingosine resulted in nearly complete loss of 
activity. Since N-methylated ceramide and N,N-dimethyl sphingosine both lack an N-H 
bond, the results indicate that the hydrogen donor capacity on the C2-amino group of 
either ceramide or sphingosine is essential for interaction with ceramidase (Usta, Bawab 
et al. 2001). 
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1.2.3. trans-Configured C4-C5 double bond  
In the binding of ceramide/sphingosine analogues with ceramidase, the C4-C5 double 
bond plays a significant role. Reduction of the C4-C5 double bond in ceramide decreased 
significantly its activity as a substrate (Usta, Bawab et al. 2001). In the binding affinity 
study of S1P analogues with S1P receptor, 4,5-dihydro-S1P showed less affinity than S1P 
itself. This finding shows that the double bond somehow plays an important role in the 
binding S1P analogues with S1P receptor (Hajduk, Huth et al. 2005). 
In comparison to trans-configured C4-C5 double bond, cis-D-erythro-ceramide did not 
exhibit any interaction with ceramidase. Also, the 4,5-cis isomer of D-erythro-
sphingosine was only a weak inhibitor of the enzyme. The preferential requirement for 
the trans double bond is probably a consequence of a steric effect, since the cis double 
bond introduces a kink in the hydrophobic chain, preventing ceramide and sphingosine 
from fitting properly into the catalytic site.  
 
1.2.4. Stereoisomers 
Lim et al. studied that the interaction of S1P stereoisomers with S1P receptors. They 
found D-erythro forms of S1P have higher affinities than the other stereoisomers. The 
results suggest that D-erythro forms of S1P are very important for the specific binding to 
EDG/S1P receptors (Lim, Oh et al. 2003). Usta et al. claimed that all stereoisomers of 
both ceramide interacted with ceramidase with high affinity. However, only D-erythro 
forms of ceramide functioned as a substrate (Usta, Bawab et al. 2001), suggesting that the 
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D-erythro form retains a unique configuration for catalysis but not for binding. Similarly, 
stereochemistry had no impact on the ability of sphingosine analogues to inhibit the 
enzyme, consistent with the conclusion that interaction with ceramidase is not 
stereospecific.   
 
1.2.5. Aliphatic tail positively interacts with hydrophobic area. 
Lim studied the effect of the aliphatic tail of S1P analogues on the interaction with S1P 
receptors. S1P analogue with m-alkylphenyl group instead of the aliphatic tail was found 
to have no impact on the binding affinity with S1P receptors. This finding together 
suggests that the aliphatic tail of S1P analogues positively interact with the hydrophobic 
area of S1P receptors, which is consistent with their computational model study (Lim, 
Park et al. 2004).    
 
In sphingosine structure based drugs design, the above findings provide the basis for 
the modification of the sphingolipid metabolites and determine how these changes may 
affect biological activity. Further modifications could focus on introduction of 
substituents into C1, C2, C4 and C5 positions of sphingosine, which could affect the 
potency, selectivity, duration of action, toxicity and stability of the sphingosine analogues.  
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1.3. Current approaches to synthesize sphingosine and its analogues 
    Since the first preparation of sphingosine in 1953 by Shapiro and Segal (Shapiro and 
Segal 1954), more than 70 sphingosine syntheses have been developed. The most 
significant approaches were thoroughly reviewed by Devant in 1992 (Devant 1992) and 
Koskinen and Koskinen in 1998 (Koskinen and Koskinen 1998). This dissertation 
distinguishes different approaches to sphingosine synthesis depending on the starting 
materials and key reaction steps. The first synthetic strategy towards sphingosine was 
published by Shapiro et al.. They utilized a modification of the Japp-Klingemann reaction 
between alkyl-substituted ethyl acetoacetate and phenyl diazonium salt in the presence of 
ammonium chloride. Erythro and threo intermediates with a ratio of 3:2 were generated 
and the overall yield of (-)-(D)-erythro-sphingosine was 10%. A strategy published in 
1957 by Grob and Gadient started with the condensation between nitroethanol and 
hexadecynal (Grob and Gadient 1957).  The strategies for the formation of trans double 
bond in the sphingosine backbone include Wittig olefination between protected sugar 
derivatives and triphenylphosphonium ylide (Gigg and Gigg 1966, Gigg, Gigg and 
Warren al. 1966, Reist and Christie 1970, Schmidt and Zimmermann 1986, S Yadav, 
Vidyanand et al. 1993, Wild and Schmidt 1994, Chaudhari, Ajish Kumar et al. 2005), 
Horner-Wadsworth-Emmons olefination (Gargano and Lees 2001, Lee, Kim and Chung  
2002, Lee, Lim and Park 2002, Lu and Bittman 2005), and other methods (He, Byun et al. 
1999, van den Berg, Korevaar et al. 2002, Rai and Basu 2004, Singh and Han 2007, Yang 
and Liebeskind 2007). Some strategies employ asymmetric epoxidation (Bernet and 
Vasella 1983, Roush and Adam 1985, Julina, Herzig et al. 1986, Shibuya, Kawashima et 
11 
 
al. 1989, Takano, Iwabuchi et al. 1991, Olofsson and Somfai 2003, Torssell and Somfai 
2004, Moreno, Murruzzu et al. 2011), other epoxidation (van den Berg, Korevaar et al. 
2004), and aldol reactions as key steps using titanium enolate (Solladie-Cavallo and 
Koessler 1994, Solladié-Cavallo and Nsenda 1998, Cai, Ling et al. 2006) and Sn(II) 
catalyst (Kobayashi, Hayashi et al. 1994).  Yet other approaches have also been reported 
(Nakamura and Shiozaki 2001, Milne, Jarowicki et al. 2002, Disadee and Ishikawa 2005, 
Kim, Lee et al. 2006, Llaveria, Díaz et al. 2008, Morales-Serna, Llaveria et al. 2008). 
    One of the most popular and reliable strategies for the synthesis of sphingosine, with 
the specific introduction of the C1-C3 chiral motif, employs protected serine derivatives 
as the source of chirality. This approach will be discussed and reviewed in this 
dissertation in detail in chronological order. 
In 1973, Newman first reported the stereoselective synthesis of sphingosine using L-
serine as the chiral center, as shown in Scheme 1.2 (Newman 1973). In this strategy, the 
amino and hydroxyl groups of L-serine were sequentially protected, followed by 
conversion of carboxyl group to the acid chloride. The acid chloride was then 
hydrogenated to aldehyde 3. Aldehyde 3 then reacted with trans-
pentadecenyldiisobutylalane to form D-erythro-O-acetyl-N-phthaloylsphingosine 4 and 
its D-threo isomer 5 in a ratio of 79:21. The isomers were separated by partition 
chromatography. After removal of the protecting groups, D-erythro-sphingosine was 
synthesized. However, this strategy lacks diastereoselectivity in introducing the side 
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chain via alkylation (Tkaczuk and Thornton 1981, Mori and Funaki 1985, Boutin and 
Rapoport 1986).   
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Scheme 1.2. Newman’s synthetic route to sphingosine. a) PhthNCO2Et, Na2CO3; b) 
Ac2O; c) SOCl2, C6H5N; d) H2, C6H5N, 40 °C, 1.5 h; e) MeOH, H+; f) NH2NH2-EtOH. 
     
    In 1984, Garner (Garner 1984, Garner and Park 1987) succeeded in preparing a 
configurationally stable Boc-protected serine acetonide aldehyde 6, which  has  been 
widely employed as a chiral building block for the synthesis of natural products bearing 
the 2-amino-1,3-diol subunit (Liang, Andersch et al. 2001). In 1988, Herold (Herold 
1988), Nimkar et al. (Nimkar, Menaldino et al. 1988), Radunz et al. (Radunz, Devant et 
al. 1988) and Garner et al. (Garner, Park et al. 1988) all started with enantiopure Boc-
protected serine acetonide aldehyde (Garner’s aldehyde) 6 to introduce the chiral centers. 
In these four publications, the most versatile synthetic scheme is that by Herold (Herold 
1988), shown in Scheme 1.3. In this strategy, Boc-protected serine aldehyde was 
13 
 
alkylated diastereoselectively by 1-pentadecynyllithium to provide either erythro 7 or 
threo 8 using selective reaction conditions with 95% d.e., respectively, followed by 
deketalization and sodium bis(2-methoxyethoxy)- aluminumhydride (Red-Al) induced 
reduction of the triple bond to afford a variety of pure N-Boc-protected sphingosine 
isomers. Four possible isomers of sphingosine (including the Z-isomer) were obtained by 
this strategy (Herold 1988). The N-Boc-protected form of sphingosine prevents oxidation 
of sphingosine in the presence of oxygen. The overall yield reported by Herold is 25%. In 
1999, Overmeire et al. (Van Overmeire, Boldin et al. 1999) applied this strategy to 
synthesize ceramide analogues containing a C7 side chain and a phenyl group substituted 
for the C13 residue. This compound reverses the inhibitory function of FB1 toxin on 
axonal growth in hippocampal neurons.  
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Scheme 1.3. Herold’s synthetic route to sphingosine.  a) 1-Pentadecynyllithium, THF, -
78 °C; b) 1-Pentadecynyllithium, THF, -78 °C, ZnBr2/Et2O; c) Amberlyst 15/MeOH; d) 
Red-Al/Et2O; e) H2/Lindlar catalyst/EtOAc.  
 
In 1990, Koshinen and Krische (Koskinen and Krische 1990) started with Boc-
protected serine derivative 11 and employed Horner-Wadsworth-Emmons olefination to 
synthesize sphingosine, shown in Scheme 1.4. A β-ketophosphonate 12 was formed by 
reacting Boc-protected serine derivative 11 with the lithium compound derived from 
dimethyl methylphosphonate and n-butyl lithium in hexanes. Horner-Wadsworth-
Emmons reaction of 12 with aliphatic aldehyde tetradecanal gave the trans-configured 
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enone 13 formation of sphingosine. Then enone 13 was stereoselectively reduced to 
desired enol 14 by L-selectride, followed by deprotection of the amino and hydroxyl 
functions to afford sphingosine. Although this modified Horner-Wadsworth-Emmons 
reaction on a serine-derived ketophosphonate provided a mild protocol to produce the 
C4-C5 trans alkene, the author did not report the diastereomeric excess. Poor 
diastereomeric excess was reported by Chung and Lee for the reduction of enone to enol 
using L-selectride (Chung and Lee 1999).  
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Scheme 1.4. Koshinen’s synthetic route to sphingosine. a) (MeO)2P(=O)-CH2-Li+, THF; 
b) C13H27CHO, K2CO3, CH3CN; c) L-selectride, THF. 
 
    In 1988 and 1990, Dondoni et al. (Dondoni, Fantin et al. 1988, Dondoni, Fantin et al. 
1990) reacted 2-(trimethylsilyl)thiazole to Boc-protected Garner aldehyde 6, Scheme 1.5, 
followed by in situ desilylation of the resulting intermediate with tetrabutylammonium 
fluoride, to stereoselectively give chiral building block anti-15a and syn-15b with 84% 
d.e.. Deblocking of the thiazole ring in 15a by formyl using NaBH4 provided aldehyde 16. 
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Aldehyde 16 was subjected to Wittig reaction using n-hexadecanylidene-
triphenylphosphorane to form trans-configured olefin 17 and alkyl chain. After 
deprotection of 17 with trifluoroacetic acid-water (98:2 mixture) and acetylation of the 
crude reaction mixture, triacetyl-C20-D-erythro-sphingosine 18 was afforded.  
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Scheme 1.5. Dondoni’s synthetic route to sphingosine. Th = 2-thiazolyl; Bn = benzyl; Ac 
= acetyl. a) NaBH4/MeOH, -10 °C; b) n-C16H33P+Ph3Br-/PhLi, Et2O-Toluene, -30 °C; c) 
CF3CO2H/H2O; d) Ac2O-pyridine. 
 
    In 2002, Murakami and Furusawa (Murakami and Furusawa 2002) treated aldehyde 6 
with 1-alkenyl-zirconocene chloride in the presence of ZnBr2 in THF to give the natural 
erythro isomers 19a with 90% d.e., Scheme 1.6. Using this strategy, derivatives with a 
short chain and aromatic in place of the C13 chain could also be synthesized (Murakami 
and Furusawa 2002, Murakami, Furusawa et al. 2005). In the same year, Chum et al. 
reacted sulfoxide to L-serine methyl ester derivative 20 to form sulfoxide intermediate 21, 
which was refluxed in CCl4 to afford 22, Scheme 1.7 (Chun, Li et al. 2002). The author 
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claimed reduction of 22 by NaBH4 and CeCl3 in MeOH gave diastereoselectively alcohol 
18, which then could be hydrolyzed by 1 M HCl in dioxane at 100 °C to sphingosine or 
its derivatives. However, the author did not report the diastereomeric excess of alcohol 18 
(Chun, Li et al. 2002).  
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Scheme 1.6. Murakami’s synthetic route to sphingosine. R = n-C13H27 or Ph; Cp = 
cyclopentadienyl; a) 25-50 mol% ZnBr2; b) aq. AcOH, 50 °C. 
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Scheme 1.7. Chum’s synthetic route to sphingosine. a) LDA, -78 °C, rt.; b) CCl4, reflux; 
c) NaBH4, CeCl3, MeOH, -15 °C; d) 1 M HCl, dioxane, 100 °C. 
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In 2007, Yang and Liebeskind improved the L-serine based approach, which provided 
the highest stereoselectivity and yield among current strategies (Yang and Liebeskind 
2007). In their approach (Scheme 1.8), they started with N-Boc-L-serine 23 to make N-
Boc-O-TBS serine thiophenyl ester 25. Compound 25 underwent a palladium-catalyzed 
copper(I)-mediated coupling with E-1-pentadecenyl boronic acid 26 to provide enone 27 
with high enantiopurity (e.e. >99%).  No E/Z isomerization of unsaturated ketone was 
observed. In turn, compound 26 was prepared by hydroboration of 1-pentadecyne with 
HBBr2·SMe2 followed by hydrolysis in ice-water. Enone 27 was diastereoselectively 
reduced by LiAl(tert-butoxy)3H at -78 °C, to give alcohol 28 with > 94% diastereomeric 
purity, followed by a simple recrystallization and final N-deprotection with TFA to give 
(-)-D-erythro-sphingosine 1.  
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Scheme 1.8. Liebeskind’s cross-coupling synthetic route starting from N-Boc-L-serine 
23. a). PhSH, HOBT, DCC, EtOAc; b) TBSCl, NMM, DMAP, DMF; c) 2.5 mol% 
Pd2(dba)3, E-1-pentadecenyl boronic acid 26, 20 mol% P(OEt)3, 1.5 equiv. CuTC; d) 
LiAl(O-tert-Bu)3H, -78 °C; e) 1 M HCl; f) TFA.   
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1.4. Aromatic sphingosine derivatives 
Recently, many sphingosine derivatives have been developed to enhance ceramide 
levels in anti-cancer treatment. For example, many anticancer drugs and stress-induced 
agonists have been employed to increase endogenous Cer levels through de novo 
synthesis of Cer or the hydrolysis of SM. In addition, treating cancer cells in vitro with 
more easily dispersed short-chain Cers (C2 to C8-Cer) almost always produces apoptosis 
and cell-cycle arrest, and those exogenous Cers compete metabolically with natural Cers 
and their metabolites (Radin 2003). In other examples, DMS (N, N-dimethylsphingosine) 
(Yatomi, Ruan et al. 1996, Edsall, Van Brocklyn et al. 1998) and sphingamine (D, L-
threo-dihydrosphingosine) (Ahn, Chang et al. 2006, Ahn and Schroeder 2010) have been 
developed and serve as pharmalogical inhibitors of SK. FTY720 (fingolimod) has also 
been studied to directly inhibit SK1 activity, reduce tumor metastasis and increase 
apoptosis (Lim, Tonelli et al. 2011).   
Sphingosine/ceramide analogues reportedly enhance antitumor activity and have been 
proposed as a potential new class of chemotherapeutic agents (Moreno, Murruzzu et al. 
2011). Sphingosine with aromatic substituents in the side chain have been developed and 
evaluated to have stronger biological activities (Lim, Park et al. 2004). Overmeire et al. 
synthesized and evaluated the biological activities of several aromatic ceramide 
analogues 30, which were able to reverse fumonisin B1 (FB1) inhibited ceramide 
synthesis (Van Overmeire, Boldin et al. 2000). Chandrasekhar et al. prepared compound 
31, which serves as a stronger sphingosine kinase inhibitor relative to the corresponding 
parent compounds and is an intermediate in the synthesis of (-)-Codonopsinine which has 
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antibiotic and hypotensive activity (Chandrasekhar, Saritha et al. 2006). Murakami et al. 
made aromatic sphingosine derivatives 32, which have been suggested as EDG/S1P 
receptor (Endothelial Differentiation Gene family of sphingosine 1-phosphate receptors) 
inhibitors and block S1P mediated Ca2+ increase (Murakami, Furusawa et al. 2005). In 
the same year, Kim et al. produced sphingosine analog SG-12, which possesses an 
aromatic ring in place of the unsaturated C14 and lacks the C4-C5 trans double bond. SG-
12 exhibited specific inhibitory effects against sphingosine kinase 2 (Kim, Kim et al. 
2005).  
OH
OH
NH2
n-C7H15
SG-12
O
OH
OH
P
O
HO
OH
R
R= H, NO2, Methylthio
OH
NHBoc
OH
MeO
30
31
BML-258
OH
OH
NH HCl
OH
NHBoc
OH
R
32
R= H, t-Bu, n-C7H15
OH
HN
OH
R
O
C5H11
R= Me, C5H11, F, OMe
33  
Figure 1.2. Structure of existing aromatic sphingosine analogues. 
 
    A synthesis of BML-258 was the subject of a patent by Zipkin (Zipkin, Spiegel et al. 
2010) utilizing Garner aldehyde 6 based strategies, Scheme 1.3. BML-258 is a water 
soluble sphingosine analogue, which is evaluated as an SK1 selective inhibitor and 
shown to be efficacious both in vitro and in vivo (Paugh, Paugh et al. 2008, Pyne, 
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Bittman et al. 2011). In 2011, several aromatic sphingosine analogs 33 were  synthesized 
by Moreno et al. (Moreno, Murruzzu et al. 2011) 
To summarize, many approaches to synthesize sphingosine and its analogs have been 
published with good to high stereoselectivity. Among these methods, the L-serine based 
approach is the most commonly employed, since L-serine bears an amino group attached 
to the C-2 chiral center and has C-1 hydroxyl functionality. The enantiopure serine 
aldehyde 6 (Garner aldehyde), which is prepared through an efficient and short synthesis 
from L-serine, is diastereoselectively alkylated by 1-alkynyllithium compound to 
introduce a second chiral center (with OH attached to C-3). Sphingosine analogues are 
then produced by reduction of the triple bond to a double bond. However, the reaction of 
the Garner aldehyde is not diastereospecific when adding alkenyl- or alkynyllithium 
reagent to introduce the second chiral center. Rather, a mixture of threo and erthyro 
products results, which require chiral separation. In most cases, threo isomer possesses a 
polarity similar to that of erythro isomer on TLC, and consequently is difficult to be 
separated by silica gel chromatography. What is more, the α stereocenter of the amino 
acid derivatives is racemized under both acidic and basic conditions. To overcome the 
potential configurational liability of the Garner aldehyde, Liebeskind utilized palladium-
catalyzed copper(I)-mediated cross-coupling of the thiophenyl ester of N-Boc-O-TBS L-
serine with E-1-pentadecenyl boronic acid and obtained high enantio- and diastereopurity 
with only traces of diastereomers detected (Yang and Liebeskind 2007). Other 
approaches provide less opportunity to introduce substituents into the C-1, C-2, C-4 and 
C-5 positions of sphingosine, which may change the affinity of sphingosine analogs for 
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enzymes in the sphingolipid metabolism pathway and as a result affect endogenous levels 
of ceramide and S1P. For example, in the L-serine based approach in Scheme 1.3, the 
ability to introduce functional groups onto the double bond (C-4 and C5) is limited. This 
limitation arises from the reduction of the triple bond to produce exclusively the trans 
disubstituted double bond. This limitation also exists in Liebeskind’s cross-coupling 
strategy, where E-1-pentadecenyl boronic acid was prepared by hydroboration of 1-
pentadecyne with HBBr2·SMe2 to produce the trans alkene 26.   
1.5. Summary of research aims 
The aim of this research is to develop a novel and effective scheme to sphingosine 
analogues that meet to following requirements. First, the synthetic route should be highly 
stereospecific, so that purification or resolution of stereoisomers is not required. Second, 
the synthesis should employ common and selective inexpensive reagents that provide 
high yields of intermediates. The synthetic route should also be scalable to provide gram 
quantities of sphingosine analogues. And finally the synthetic route should also offer an 
opportunity to introduce modified groups into the C-1, C-2, C-4 and C-5 positions. 
Unlike the L-serine based synthetic routes, this research sought to prepare the 
fundamental stereochemical framework of a trans double bond and two stereocenters 
starting first with formation of a enantiomerially-pure chiral alcohol with a trans double 
bond.  Once synthesized, the chiral alcohol was reacted to introduce the N as the second 
chiral center.    
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As shown in Scheme 1.9, the key entry point of this research was the synthesis of a 
family of aryl trans-γ, δ-unsaturated-β-ketoesters A with the stereospecific formation of a 
trans double bond using the Horner-Wadsworth-Emmons olefination. Once in hand, the 
trans-γ, δ-unsaturated-β-ketoesters were asymmetrically reduced to enantiopure trans-γ, 
δ-unsaturated-β-hydroxyesters B through the use of commercially available 
ketoreductases. Diastereospecific α-amination then introduced the second chiral center 
bearing the amino group in the form of hydrazine C, which was followed by cleavage of 
the N-N bond of the hydrazino by E1cB non-reductive elimination to yield the aromatic 
sphingosine derivative D.  
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Scheme 1.9. The overview for the stereospecific synthesis of sphingosine analogues in 
the dissertation.  
 
Another aim of this research is development of a preparative scale synthesis of a dimer 
of serotonin (5-HT) 5,5’-dihydroxy-4,4’-bitryptamine (DHBT). This research is trying to 
resolve atropisomers of DHBT by chiral capillary electrophoresis, which need to be 
considered when evaluating possible neurodegenerative roles of DHBT in biological 
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systems. This research is the not the part of the main focus of this dissertation and will be 
included as Appendix C.   
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Chapter 2 
Stereoselective Synthesis of Aryl γ, δ-unsaturated β-hydroxyesters by 
Ketoreductases1 
 
2.1. Introduction     
    Enantiomerically pure γ,δ-unsaturated-β-hydroxyesters and their derivatives are 
important chiral building blocks for synthesis of many biologically active compounds, 
pharmaceutical products and their intermediates, such as (-)-CP2-Disorazole C1 (Hopkins, 
Schmitz et al. 2011), turnagainolides A and B (Li, Carr et al. 2011), epothilone (Reiff, 
Nair et al. 2004), and Seimatopolide A (Schmidt, Kunz et al. 2012). Many traditional 
methods have been employed to make β-hydroxyesters asymmetrically, for example, (1) 
enantioselective Mukaiyama aldol addition between aldehyde and methyl (ethyl) acetate 
O-Silyl enolates with a chiral Ti(IV) complexes as catalyst (Smrčina, Lorenc et al. 1991, 
Carreira, Singer et al. 1994, Mukaiyama 2004); (2) enantioselective ruthenium-catalyzed 
hydrogenation of saturated α-ketoesters (Rimoldi, Pellizzoni et al. 2011), β-ketoesters 
(Taber and Silverberg 1991, Greck, Bischoff et al. 1993, Genêt, Pfister et al. 1994, Genêt, 
Pinel et al. 1994, Burk, Harper et al. 1995, Girard, Greck et al. 1996, Zhang, Qian et al. 
2000, Zhou, Tang et al. 2002, Hu, Ngo et al. 2004, Seashore-Ludlow, Saint-Dizier et al. 
2012) and α, β-unsaturated carbonyls (Ohkuma, Koizumi et al. 1998, Arai, Azuma et al. 
1 Zhipeng Dai, Kate Guillemette, and Thomas K. Green. (2013). Journal of Molecular Catalysis B: 
Enzymatic. 97: 264-269 
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2008); and (3) chiral oxazaborolidine-catalyzed reduction of prochiral ketones, cyclic and 
acyclic α, and β-enones (Corey, Bakshi et al. 1987, Corey, Bakshi and Shibata et al. 1987, 
Mathre, Thompson et al. 1993, Corey and Helal 1998, Kawanami, Murao et al. 2003).   
    All of these methods, while potentially providing high enantioselectivity, have 
disadvantages. The Mukaiyama aldol methods often require an expensive chiral ligand 
(e.g. BINAP) and multiple steps to make the catalyst (Smrčina, Lorenc et al. 1991). 
While ruthenium-catalyzed hydrogenation has been shown to selectively reduce the 
carbonyl of β-ketoesters chemoselectively in the presence of a nonconjugated carbon-
carbon double bond (Taber and Silverberg 1991, Greck, Ferreira et al. 1996), we and 
others (Ma, Li et al. 2012) have found that partial hydrogenation of the double bond of 
conjugated γ, δ-unsaturated-β-ketoesters often occurs, and is difficult to control. Recently, 
Ma et al. published a Ru-catalyzed hydrogenation of γ-halo-γ, δ-unsaturated-β-ketoesters 
in up to 97% e.e. (Ma, Li et al. 2012), where halogen at the γ-position is needed to protect 
the γ, δ-carbon-carbon double bond with further organometallic transformation required 
to remove the vinyl halide moiety. The enantioselectivity of chiral oxazaborolidines 
catalysts are sensitive to moisture and temperature and must be conducted under strictly 
anhydrous conditions and typically at low temperature (-20 °C and below). Also, the use 
of BH3·THF (or BH3·Me2S) is often incompatible with carbon-carbon double bonds. 
Although these chemical methods using chiral auxiliaries are frequently used, other 
limitations remain in many cases. The limitation arises from the incompatibility of 
catalytic conditions with a number of functionalities (Genêt, Pinel et al. 1994, Akutagawa 
1995, Schmidt 2004) and the catalytic behavior (enantiomeric purity and productivity) 
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being sensitive to even slight modifications in the substances due to the change of steric 
and electronic properties.  
    With the advantages of high enantioselectivity, broader substrate acceptance, mild and 
environmental friendly reaction conditions, tolerance of organic solvents and easy 
separation, biocatalysts using whole cells and isolated enzymes have received increasing 
interest toward the production of optically pure β-hydroxyesters and their derivatives 
(Kaluzna, Matsuda et al. 2004, Zhu, Yang et al. 2006, Kalaitzakis, Kambourakis et al. 
2007, Matsuda, Yamanaka et al. 2009, Turner 2009, Huisman, Liang et al. 2010). For 
instances, the asymmetric reduction of α- and/or β-ketoesters was evaluated by means of 
whole cells of Candida parapsilosis ATCC 7330 (on the reduction alkyl 2-oxo-4-
arylbutanoates) (Baskar, Pandian et al. 2004), the recombinant Escherichia Coli (for the 
synthesis of 3-hydroxybutyrate) (Schroer, Mackfeld et al. 2007), Chlorella strains 
(toward the reduction of α-ketoesters) (Ishihara, Yamaguchi et al. 2000), yeast (reduction 
of α- and β-ketoesters) (Kaluzna, Matsuda et al. 2004, Rimoldi, Cesarotti et al. 2011), 
carbonyl reductase from Candila magnolia (Zhu, Yang et al. 2006), nicotinamide-
dependent ketoreductases (reduction of β-ketoesters with alkyl substituents at α- or β-
position) (Kambourakis and Rozzell 2004, Zhu, Mukherjee et al. 2006), and NADPH-
dependent ketoreductases (toward the reduction of α-alkyl-β-ketoesters) (Kalaitzakis, 
Rozzell et al. 2005). What is more, Candida parapsilosis ATCC 7330-induced 
deracemisation of unsaturated aryl β-hydroxyesters to a single enantiomer has also been 
reported (Padhi and Chadha 2005, Saravanan, Selvakumar et al. 2012).  
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This chapter describes the synthesis of a series of aryl trans-γ, δ-unsaturated-β-
hydroxyesters from aryl trans-γ, δ-unsaturated-β-ketoesters via the action of twenty-four 
isolated NAD(P)H dependent ketoreductases from Codexis. Either enantiomer of γ, δ-
unsaturated β-hydroxyesters can be synthesized with high enantioselectivity (>99% e.e.) 
and chemoselectivity (no olefin reduction) in good to excellent yield in one step by one 
or more enzymes. Additionally, conversions and purifications were achieved 
economically, safely and readily under the enzymatic reaction condition used.     
Contribution:  Kate Guillemette contributed to KRED reduction of γ, δ-unsaturated β-
ketoester 2C. 
 
2.2. Experimental 
2.2.1. Materials 
All chemicals were purchased from Sigma-Aldrich Chemical Company unless 
otherwise noted. Methylene chloride was distilled from CaCl2 and stored over 4 Å 
molecular sieves. Spectroscopy grade chloroform was used for all optical rotation 
measurements. Cyclodextrins used for capillary electrophoresis, heptakis(2,3-di-O-
methyl-6-O-sulfobutyl) cyclomaltoheptaose, sodium salt (NaSBDM-β-CD) and heptakis 
(2, 3-di-O-ethyl-6-O-sulfopropyl) cyclomaltoheptaose potassium salt (KSPDE-β-CD), 
were synthesized according to procedures reported in the literature (Kirschner, Jaramillo 
et al. 2008). Codex® KRED screening kit was purchased from Codexis, Inc. Both 
reconstituted KRED Recycle Mix N (containing 250 mM potassium phosphate, 2 mM 
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magnesium sulfate, 1.1 mM NADP+, 1.1 mM NAD+, 80 mM D-glucose, 10 U/mL 
glucose dehydrogenase, pH 7.0) and reconstituted KRED Recycle Mix P (containing 125 
mM potassium phosphate, 1.25 mM magnesium sulfate, 1.0 mM NADP+, pH 7.0) are 
available from Codexis, Inc.. Aluminum coated silica gel WF254s plates were used to 
monitor reactions products and flash chromatography eluents. Column chromatography 
was performed with silica gel SiliaFlash®P60 (40-60 µm, 230-400 mesh). 
 
2.2.2. Instrument 
1H and 13C NMR spectra were recorded in CDCl3 solution with a Varian 300 MHz 
instrument (300 MHz for 1H NMR, 75 MHz for 13C NMR). Chemical shifts are reported 
in ppm relative to TMS as internal standard. HPLC was performed on Agilent 1100 series 
with isocratic pump and UV-visible detector. A Phenomenex® Lux 3 µ cellulose-1 
column (50 x 4.60 mm) was used for the chiral separation at 23 °C. The mobile phase 
consisted of hexanes and isopropanol in the ratio of 90:10, and flow rate of 0.5 mL/min. 
Optical rotations were measured on Krüss P3000 polarimeter operating at the sodium D 
line 589 nm and reported as follows: [𝛼58923 ] , concentration (g/100ml), and solvent. 
Capillary electrophoresis was performed with an Agilent 3D Capillary Electrophoresis 
System using bare fused silica capillary (purchased from Polymicro Technologies, L.L.C.) 
(50 μm i.d., 32.5 cm total length, 24.0 cm to detector) under reverse polarity (-10 or -15 
kV), and detection was by UV absorbance at 254 nm. Prior to first use, the capillary was 
primed for 2 min with 1 M NaOH solution and then for 2 min with 0.1 M NaOH solution. 
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For each use, the capillary was preconditioned for 1 min using background electrolyte 
(BGE). BGE was either 5.0 mM NaSBDM-β-CD or 5.0 mM KSPDE-β-CD as a chiral 
selector in 25 mM tris buffer, pH 2.5. Samples (diluted 10 fold into 90:10 v/v deionized 
water/acetone solvent) were injected into the capillary under 50.0 mbar pressures for 3 
seconds. At the end of each run, the capillary was post-conditioned with 0.1 M NaOH 
solution for 1 min and then with deionized water for 1 min.   
 
2.2.3. Synthesis of γ, δ-unsaturated β-keto ethyl esters 2A-2F 
(E)-Ethyl 4-(diethoxyphosphinyl)-3-oxobutanoate (2.234 g, 6.6 mmol), prepared 
according to the literature (Moorhoff 2003), in 20 mL anhydrous THF was reacted with 
2.0 equivalents of n-BuLi (6.0 mL, 13.2 mmol, 2.2 M in hexanes) at 0 °C. After gas 
formation ceased, strirring was continued for 1 h at room temperature. One equivalent of 
aldehyde (6.0 mmol) was added over 10 min, and the reaction mixture was stirred at 
room temperature for another 2.5 h. After completion, the reaction was quenched by 
adding 15 mL of saturated NH4Cl. The reaction mixture was concentrated under vacuum 
at 50 - 60 °C. The residue was extracted by CH2Cl2 (3 x 15 mL), the combined organic 
extracts were washed with saturated NaCl (2 x 15 mL), and then dried with anhydrous 
Na2SO4. The organic solvent was removed under vacuum at 30 °C. Product was isolated 
by column chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent and verified by 
1H and 13C NMR spectroscopy.    
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2.2.4. Synthesis of racemic γ, δ-unsaturated β-hydroxyesters 3A-3F 
In a round bottom flask β-ketoester (1 mmol) was dissolved in 5 mL ethanol. In portion, 
cautiously and intermittently, 0.4 equivalent of NaBH4 (15 mg, 0.4 mmol) was added and 
the mixture was stirred for 30 min at room temperature. The reaction mixture was 
concentrated under vacuum at 60 °C. The product was isolated by column 
chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent and verified by 1H and 13C 
NMR spectroscopy. 
 
2.2.5. Stereoselectivity of enzymatic formation of β-hydroxyesters 3A-3F using 
NADH system (enzyme 1-5) 
Into a solution of β-ketoester (25 µmol) in 50 μL methanol, was added KRED Mix N 
(57.4 mg in 1.0 mL deionized H2O) and 1.0 mg ketoreductase. The mixture was shaken at 
32 ± 1 °C. After 24 h, the reaction was extracted by EtOAc (2 x 1 mL). The combined 
organic extract was dried over anhydrous Na2SO4 and was subjected to chiral HPLC or 
CE analysis, and 1H NMR spectroscopy.   
  
2.2.6. Stereoselectivity of enzymatic formation of β-hydroxyesters 3A-3F using 
NADPH system (enzyme 6-24) 
Into a solution of β-ketoester (25 µmol) in 400 μL isopropanol and 50 μL methanol, 
was added KRED Mix P (29.1 mg in 1.0 mL deionized H2O) and 1.0 mg ketoreductase. 
The mixture was stirred at 32 ± 1 °C. After 24 h, the reaction was extracted by EtOAc (2 
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x 1 mL). The combined organic extract was dried over anhydrous Na2SO4 and was 
subjected to chiral HPLC or CE analysis, and 1H NMR spectroscopy. For β-ketoesters 
2A-2E except 2D, the reactions were scaled up by a factor of 20 or 100 using enzymes 
that yielded high conversions and e.e., and all products were isolated by column 
chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent and verified by 1H and 13C 
NMR spectroscopy.   
 
2.2.7. Synthesis of MTPA ester of γ, δ-unsaturated β-hydroxyesters (Hoye, Jeffrey et 
al. 2007) 
Into a solution of 64 µmol β-hydroxy ester (racemic or made by enzyme 8 KRED-P1-
B05 or enzyme 23 KRED-P3-G09) and dry pyridine (16 µL, 200 µmol, 3.1 equiv.) in 1.0 
mL anhydrous CH2Cl2, was added the (R)-(-)-α-Methoxy-α-(trifluoromethyl) 
phenylacetyl chloride [R-(-)-MTPA-Cl] (23 µL, 120 µmol, 1.9 equiv.). The reaction 
mixture was stirred at ambient temperature till the reaction was completed as monitored 
by TLC plate (eluent: 10:1= CH2Cl2: EtOAc) (usually 3 h). After completion, the reaction 
was quenched by 2 mL H2O, extracted by EtOAc (2 x 5 mL). The combined organic 
layer was dried over anhydrous Na2SO4 and the solvent was removed under vacuum. The 
product MTPA ester of γ,δ-unsaturated β-hydroxyesters was isolated by column 
chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent. (S)-MTPA ester spectra 
are included in Supporting Information.   
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2.2.8. Procedure of Mukaiyama Aldol condensation based synthesis of trans-γ, δ-
unsaturated β-hydroxyester  
5% Ti catalyst (0.109 mmol) was dissolved in 5.0 mL anhydrous Et2O, and the 
solution was cooled to -78 °C. Trans-cinnamaldehyde (288.1 mg, 2.18 mmol) in 1.0 mL 
anhydrous Et2O and 2.0 equiv. of silyl ketene acetyl (382.6 mg, 2.616 mmol) in 1.0 mL 
anhydrous Et2O were added sequentially. The reaction mixture was warmed to -10±1°C, 
and the reaction mixture was stirred for another 5 h. After the reaction was completed, 
the reaction was quenched by saturated aqueous NaHCO3 solution. The organic layer was 
washed with a saturated aqueous NaCl solution, dried over anhydrous Na2SO4 and 
concentrated under vacuum. The residue was taken up in THF and treated with 2.0 to 3.0 
equiv. of Bu4NF for 10 min, and then partitioned between Et2O and 1 M aqueous HCl. 
The organic layer was washed with a 5% aqueous NaHCO3 solution, saturated aqueous 
brine, dried over anhydrous Na2SO4 and concentrated under vacuum. Flash 
chromatography on silica gel using 10:1 CH2Cl2/hexane to remove the catalyst ligand 
followed by 10:1 CH2Cl2/EtOAc afforded the aldol adduct as slightly yellow oil. The 1H 
NMR spectrum of methyl (3S, 4E)-3-hydroxy-5-phenylpent-4-enoate is shown in Figure 
A2.50. 
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2.2.9. Procedure of Me-CBS-BH3 catalyzed synthesis of trans-γ, δ-unsaturated β-
hydroxy ester 
    Into 0.025 mmol of Me-CBS-borane (8 mg) and 1.2 equivalents of BH3-Me2S (0.03 
mmol, 0.03 ml, 1M in THF) in 0.5 ml anhydrous THF under N2 at -20 °C, a solution of 
ethyl (4E)-5-(4-methylphenyl)-3-oxopent-4-enoate (55 mg, 0.25 mmol) in 0.5 ml 
anhydrous THF was added over 20 min. After the completion of addition, the reaction 
was quenched by adding 5 ml of methanol, and then diluted with 20 ml H2O. The 
reaction mixture was extracted by EtOAc (3 x 15 ml). The combined organic phase was 
washed with water, saturated aqueous brine and dried over MgSO4. Purification was 
carried by column chromatography on silica gel using 10:1 CH2Cl2/EtOAc. Isolated 
yield%: 50%. The 1H NMR spectrum of methyl (3S, 4E)-3-hydroxy-5-phenylpent-4-
enoate is shown in Figure A2.51. 
 
2.3. Results and discussion 
2.3.1. Preparation of γ, δ-unsaturated β-keto ethyl esters 2A-2F 
    By optimizing previously reported procedures (Svendsen and Boll 1973, Bodalski, 
Pietrusiewicz et al. 1980, Vandengoorbergh and Vandergen 1980, Moorhoff and 
Schneider 1987, du Pisani, Schneider et al. 2002), synthesis of trans-γ, δ-unsaturated β-
keto ethyl esters 2A-F, shown in Scheme 2.1, was accomplished via the condensation of 
appropriate aldehydes with the anion from 4-(diethoxyphosphinyl)-3-oxobutanoate 
(Moorhoff 2003) by two equivalents of n-BuLi at room temperature. No Z-configured 
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olefins were detected by 1H NMR (E-olefins have a coupling constant with a value of 15 
Hz in 1H NMR spectrometry). The condensation afforded yields of 75% - 90% for 2A-E, 
but the keto ester 2F was formed in only 15% yield when phenylacetaldehyde 1F was 
used under the same reaction condition. The low yield could possibly be attributed to the 
α-hydrogen of phenylacetaldehyde, which is activated by the phenyl and formyl groups 
and easily deprotonated under basic conditions. This deprotonation could possible lead to 
an intermolecular aldol condensation, although this product are not isolated and identified. 
EtO P
OEt
O O O
EtO OEt
O O
R
1). 2 eq. n-BuLi
2). 1 eq. RCHO
3). NH4Cl solution
2A phenyl
2B 4-Me-phenyl
2C 4-Cl-phenyl
2D 4-NO2-phenyl
2E 4-n-Bu-phenyl
2F benzyl  
Scheme 2.1. Synthesis of γ, δ-unsaturated-β-hydroxyesters from appropriate aldehydes 
and 4-(diethoxyphosphinyl)-3-oxobutanoate in the presence of two equivalents of n-BuLi. 
 
 
2.3.2. Stereoselectivity of enzymatic formation of β-hydroxyesters 3A-3F     
    The five para-substituted phenyl (2A-E) and one benzyl (2F) trans-γ, δ-unsaturated β-
keto esters were selected as substrates to evaluate the stereoselectivity of twenty-four 
isolated ketoreductases listed in Table 2.1 from the Codex® ketoreductase screening kit 
which includes five wild type KREDs 1-5 and nineteen engineered KREDs 6-24. All 
KREDs reactions used the NADPH recycling system except enzyme 4 (KRED-NADH-
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101) and 5 (KRED-NADH-110) which used NADH instead of NADPH, as shown in 
Scheme 2.2. For engineered KREDs 6-24 which have high tolerance to high 
concentrations of isopropanol (IPA), IPA was used to assist in dissolving poorly water 
soluble substances and served to recycle NADPH cofactor from NADP+, and the 
reconstituted KRED recycle Mix P used as the reaction medium. However, for wild type 
KREDs 1-5, the reconstituted KRED recycle Mix N containing D-glucose/glucose 
dehydrogenase (GDH) and NAD(P)+ was used to provide a cofactor recycle system. In 
each case, methanol was used as co-solvent to enhance the solubility of β-keto esters, but 
the amount of co-solvent was no more than 5% of the total volume of reaction solution as 
recommended in the protocol provided by Codexis.    
OEt
O O
R
∗ OEt
OH O
R
2A-2F 3A-3F
KRED
NAD(P)H NAD(P)+
KRED Recycling Mix P
O OH
or
Glucose
GDH
GluconolactoneGluconic acid
 
Scheme 2.2. Enzymatic reduction of γ,δ-unsaturated β-ketoesters with NAD(P)H-
dependent Codex® ketoreductases. 
     
    In the protocol provided by the Codex®, 1-4 mg of KREDs was recommended to 
reduce 1 mmol of substance. Instead, in our experiment 40 mg/mmol ratio of KREDs 
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relative to unsaturated β-keto esters was used to perform all the microscale reactions 
(using 25 µmol of unsaturated β-keto esters) shown in Table 2.1. All reactions were 
carried out at 30-32 °C. Approximate yields for the microscale reactions were determined 
by integration of the vinyl hydrogen regions of the 1H NMR spectra of the crude mixtures, 
which also served to establish whether the double bond was reduced to other byproducts. 
There was no evidence of double bond reduction in any reaction. When conversion of β-
keto esters was greater than 3%, only the presence of unreacted β-keto esters and product 
β-hydroxy ester was observed in the spectrum (See example spectra in Figure A2.43).      
    To determine the absolute configuration of β-hydroxy esters, the reductions of β-keto 
esters with enzyme 8 and 23, which provide >99% ee of R and S isomers, respectively, 
were scaled by a factor of 10 (0.25 mmol) by using the same relative ratio of enzyme to 
β-keto esters as the microscale reaction. The Mosher ester method was then used to 
determine the absolute configuration of each enantiopure β-hydroxy ester from enzyme 8 
or 23 by comparison with the racemic mixture (Figure A2.37-A2.42) (Hoye, Jeffrey et al. 
2007). Optical rotations of both enantiomers of aryl γ, δ-unsaturated β-hydroxy esters 3 
except 3D were also measured (Table 2).  Comparing the signs of measured values of 3A 
with those of known literature values, the absolute configurations of β-hydroxy esters 
were further confirmed (Carreira, Singer et al. 1994, Padhi and Chadha 2005). The 
percent enantiomeric excess (% e.e.) was determined by either chiral HPLC or chiral 
capillary electrophoresis using a charged cyclodextrin as chiral selector (Figure A2.44-
A2.49). 
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    The data reported in Table 2.1 present the results of the reduction of γ, δ-unsaturated 
β-keto esters under the action of twenty-four KREDs 1-24. With exceptions of eight 
enzymes (P1-A04, P1-C01, P1-H08, P1-H10, P2-D03, P2-D12, P2-H07 and P2-D11) 
which have no (or very weak) effect on the conversion of β-keto esters and two enzymes 
(P1-B10 and P1-B12) which provide low to medium enantiomeric excess of the desired 
β-hydroxy esters, most enzymes showed activity and excellent stereoselectivity for the 
reduction of β-keto esters 2A-2F toward β-hydroxy esters 3A-3F. We do not discern any 
trends, either in terms of e.e. or conversion, as the substituent on the aromatic rings 
changes from weakly electron-donating (2B and 2E, alkyl) to strongly electron-
withdrawing (2D, nitro).   
    Both (R) and (S) enantiomers of each β-hydroxy ester were produced impressively in 
optically pure form (>99% e.e.) by a number of KREDs. (S)-enantiomers β-hydroxy 
esters were made from four enzymes (130, NADH-101, P3-G09 and P3-H12) while (R)-
enantiomers can be accessed using nine enzymes (101, 119, P1-B02, P1-B05, P2-B02, 
P2-C02, P2-C11, P2-D11 and P2-G03). For each β-keto esters, at least one enzyme could 
be used to catalyze the formation of the corresponding (S)-enantiomer and several 
enzymes could be used to produce the corresponding (R)-enantiomer, both with excellent 
stereoselectivity and good conversion. For example, in the formation of (S)-3A, three out 
of four enzymes (NADH-101, P3-G09 and P3-H12) had low conversion with over 99% 
enantiomeric excess. However, enzyme 3 (130) could catalyze formation of (S)-3A with 
both excellent stereoselectivity (>99%) and conversion (84%). Seven out of nine 
enzymes catalyzed the formation of (R)-3A with over 99% e.e. and 83-99% conversion. 
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Impressively, the 1H NMR spectra of several crude products (e.g. those from enzyme 8) 
showed no impurities, and were essentially identical to the spectrum of the “purified” 
product.   
For β-keto esters 2A – E except 2D, the reactions were scaled up by a factor of 20 or 
100 using chosen ketoreductases, as shown in Table 2.2. The product γ, δ-unsaturated β-
hydroxy esters 3 were isolated by chromatography on silica gel using 10:1 
CH2Cl2/EtOAc. Isolated yields were slightly lower compared to NMR yields in Table 2.1. 
The same optical purity was obtained in all scaled reactions, compared to the one 
obtained from crude product as shown in Table 2.1.  
In the case of β-keto ester 2F, 1,3-hydrogen rearrangement occurred to a small extent 
when some ketoreductases were used, which produced not only ethyl (4E)-3-hydroxy-6-
phenylhex-4-enoate 3F, but also ethyl (5E)-3-hydroxy-6-phenylhex-5-enoate 3F’, as 
shown in Scheme 2.3. In the rearrangement process, the hydrogen was transferred 
without formation of the Z-isomer. Evidence of 1,3-hydrogen rearrangement comes from 
the HPLC ultraviolet absorption spectra of 3F and 3F’ which show different absorption 
maxima (λmax) for 3F and 3F’. Indeed, a λmax at 250 nm is observed in the UV spectrum 
of 3F’ while a λmax of 206 nm is the spectrum of 3F (Figure A2.34 and A2.35). Further 
conclusive evidence for allylic rearrangement was obtained by examination of the 1H 
NMR spectra of the crude products (Figure A2.33).  
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OEt
O O
KRED
2F
Ph ∗
OEt
OH O
Ph
∗
OEt
OH O
Ph
3F 3F'  
Scheme 2.3. Enzymatic reduction of 2F to 3F and rearranged product 3F’. 
 
The pathway for the formation of 3F’ is not clear. Double bond migration of 2F may 
occur prior to enzymatic reduction to 3F’. Alternatively, 2F may be enzymatically 
reduced to 3F, followed by isomerization to 3F’. Current literature is lacking on the 
mechanistic aspects of this process and further studies will be required. Nevertheless, 
product (R)-3F can be obtained in pure form with high e.e. and conversion (Enzymes 5 
and 20) but further optimization is required for obtaining pure (S)-3F with high yield and 
conversion.      
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Table 2.1. Stereocontrolled reduction of γ, δ-unsaturated β-ketoesters to γ, δ-unsaturated 
β-hydroxyesters by twenty-four Codex® ketoreductases. 
 KRED 
3A 3B 3C 3D 3E 3F 3F’ 
e.e.a. b 
% 
Conv.c 
(%) 
e.e.a. b 
% 
Conv. c 
(%) 
e.e.b 
% 
Conv.c 
(%) 
e.e.a. b 
% 
Conv.c 
(%) 
e.e.a 
% 
Conv.c 
(%) 
e.e. a 
% 
Conv.c 
(%) 
e.e. a 
% 
Conv.c 
(%) 
1 101 >99 92 >99 67 >99 77 >99 62 >99 49 91 >99 - - 
2 119 >99 94 >99 96 94 95 >99 24 >99 87 96 >99 - - 
3 130 ->99 84 ->99 84 -93 85 ->99 6 ->99 74 -85 81 - - 
4 NADH-101 ->99 w ->99 w - - <3 <3 - - ->99 50 - - 
5 NADH-110 >99 94 >99 75 >99 66 >99 13 >99 8 >99 >99 - - 
6 P1-A04 -  - - - - - - - - - - - - - 
7 P1-B02 84 88 90 90 >99 >99 >99 86 54 87 98 97 8 3 
8 P1-B05 >99 >99 >99 79 >99 >99 >99 92 >99 >99 82 89 90 11 
9 P1-B10 53 28 84 13 68 40 72 <3 - - 52 <3 -68 <3 
10 P1-B12 49 31 45 28 50 <3 >99 <3 - - 38 <3 -76 <3 
11 P1-C01 90 <3  - - - - - - - - - - - - 
12 P1-H08 98 <3 95 8 40 <3 54 <3 - - - - - - 
13 P1-H10 - - - - - - - - - - 48 <3 14 <3 
14 P2-B02 >99 >99 >99 >99 >99 >99 96 96 >99 >99 >99 97 95 3 
15 P2-C02 >99 93 >99 >99 >99 >99 25 90 >99 >99 >99 98 >99 2 
16 P2-C11 >99 96 >99 93 >99 >99 >99 96 >99 98 >99 94 >99 6 
17 P2-D03 94 <3 - - 80 <3 - - - - - - - - 
18 P2-D11 96 33 >99 10 92 <3 - - - - - - - - 
19 P2-D12 95 <3 96 <3 82 <3 - - - - - - -46 <3 
20 P2-G03 >99 94 >99 97 >99 >99 >99 81 >99 >99 >99 >99 - - 
21 P2-H07 - - - - - - - - - - - - - - 
22 P3-B03 - - - - - - - - - - - - - - 
23 P3-G09 ->99 15 ->99 38 ->99 >99 ->99 73 ->99 40 ->99 43 ->99 9 
24 P3-H12 ->99 8 ->99 <3 ->99 20 ->99 43 ->99 15 -90 62 21 31 
a. The percent e.e. was measured by chiral HPLC. The positive e.e. value indicates that (R)-enantiomer is the major product, 
while negative e.e. value indicates that (S)-enantiomer is the major product. In each case, the racemic mixture was prepared 
for calibration. Absolute configuration of stereogenic C-3 was identified by 1H NMR analysis of corresponding MTPA 
ester.(Hoye, Jeffrey et al. 2007)   
b. The percent e.e. was determined by CE using charged β-CD as a chiral selector.  
c. The conversion was obtained by 1H NMR integration using d-chloroform as a solvent. When <3% conversion is reported, 
the presence of byproducts made the measurement uncertain, although a small amount of product is detected. If no value is 
given, the product was not detected by either HPLC, CE, 1H NMR spectroscopy or TLC. 
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Table 2.2. Isolated yields of γ, δ-unsaturated-β-hydroxyesters 3 using ketoreductases 
which provide both good yield and high enantioselectivity. 
# Substance KRED 
Isolated 
Yield (%) 
e.e.a 
(%) 
23
589[ ]α  
3A OEt
OOH
 
P2-B02 90 >99 
 
+14° (c 0.57, CHCl3) 
lit. +13.6° (Carreira, 
Singer et al. 1994) 
   
 OEt
OOH
 
130 70 ->99 
-16° (c 0.34, CHCl3)     
lit. -2.6° (Padhi and Chadha 
2005), -6.8° (Saravanan, 
Selvakumar et al. 2012) 
3B OEt
OOH
 
P1-B05 79 >99 +20°  (c 0.10, CHCl3) 
 OEt
OOH
 
130 75 ->99 -15°  (c 0.33, CHCl3) 
3C OEt
OOH
Cl  
P2-C11 85 >99 +15°  (c 0.13, CHCl3) 
 OEt
OOH
Cl  
P3-G09 81 ->99 -16°  (c 0.16, CHCl3) 
3E OEt
OOH
 
P1-B05 77 >99 +20°  (c 0.10, CHCl3) 
 OEt
OOH
 
130 64 ->99 -11°  (c 0.55, CHCl3) 
a. The percent e.e. was measured by chiral HPLC.   
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Besides KREDs induced reduction of trans-γ, δ-unsaturated β-ketoesters, this 
dissertation research also describes the synthesis of trans-γ, δ-unsaturated β-
hydroxyesters via Mukaiyama aldol condensation and the reduction of trans-γ, δ-
unsaturated β-ketoesters by Me-CBS-BH3 catalyst. 
 
2.3.4. Mukaiyama Aldol condensation based synthesis of trans-γ, δ-unsaturated β-
hydroxy Ester 
Carreira et al. established an enantioselective aldol addition reaction with methyl and 
ethyl acetate O-silyl enolate, catalyzed by a chiral tridentate chelated titanium (IV) 
catalyst and reported excellent e.e. (95-97%) and 72-98% yields (Carreira, Singer et al. 
1994). The aldol condensation between trans-cinnamaldehyde and silyl ketene acetal is 
shown in Scheme 2.4. The condensation was catalyzed by Ti(IV) catalyst prepared from 
Ti(OiPr)4 and tridentate ligands (Scheme 2.5. more detail for preparation of the catalyst 
the reader should see the reference by Carreira (Carreira, Singer et al. 1994)). Silyl ketene 
acetal is not commercially available and was prepared by the reaction between methyl 
acetate ester, LDA and chlorotrimethylsilane, followed by distillation (Scheme 2.6) 
(Oisaki, Suto et al. 2003). Mukaiyama aldol reaction provides trans-γ, δ-unsaturated β-
hydroxy ester 80% yield and 75% e.e. 
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-10°C, Et2O, 4h
2. Bu4NF, THF
75% ee
 
Scheme 2.4. Aldol condensation between trans-cinnamaldehyde and silyl ketene acetal. 
 
 
CHO
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Scheme 2.5. Preparation of titanium catalyst from 2-amino-2’-hydroxy-1, 1’-binaphthyl, 
Ti(OiPr)4 and 3,5-di-tert- butylsalicylic acid. 
 
 
 
N
Li CH3COOCH3 / (CH3)3SiCl
OTMS
OCH3
a, -78 °C, 15 min
b, r.t. 3 h  
Scheme 2.6. Preparation of Ketene Silyl Acetyl. 
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2.3.5. Me-CBS-BH3 catalyzed synthesis of trans-γ, δ-unsaturated β-hydroxyester 
Corey and co-workers developed the chiral oxazaborolidine-catalyzed reduction of 
prochiral ketones, cyclic and acyclic α, β-enones (Corey, Bakshi et al. 1987, Corey, 
Bakshi and Shibata et al. 1987, Mathre, Thompson et al. 1993, Corey and Helal 1998, 
Kawanami, Murao et al. 2003). Owing to the stability of oxazaborolidine catalyst and use 
of BH3·THF (or BH3·Me2S) which is obviously incompatible with C-C double bonds, the 
Me-CBS catalyst system produced a saturated byproduct and relatively lower e.e. when 
we used γ, δ-unsaturated β-ketoesters as substrates. Scheme 2.8 shows the reduction of 
ethyl (4E)-3-oxo-5-phenylpent-4-enoate (2A) by 1.2 equivalent of borane-methyl sulfide 
complex (BMS) in the presence of 10% of methyl oxazaborolidine-borane complex (Me-
CBS-BH3) (Scheme 2.7), formed by reacting Me-CBS with BMS at -20 °C. The trans-γ, 
δ-unsaturated β-hydroxy ester was formed with 50% yield, but only 44% e.e. was 
obtained according to either chiral HPLC analysis or capillary electrophoresis with 
anionic β-cyclodextrins as chiral selector.  
N
B
O
H
Me
H3B
Ph
Ph
N
B
O
H
Me
Ph
Ph
Me2S-BH3
RT, 0.5h
Me2S
 
Scheme 2.7. Preparation of Me-CBS-BH3 catalyst from methyl oxazaborolidine and 
borane-methyl sulfide complex (BMS). 
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N
B
O
H
Me
H3B
Ph
Ph
10%
1.2 equiv of BMS
CH2Cl2, -20 °C
OEt
OO
OEt
OOH
e.e  44%
 
Scheme 2.8. Me-CBS-BH3 catalyst catalyzed reduction of trans γ, δ-unsaturated β-
ketoester. 
 
2.4. Summary of formation of aryl γ, δ-unsaturated β-hydroxyesters 
Twenty four NAD(P)H-dependent ketoreductases were evaluated for the reduction of 
trans-γ, δ-unsaturated β-keto esters to their corresponding β-hydroxy esters. These 
ketoreductases includes five wild type enzymes and nineteen engineered enzymes. Five 
para-substituted phenyl and one benzyl γ, δ-unsaturated β-keto esters were selected as 
substrates, which were prepared via Horner-Wadsworth-Emmons olefination. For each β-
keto esters, 40 mg/mmol ratio of KREDs relative to ester was used with a reaction time 
of 24 h at 32 ± 1 °C. All products were successfully characterized by NMR spectroscopy 
for percent yield, and chiral HPLC or capillary electrophoresis with anionic β-
cyclodextrins for enantiomeric excess. At least one enzyme catalyzed the formation of 
the corresponding (S)-enantiomer of γ,δ-unsaturated β-hydroxyesters and several 
enzymes afforded the corresponding (R)-enantiomer, both in excellent stereoselectivity 
(>99%) and with good to excellent conversion for at least one ketoreductase. The scaled 
reaction with chosen enzyme shows that the isolated yields are very close to the 
conversion monitored by NMR spectroscopy and with same optical purity (>99%). 
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The practical synthesis of γ, δ-unsaturated β-hydroxyesters have also been performed 
by using traditional chemical methods, including Mukaiyama aldol condensation between 
trans-cinnamaldehyde and silyl ketene acetal, as well as Me-CBS-Borane catalyzed 
reduction of γ, δ-unsaturated β-ketoxyester. Both chemical methods provided good 
isolated yield of the product, however poor enantioselectivity were obtained under each 
case.   
These results suggest that Codexis ketoreductases offer potential for large scale 
synthesis of either enantiomer of aryl γ, δ-unsaturated-β-hydroxyesters with excellent 
stereoselectivity.  
 
2.5. Physical Data 
2.5.1. Physical Data and NMR Spectra of γ, δ-unsaturated β-ketoesters 2A – 2F 
2.5.1.1. (E)-ethyl 3-oxo-5-phenylpent-4-enoate (2A).  
O
O O
2A (E)-ethyl 3-oxo-5-phenylpent-4-enoate  
A slightly yellow solid; Isolated yield (%): 85%. 1H NMR (300 MHz, CDCl3): δ 12.00 
(dd, J = 3Hz, 0.8H), 7.60 (d, J = 15 Hz, 1H), 7.31-7.55 (m, 10 H), 6.80 (d, J = 15, 1H), 
6.43 (dd, J = 3, 15 Hz, 0.8H), 5.17 (s, 0.8H), 4.18-4.26 (m, J = 9Hz, 3.6H), 3.70 (s, 2H), 
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1.31 (t, J = 9 Hz, 2.4H), 1.28 (t, J = 9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 192.0, 
172.8, 169.2, 167.4, 144.6, 136.7, 135.3, 134.0, 130.9, 129.3, 129.0, 128.8, 128.5, 127.6, 
125.2, 121.9, 91.9, 61.4, 60.2, 47.6, 14.3, 14.1 
 
2.5.1.2. (E)-ethyl 3-oxo-5-(p-tolyl)pent-4-enoate (2B).  
O
O O
2B (E)-ethyl 3-oxo-5-(p-tolyl)pent-4-enoate  
Slightly yellow solid; Isolated yield (%): 88%. 1H NMR (300 MHz, CDCl3): δ 12.01 (d, J 
= 3 Hz, 0.7H), 7.53 (d, J = 15 Hz, 1H), 7.13-7.44 (m, 4H), 7.13-7.19 (m, 3.5H), 6.74 (d, J 
= 15, 1H), 6.47 (dd, J = 3, 15 Hz, 0.7H), 5.12 (s, 0.7H), 4.16-4.24 (m, J = 9Hz, 3.4H), 
3.67 (s, 2H), 2.35 (s, 3H), 2.33 (s, 1.4H), 1.23-1.29 (m, J = 9Hz, 5H); 13C NMR (75 MHz, 
CDCl3): δ 192.02, 172.89, 169.47, 167.47, 144.67, 141,52, 139.59, 136.75, 132.58, 
131.33, 129.75, 129.55, 128.55, 127.55, 124.31, 120.82, 91.52, 72.62, 61.36, 60.16, 47.47, 
21.52, 21.38, 14.30, 14.15 
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2.5.1.3. (E)-ethyl 5-(4-chlorophenyl)-3-oxopent-4-enoate (2C).  
O
O O
Cl
2C (E)-ethyl 5-(4-Chlorophenyl)-3-oxopent-4-enoate  
Slightly yellow solid; Isolated yield (%): 90%. 1H NMR (300 MHz, CDCl3): δ 11.98 (dd, 
J = 3Hz, 1H), 7.30-7.56 (m, 10H), 6.78 (d, J = 15 Hz, 1H), 6.40 (dd, J = 3, 15 Hz, 1H), 
5.16 (s, 1H), 4.22 (m, J = 6Hz, 4H), 3.68 (s, 2H), 1.31 (t, J = 6 Hz, 3H), 1.28 (t, J = 6 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 191.93, 172.98, 168.98, 167.50, 143.22, 137.10, 
135.50, 135.31, 134.11, 132.81, 129.87, 129.53, 129.27, 128.93, 125.77, 122.67, 92.55, 
61.71, 60.54, 48.00, 14.51, 14.36 
 
2.5.1.4. (E)-ethyl 5-(4-nitrophenyl)-3-oxopent-4-enoate (2D) 
 
 
 Slightly yellow solid; Isolated yield (%): 78%. 1H NMR (300 MHz, CDCl3): δ 11.95 (dd, 
J = 3Hz, 1H), 8.23 (m, J = 3, 9, 15 Hz, 2.1H), 7.63 (m, J = 3, 9, 15 Hz, 2.12H), 7.46 (d, J 
= 15 Hz, 1H), 6.95 (d, J = 15, 0.04H), 6.56 (dd, J = 3, 15 Hz), 5.25 (s, 1H), 4.26 (q, J = 6 
Hz, 2H), 4.20 (q, J = 6 Hz, 0.8H), 3.72 (s, 0.08H), 1.33 (t, J = 6 Hz, 3H), 1.30 (t, J = 6 Hz, 
O
O O
2D (E)-ethyl 5-(4-nitrophenyl)-3-oxopent-4-enoate
O2N
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0.12H); 13C NMR (75 MHz, CDCl3): δ 191.45, 172.52, 167.66, 167.05, 148.76, 147.77, 
141.68, 141.17, 140.24, 133.82, 129.07, 128.49, 128.04, 126.15, 124.21, 124.14, 93.98, 
61.64, 60.58, 47.98, 14.25, 14.13 
 
2.5.1.5. (E)-ethyl 5-(4-butylphenyl)-3-oxopent-4-enoate (2E) 
                           
O
O O
2E (E)-ethyl 5-(4-butylphenyl)-3-oxopent-4-enoate  
Slightly yellow solid; Isolated yield (%): 85%. 1H NMR (300 MHz, CDCl3): δ 12.0 (d, J 
= 3 Hz, 0.6H), 7.58 (d, J = 15 Hz, 1H), 7.39-7.49 (m, 3.8H), 7.17-7.23 (m, 3.2H), 6.76 (d, 
J = 15 Hz, 1H), 6.40 (dd, J = 3, 15 Hz, 0.6 H), 5.15 (s, 0.6H), 4.21 (m, J = 6 Hz, 3.2H), 
3.69 (s, 2H), 2.60 (m, 3.2H), 1.55-1.65 (m, 3.2H), 1.21-1.41 (m, 8H), 0.93 (t, J = 6, 4.8H); 
13C NMR (75 MHz, CDCl3): δ 192.03, 172.90, 169.49, 167.48, 146.59, 144.78, 144.67, 
136.80, 132.81, 131.52, 129.13, 128.91, 128.58, 127.56, 124.32, 120.86, 90.51, 61.42, 
60.17, 47.61, 35.62, 35.52, 33.45, 33.34, 22.34, 22.32, 14.31, 14.14, 13.94, 13.92 
 
2.5.1.6. (E)-ethyl 3-oxo-6-phenylhex-4-enoate (2F) 
O
2F (E)-ethyl 3-oxo-6-phenylhex-4-enoate
O O
 
59 
 
Slightly yellow oil; Isolated yield (%): 15%. 1H NMR (300 MHz, CDCl3): δ 11.88 (d, J = 
3Hz, 0.8H), 7.15-7.35 (m, 9H), 6.99 (dt, J = 9, 15 Hz, 1H), 6.80 (dt, J = 9, 15 Hz, 0.8H), 
6.15 (dt, J = 3, 15 Hz, 1H), 5.80 (dq, J = 3, 15 Hz, 0.8H), 4.99 (s, 1H), 4.13 – 4.23 (m, J 
= 6Hz, 3.4H), 3.57 (s, 2H), 3.50-3.57 (dq, J = 3, 6 Hz, 3.6H), 1.28 (t, J = 6 Hz, 2.4H), 
1.24 (t, J = 6 Hz, 3H) 192.13, 172.90, 169.12, 167.32, 147.78, 138.97, 138.49, 137.21, 
130.34, 128.80, 128.79, 128.75, 128.61, 126.87, 126.49, 125.37, 90.66, 61.37, 60.10, 
46.98, 38.80, 38.77, 14.27, 14.06 
 
2.5.2. Physical Data and NMR spectra of γ, δ-unsaturated β-hydroxyesters 3A-3F 
2.5.2.1. (E)-ethyl 3-hydroxy-5-phenylpent-4-enoate (3A) 
∗
O
OOH
3A   (E)-ethyl 3-hydroxy-5-phenylpent-4-enoate  
Slightly yellow oil; R-3A: [𝛼58923 ]+14° (c = 0.57, CHCl3), lit. +13.6° (Carreira, Singer et 
al. 1994); S-3A: [𝛼58923 ]-16° (c = 0.34, CHCl3), lit. -2.6° (Padhi and Chadha 2005), -6.8° 
(Saravanan, Selvakumar et al. 2012); 1H NMR (300 MHz, CDCl3): δ 7.22-7.39 (m, 5H), 
6.65 (d, J = 15 Hz, 1H), 6.25 (dd, J = 6, 15 Hz, 1H), 4.73 (m, J = 3, 6 Hz, 1H), 4.20 (q, J 
= 6 Hz, 2H), 3.15 (br, 1H), 2.56-2.70 (m, 2H), 1.27 (t, J = 6 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 172.23, 135.42, 130.73, 129.94, 128.57, 127.79, 126.53, 68.87, 60.85, 41.51, 
14.18 
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2.5.2.2. (E)-ethyl 3-hydroxy-5-(p-tolyl)pent-4-enoate (3B) 
∗
O
OOH
3B   (E)-ethyl 3-hydroxy-5-(p-tolyl)pent-4-enoate  
Slightly yellow oil; R-3B: [𝛼58923 ]+20° (c = 0.1, CHCl3); S-3B: [𝛼58923 ]-15° (c = 0.33, 
CHCl3), lit. -2.6° (Padhi and Chadha 2005), -6.8° (Saravanan, Selvakumar et al. 2012); 
1H NMR (300 MHz, CDCl3): δ 7.26 (d, J = 7 Hz, 2H), 7.11 (d, J = 7 Hz, 2H), 6.61 (d, J = 
15 Hz, 1H), 6.17 (dd, J = 6, 15 Hz, 1H), 4.70 (m, J = 3, 6 Hz, 1H), 4.18 (q, J = 6 Hz, 2H), 
3.10 (d, J = 6 Hz, 1H), 2,54-2.69 (m, 2H), 2.33 (s, 3H), 1.27 (t, J = 6 Hz, 3H); 13C NMR 
(75 MHz, CDCl3): δ 172.29, 137.65, 133.61, 130.68, 129.25, 128.89, 126.44, 68.98, 
60.82, 41.57, 21.19, 14.18 
 
2.5.2.3. (E)-ethyl 5-(4-chlorophenyl)3-hydroxypent-4-enoate (3C) 
                             
∗
O
OOH
3C   (E)-ethyl 5-(4-chlorophenyl)-3-hydroxypent-4-enoate
Cl
 
Slightly yellow oil; R-3C: [𝛼58923 ]+15° (c = 0.13, CHCl3); S-3C: [𝛼58923 ]-16° (c = 0.16, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.27 (br, 4H), 6.60 (d, J = 15 Hz, 1H), 6.19 (dd, 
J = 6, 15 Hz, 1H), 4.71 (q, J = 6 Hz, 1H), 4.18 (q, J = 6 Hz, 2H), 3.31 (br, 1H), 2.25-2.69 
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(m, 2H), 1.26 (t, J = 6 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 172.14, 134.94, 133.35, 
130.64, 129.40, 128.70, 127.72, 68.66, 60.89, 41.44, 14.17 
 
2.5.2.4. (E)-ethyl 3-hydroxy-5-(4-nitrophenyl)pent-4-enoate (3D) 
∗
O
OOH
3D   (E)-ethyl 3-hydroxy-5-(4-nitrophenyl)pent-4-enoate
O2N
 
Slightly yellow oil; 1H NMR (300 MHz, CDCl3): δ 8.17 (dt, J = 2, 7Hz, 2H), 7.50 (dt, J = 
2, 7 Hz, 2H), 6.76 (d, J = 15Hz, 1H), 6.42 (dd, J = 6, 15 Hz, 1H), 4.75-4.82 (m, 1H), 4.20 
(q, J = 6 Hz, 2H), 3.27 (br, 1H), 2.58-2.75 (m, 2H), 1.29 (t, J = 6 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 172.06, 146.97, 142.99, 134.83, 128.35, 127.03, 123.96, 68.26, 61.03, 
41.11, 14.15 
 
2.5.2.5. (E)-ethyl 5-(4-butylphenyl)-3-hydroxypent-4-enoate (3E) 
∗
O
OOH
3E   (E)-ethyl 5-(4-butylphenyl)-3-hydroxypent-4-enoate  
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Slightly yellow oil; R-3E: [𝛼58923 ]+20° (c = 0.1, CHCl3); S-3E: [𝛼58923 ]-11° (c = 0.55, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.28 (d, J = 7 Hz, 2H), 7.12 (d, J = 7 Hz, 2H), 
6.62 (d, J = 15 Hz, 1H), 6.17 (dd, J = 6, 15 Hz, 1H), 4.70 (m, J = 6 Hz, 1H), 4.17(q, J = 
6Hz, 2H), 3.15 (br, 1H), 2.56-2.67 (m, 4H), 1.53-1.63 (m, 2H), 1.28-1.40 (m, 2H), 1.26 (t, 
J = 6 Hz, 3H), 0.92 (t, J = 6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 172.22, 142.71, 
133.85, 130.68, 129.00, 128.63, 126.44, 69.00, 60.81, 41.63, 35.36, 33.56, 22.33, 14.18, 
13.95 
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Appendix A, Supplementary for Chapter 2 
 
Figure A2.1. 1H NMR spectrum of 2A in CDCl3. 
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Figure A2.2. 13C NMR spectrum of 2A in CDCl3. 
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Figure A2.3. gCOSY spectrum of 2A in CDCl3. 
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Figure A2.4. 1H NMR spectrum of 2B in CDCl3. 
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Figure A2.5. 13C NMR spectrum of 2B in CDCl3. 
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Figure A2.6. gCOSY spectrum of 2B in CDCl3. 
75 
 
 
Figure A2.7. 1H NMR spectrum of 2C in CDCl3. 
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Figure A2.8. 13C NMR spectrum of 2C in CDCl3. 
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Figure A2.9. gCOSY spectrum of 2C in CDCl3. 
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Figure A2.10. 1H NMR spectrum of 2D in CDCl3. 
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Figure A2.11. 13C NMR spectrum of 2D in CDCl3. 
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Figure A2.12. gCOSY spectrum of 2D in CDCl3. 
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Figure A2.13. 1H NMR spectrum of 2E in CDCl3. 
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Figure A2.14. 13C NMR spectrum of 2E in CDCl3. 
83 
 
 
Figure A2.15. gCOSY spectrum of 2E in CDCl3. 
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Figure A2.16. 1H NMR spectrum of 2F in CDCl3. 
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Figure A2.17. 13C NMR spectrum of 2F in CDCl3. 
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Figure A2.18. gCOSY spectrum of 2F in CDCl3. 
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Figure A2.19. 1H NMR spectrum of 3A in CDCl3. 
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Figure A2.20. 13C NMR spectrum of 3A in CDCl3. 
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Figure A2.21. gCOSY spectrum of 3A in CDCl3. 
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Figure A2.22. 1H NMR spectrum of 3B in CDCl3. 
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Figure A2.23. 13C NMR spectrum of 3B in CDCl3. 
92 
 
 
Figure A2.24. gCOSY spectrum of 3B in CDCl3. 
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Figure A2.25. 1H NMR spectrum of 3C in CDCl3. 
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Figure A2.26. 13C NMR spectrum of 3C in CDCl3. 
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Figure A2.27. 1H NMR spectrum of 3D in CDCl3. 
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Figure A2.28. 13C NMR spectrum of 3D in CDCl3. 
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Figure A2.29. gCOSY spectrum of 3D in CDCl3. 
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Figure A2.30. 1H NMR spectrum of 3E in CDCl3. 
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Figure A2.31. 13C NMR spectrum of 3E in CDCl3. 
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Figure A2.32. gCOSY spectrum of 3E in CDCl3. 
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Figure A2.33. 1H NMR spectrum of olefinic and methylene hydrogens in 3F and 3F’. a): 
purified enzymatic products 3F and 3F’ from β-ketoester 2F reduced by enzyme 23 
(KRED-P3-G09). 1H NMR of olefinic protons in 3F and 3F’ made from enzyme 23 
(KRED-P3-G09) are displayed. Hc (d, J =15 Hz) and Hd (dt, J =9, 15Hz) resonance at 
6.48 and 6.25 ppm were assigned as olefinic protons of 3F’ while Ha (d, J =15 Hz) and 
Hb (dt, J =9, 15Hz) resonance at 5.57 and 5.90 ppm belong to olefinic protons of 3F, 
which confirmed the allylic rearrangement. b): β-ketoester 2F in keto-enol form. 
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Figure A2.34. Ultraviolet absorption spectrum of ethyl (5E)-3-hydroxy-6-phenylhex-5-
enoate 3F’. 
 
 
Figure A2.35. Ultraviolet absorption spectrum of ethyl (4E)-3-hydroxy-6-phenylhex-4-
enoate 3F. 
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A.1. Determination of absolute configuration of β-hydroxyesters  
    The absolute configuration of γ, δ-unsaturated β-hydroxyesters was assigned according 
to Mosher ester technique (Hoye, Jeffrey et al. 2007). In this report, the absolute 
configuration assignment of 3C is discussed in detail as a reference. Racemic β-
hydroxyester (RS)-3C (made from the reduction of β-ketoester 2C by NaBH4) reacted 
with R-(-)-MTPA-Cl 5R (R-(-)-α-methoxyl-α-trifluoromethylphenylacetyl chloride) to 
form a mixture of diastereomeric pair (R)-3C-(S)-MTPA ester and (S)-3C-(S)-MTPA 
ester, as shown in Scheme A2.1. Relying on the fact that the underlined atoms in C(H)-
O-C(=O)-C-CF3 substructure (Figure 2.1, highlighted in red) are coplanar (Hoye, Jeffrey 
et al. 2007), the olefinic protons Ha and Hb are in the shielding region of the MTPA 
phenyl moiety in (R)-3C-(S)-MTPA ester (Figure  A2.36a), while Ha’ and Hb’ are in the 
less shield region of MTPA phenyl moiety in (S)-3C-(S)-MTPA ester (Figure A2.36b). 
Considering that the protons in diastereomers show different arrays of chemical shifts in 
1H NMR spectra, more shielded protons Ha and Hb display in the upfield region relative 
to less shielded protons Ha’ and Hb’, as shown in Figure A2.37a. Therefore, Ha at 6.6 
ppm and Hb at 6.0 ppm belong to the diastereomer (R)-3C-(S)-MTPA ester, and the 
corresponding β-hydroxyester has a configuration of ‘R’. 
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Scheme A2.1. Synthesis of diastereomeric pair (R)-3C-(S)-MTPA ester and (S)-3C-(S)-
MTPA ester from racemic β-hydroxyester (RS)-3C and R-(-)-MTPA-Cl 5R. 
. 
 
Figure A2.36. Structure of (a) (R)-3C-(S)-MTPA ester and (b) (S)-3C-(S)-MTPA ester 
and their hyperchem models at the bottom. 
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Figure A2.37. 1H NMR spectra of olefinic protons Ha (Ha’) and Hb (Hb’) in CDCl3. (a) 
diastereomers (R)-3C-(S)-MTPA ester and (S)-3C-(S)-MTPA ester, (b) (R)-3C-(S)-
MTPA ester. 
 
    The absolute configuration of the unknown β-hydroxyester 3C (>99% e.e. made with 
enzyme 8) also reacted with R-(-)-MTPA-Cl 5R to form (?)-3C-(S)-MTPA ester. By 
comparing the 1H NMR spectrum of (?)-3C-(S)-MTPA ester with that of diastereomers 
(R)-3C-(S)-MTPA ester and (S)-3C-(S)-MTPA ester, the absolute configuration of β-
hydroxyester 3C was determined as “R” in the case of enzyme 8. After the absolute 
configuration of β-hydroxyester from one enzymatic reaction was assigned, the absolute 
106 
 
configuration and e.e.% of other enzymatic reaction products β-hydroxyesters from the 
same β-ketoesters could also be confirmed by comparing the retention times on chiral 
HPLC and/or CE analysis.  
 
 
Figure A2.38. 1H NMR spectra of (S)-MTPA ester of 3A in CDCl3. Top: (S)-MTPA 
ester of 3A made by enzyme 8 (KRED-P1-B05); Bottom: (S)-MTPA ester of Racemic-
3A. 
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Figure A2.39. 1H NMR spectra of (S)-MTPA ester of 3B in CDCl3. Top: (S)-MTPA ester 
of 3B made by enzyme 8 (KRED-P1-B05); Bottom: (S)-MTPA ester of Racemic-3B.  
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Figure A2.40. 1H NMR spectra of (S)-MTPA ester of 3C in CDCl3.Top: (S)-MTPA ester 
of 3C made by enzyme 8 (KRED-P1-B05); Bottom: (S)-MTPA ester of Racemic-3C.   
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Figure A2.41.  1H NMR spectra of (S)-MTPA ester of 3D in CDCl3. Top: (S)-MTPA 
ester of 3D made by enzyme 8 (KRED-P1-B05); Bottom: (S)-MTPA ester of Racemic-
3D. 
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Figure A2.42.  1H NMR spectra of (S)-MTPA ester of 3E in CDCl3. Top: (S)-MTPA 
ester of 3E made by enzyme 23 (KRED-P3-G09); Bottom: (S)-MTPA ester of Racemic-
3E.  
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Figure A2.43. Stacked 1H NMR spectra of crude enzymatic product 3E in CDCl3. 1): 
Enzyme #1; 2): Enzyme #2; 3): Enzyme #3; 4): Enzyme #5; 5): Enzyme #7; 6): Enzyme 
#8; 7): Enzyme #14; 8): Enzyme #15; 9): Enzyme #16; 10): Enzyme #20; 11): Enzyme 
#23 
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Figure A2.44. Chiral HPLC chromatograph of 3A. Top spectrum: Racemic; Middle 
spectrum: crude product made from Enzyme # 8; Bottom Spectrum: crude product made 
from Enzyme # 23; HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 
mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min.  
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Figure A2.45. Chiral HPLC chromatograph of 3B. Top spectrum: Racemic; Middle 
spectrum: crude product made from Enzyme #5; Bottom Spectrum: crude product made 
from Enzyme #3; HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 
mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure A2.46. Chiral HPLC chromatograph of 3C. Top spectrum: Racemic; Middle 
spectrum: crude product made from Enzyme # 8; Bottom Spectrum: crude product made 
from Enzyme # 23; HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 
mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure A2.47. Chiral HPLC chromatograph of 3D. Top spectrum: Racemic; Middle 
spectrum: crude product made from Enzyme # 8; Bottom Spectrum: crude product made 
from Enzyme # 23; HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 
mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min.  
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Figure A2.48. Chiral HPLC chromatograph of 3E. Top spectrum: Racemic; Middle 
spectrum: crude product made from Enzyme # 8; Bottom Spectrum: crude product made 
from Enzyme # 23; HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 
mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure A2.49. CE Electropherogram for 3C. Top: racemic-3C; Middle: product made 
from enzyme 8 (P1- B05); Bottom: product made from enzyme 8 spiked with racemic. 
CE condition: 50.0 μm i.d., bare fused silica capillary, 32.5 cm total length, 24.0 cm to 
detector; detection 214 nm; Injection: 50.0 mBar/1s;  BGE:  5.0 mM KSPDE in 25.0 mM 
phosphate, pH=2.5; reverse polarity, -15 kV. Crude product was injected directly. 
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Figure A2.50. 1H NMR spectra of methyl (3S, 4E)-3-hydroxy-5-phenylpent-4-enoate 
made from Mukaiyama aldol condensation.  
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Figure A2.51. CE Electropherogram for trans γ, δ-unsaturated β-ketoester made from 
Mukaiyama Aldol condensation and Me-CBS-BH3 catalyst. Capillary: 50μm i.d., 32.5 cm 
total, 24.5 cm to detector; Voltage: 5.0 KV (normal polarity); Buffer: 20.0 mM Borate 
buffer, pH = 9.0; 15.0 mM KSPDM-β-CD; Injection: 50.0 mBar/1s. 
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Chapter 3 
A Total New Synthesis of Ceramide and Sphingosine Analogues2 
 
3.1. Introduction 
    Ceramide (Cer) is involved in regulation of anti-proliferative and apoptotic responses 
in various cancer cells (Hannun and Obeid 2002, Ogretmen and Hannun 2004). In 
sphingolipid metabolism cascade, Cer can be formed from the hydrolysis of 
sphingomyelin (SM) catalyzed by acid and neutral sphingomyelinase (SMase) or 
synthesized de novo from serine and palmitoyl-CoA (Ogretmen and Hannun 2004). 
Reciprocally, the level of Cer can be decreased by being converted to other 
interconnected bioactive sphingolipid species, which reduce the apoptotic effectiveness 
of Cer. Cer can be broken down by one of many ceramidases (CDase), leading to the 
formation of sphingosine (SP), which is either acylated back to Cer via ceramide synthase 
(CS) or phosphorylated to S1P by sphingosine kinase (SK), of which there are two 
isoforms, SK1 and SK2 (Hannun and Obeid 2008). According to the Cer-SP-S1P rheostat 
model, both Cer and sphingosine are apoptosis-induced lipids, whereas S1P lead to cell 
proliferation, inflammation and are referred as a tumour-promoting lipid (Spiegel and 
Milstien 2003, Milstien and Spiegel 2006, Wymann and Schneiter 2008, Pyne and Pyne 
2010). Cer can be phosphorylated into ceramide 1-phospate (Cer1P) by ceramide kinase 
(CK), which antagonizes the pro-apoptotic action of ceramide and promotes 
2 Zhipeng Dai and Thomas K. Green. Submitted to The Journal of Organic Chemistry. 
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inflammation (Wymann and Schneiter 2008). Cer can also be glycosylated to 
glucosylceramide (GluCer) mediated by glucosylceramide synthase (GCS) to result in the 
development of a multidrug resistance in many cancer cells (Ogretmen and Hannun 2004, 
Reynolds, Maurer et al. 2004). However, the intervention by stimulating or blocking only 
one or two of the pathways in Cer fails to control cancer cells proliferation, because 
cancer cells have developed strategies to escape apoptosis and accelerate proliferation by 
attenuating the pro-apoptotic effects of Cer (Kolesnick, Goñi et al. 2000, Radin 2003). 
Different strategies have been developed to enhance the level of ceramide. For 
example, many anticancer drugs and stress-induced agonists are involved in the increase 
of endogenous Cer levels through de novo synthesis of Cer or the hydrolysis of SM. In 
addition, treating cancer cells in vitro with more easily dispersed short-chain Cer 
derivatives (C2 to C8-Cer) almost always produces apoptosis and cell-cycle arrest, and 
those exogenous Cers compete metabolically with natural ones and their metabolites 
(Radin 2003). Currently, a number of anticancer agents in clinical trials act to increase 
Cer levels by inhibiting the conversion of GluCer and Cer1P from Cer, or blocking the 
hydrolysis of Cer to S1P (Radin 2003). Sphingosine analogues such as DMS (N, N-
dimethylsphingosine) (Yatomi, Ruan et al. 1996, Edsall, Van Brocklyn et al. 1998) and 
sphingamine (D, L-threo-dihydrosphingosine) (Ahn, Chang et al. 2006, Ahn and 
Schroeder 2010) have been developed and serve as pharmalogical inhibitors of SK. 
FTY720 (fingolimod) has also been found to directly inhibit SK1 activity, reduce tumor 
metastasis and increase apoptosis (Lim, Tonelli et al. 2011). Aromatic sphingosine 
analogues have received considerable attention because they are stronger sphingosine 
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kinase inhibitors than natural sphingosine (Lim, Park et al. 2004, Murakami, Furusawa et 
al. 2005, Moreno, Murruzzu et al. 2011). For instance, a water soluble sphingosine 
analogue BML-258, in Figure 3.1, is an SK1 selective inhibitor and efficacious both in 
vitro and in vivo (Paugh, Paugh et al. 2008, Pyne, Bittman et al. 2011).  
 
OH
HN
OH
CH3CH3
1
2
3
4
5
 
Figure 3.1. Structure of BLM-258, (2R, 3S, 4E)-N-methyl-5-(4’-pentylphenyl-2-
aminopent-4-ene-1, 3-diol). 
 
Owing to this important bioactivity, many synthetic approaches have been developed 
to synthesize sphingosine and its analogues (Kobayashi, Hayashi et al. 1994, van den 
Berg, Korevaar et al. 2002, Cai, Ling et al. 2006, Yang and Liebeskind 2007, Llaveria, 
Díaz et al. 2008, Kumar, Dubey et al. 2010, van den Berg, van den Elst et al. 2011). Most 
syntheses begin with protected serine aldehyde (Dondoni, Fantin et al. 1988, Garner, Park 
et al. 1988, Herold 1988, Nimkar, Menaldino et al. 1988, Radunz, Devant et al. 1988, 
Van Overmeire, Boldin et al. 1999, Lim, Park et al. 2004, Murakami, Furusawa et al. 
2005, Chandrasekhar, Saritha et al. 2006, Wong, Tan et al. 2009, Zipkin, Spiegel et al. 
2010) and its derivatives (Moreno, Murruzzu et al. 2011). The synthesis of BLM-258, 
reported by Zipkin et al. (Zipkin, Spiegel et al. 2010), is a protected serine aldehyde-
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based synthesis, which however is not highly stereospecific with respect to the C-2 and 
C-3 stereocenters. In fact, their first step in the synthesis results in a mixture of threo and 
erthyro products (7.6:1) which required separation by preparative HPLC (Zipkin, Spiegel 
et al. 2010). 
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OH O
OC2H5
OH O
OC2H5
OH O
OC2H5
OH O
OC2H5
OH O
OC2H5
Cl
R-3A S-3A
R-3E S-3E
Racemic-3B
Racemic-3C  
Figure 3.2. Structure of trans-γ, δ-unsaturated β-hydroxyesters. Enantiopure (>99%) R-
3A, R-3E and S-3E are prepared from reduction of corresponding trans-γ, δ-unsaturated 
β-ketoesters by KREDs (Dai, Guillemette et al. 2013). S-3A (e.e. 75%) was prepared 
according to the literature (Carreira, Singer et al. 1994). Racemic-3B and 3C were 
prepared from reduction of corresponding trans-γ, δ-unsaturated β-ketoesters by NaBH4.  
 
    This chapter describes a totally new synthetic route to obtain a family of aromatic 
sphingosine derivatives starting with racemic and chiral trans-γ,δ-unsaturated β-
hydroxyesters (Figure 3.2). The common structural feature of the targeted aromatic 
ceramide and sphingosine based analogues is represented by the general structure below 
(Figure 3.3). The focus of this chapter is to describe the stereoselective synthesis of this 
fundamental stereochemical framework.  
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Figure 3.3. Basic Structural Feature of Sphingosine derivatives. 
 
 
3.2. Results and discussion 
    Enantiopure trans-γ, δ-unsaturated β-hydroxyesters 3, shown in Scheme 3.1, were used 
as the building blocks to introduce the first chiral center. Strategies for the 
diastereoselective formation of hydrazino and nonreductive eliminative cleavage of the 
hydrazino N-N bonds were required for the stereoselective attachment of the amino group. 
Diastereospecific electrophilic amination of the trans-γ, δ-unsaturated β-hydroxyesters 3 
by di-tert-butyl azodicarboxylate (DBAD) produced anti N-Boc-α-hydrazino-β-
hydroxyesters 4, which introduced the second chiral center in the form of a hydrazino 
functionality.  In the presence of excess NaBH4, ethyl esters in anti N-Boc-α-hydrazino-
β-hydroxyesters 4 were reduced into alcohols to afford N-Boc-2-hydrazino 1, 3-diols 5. 
After the protection of 1,3-diols 5 in the form of 1,3-dioxanes 6, nonreductive eliminative 
cleavage of the hydrazino N-N bond in 1,3- dioxanes 6 gave 1,3-dioxanes-2-carbamate 8 
through intermediate 7. Ceramide and sphingosine derivatives 9 were then synthesized 
economically and stereospecificly after the deprotection of 1,3- dioxanes 2-carbamate 8.  
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    Scheme 3.1 describes the generalized stereoselective synthesis of sphingosine 
analogues starting from trans-γ, δ-unsaturated β-(S)-hydroxyesters S-3A (75% e.e.) and 
S-3E (>99% e.e.).   
a. 1.1 equiv MeZnBr, 0 0C, 1h
b. 2 equiv LDA, -78 0C, 1h
c. 2 equiv DBAD, -78 0C, 2h
d. saturated NH4Cl (aq.)
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R = 4-n-Bu-phenyl  (R,R-4E)
R = phenyl  (R,S-5A)
R = 4-n-Bu-phenyl  (R,S-5E)
R = phenyl  (R,S-6A)
R = 4-n-Bu-phenyl  (R,S-6E)
R = phenyl  (R,S-7A)
R = 4-n-Bu-phenyl  (R,S-7E)
R = phenyl  (R,S-8A)
R = 4-n-Bu-phenyl  (R,S-8E)
R = phenyl  (R,S-9A)
R = 4-n-Bu-phenyl  (R,S-9E)
 
Scheme 3.1. General reaction scheme for the stereospecific synthesis of ceramide and 
Sphingosine derivatives from trans-γ, δ-unsaturated β-(S)-hydroxyesters S-3A and S-3E. 
 
3.2.1. Anti N-Boc-α-hydrazino-β-hydroxyesters (4) 
    The diastereospecific formation of anti N-Boc-α-hydrazino-β-hydroxyesters 4 was 
performed via electrophilic amination of the β-hydroxyesters 3 with di-tert-
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butylazodicarboxylate (DBAD) according to the procedure described by Greck and 
Phansavath and their colleagues (Greck, Bischoff et al. 1993, Girard, Greck et al. 1996, 
Greck and Genet 1997, Labeeuw, Phansavath et al. 2003). In order to obtain high 
diastereoisomeric excesses, the zinc enolate form of β-hydroxyesters 3 was required and 
obtained by adding one equivalent of methylzinc bromide at 0 °C for 1 h followed by two 
equivalents of lithiumdiisopropylamide at -78 °C for another 1 h (Scheme 3.2). Then, 
electrophilic amination was achieved through Michael addition to DBAD at -78 °C for 
another 2 h. The product was isolated by normal phase chromatography using a mobile 
phase consisting of CH2Cl2/EtOAc (10:1). The isolated percent yield is typically 50-60%. 
Unreacted β-hydroxyesters 3 could be recovered without racemization. Due to the rigid 
zinc enolate form of β-hydroxyesters 3, the hydroxyl and hydrazino functionalities were 
preferentially formed as the anti-configurational isomer in excellent diastereoisomeric 
excesses (>99%). No syn-diastereoisomer was detected as indicated by 1H NMR by the 
absence of additional signals in the δ 4 - 7 ppm range and the existence of only one set of 
signals in the 13C NMR spectrum.  
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Scheme 3.2. Chelated zinc enolates of β-hydroxyesters 3. 
         
     Intermediates 4-6, which all possess the N-Boc-α-hydrazino function, in many cases 
exhibit extremely broadened 1H and 13C resonances in their NMR spectra, in spite of 
being pure compounds as indicated by TLC and mass spectrometry (See Figures 3.09-
3.32, Appendix B). The broad resonances are characteristic of molecules that undergo 
restricted bond rotation due to steric hindrance. The N-Boc-α-hydrazino function 
possesses two carbamate functions, which are known to undergo restricted intramolecular 
rotation about the carbamate C-N bond (Cox and Lectka 1998, Anand, Roy et al. 2007). 
As shown in Scheme 3.3, the delocalization of the N-lone electron pair in carbamate 
provides two conformers (a and b). Examples from the literature show the energy barrier 
to rotation to be around 16 kcal/mol (Anand, Roy et al. 2007). The interconversion 
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between two conformers is slow at ambient temperatures, owing to the restricted rotation 
in the amide portion of the carbamate. As the result, dynamic 1H NMR spectroscopy on 
carbamates shows extreme broadening of 1H NMR signals of the hydrogens (Pirkle, 
Simmons et al. 1979, Modarresi-Alam, Najafi et al. 2007). In anti N-Boc-α-hydrazino-β-
hydroxyesters 4, there are two carbamate groups. Theoretically, four conformers exist in 
anti N-Boc-α-hydrazino-β-hydroxyesters 4 due to the restricted rotation barrier of both 
carbamates C-N. 
O N
O
R2
R1
a b
R
O N
O
R2
R1R
O N
O
R1
R2R
Carbamate  
Scheme 3.3. Restricted rotation in carbamate. N-lone electron pair delocalization (a and 
b).  R1 ≠ R2 
 
   Consistent with previous findings, the 1H NMR spectra at 25 °C of anti N-Boc-α-
hydrazino-β-hydroxyesters 4, such as methyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) 
hydrazino]-2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enonate 4A (Figure 3.4), reveals 
broad OH, H-2 and H-3 signals. (Figure 3.5A). In fact, the OH and H-2 hydrogens both 
show major and minor resonances, which is probably attributed to major and minor 
conformations which interconvert very slowly on the NMR timescale at 25 °C. The major 
and minor resonances of both the OH and H-2 resonances, respectively, coalesce into one 
broad peak when the 1H NMR spectrum was collected at 55 °C, and the H-3 resonance 
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sharpens into a pentet. (Figure 3.5B). This coalescence behavior is consistent with a 
molecule that undergoes highly restricted rotation. As the temperature is increased, the 
rate of the interconversion of the conformers increases, and the resonances are observed 
as an average of the separate resonances. For 4A, this restricted rotation could involve a 
combination of C-N carbamate and/or C-C bond bonds. Further investigation is required 
to fully characterize the dynamic behavior of these intermediates.    
 
O
CH3
OH O
N
O
CH3
HN
O
CH3
CH3
CH3
O
O
CH3
CH3
2 13
4
5
 
Figure 3.4. Methyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-
phenyl-D-erythro-pent-4-enonate (4A). 
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Figure 3.5. 1H NMR spectrum of methyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) 
hydrazino]-2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enonate (4A) in CDCl3. (A) at 
25 °C; (B) at 55 °C. 
 
Thus, we have successfully introduced protected amino moieties as N-Boc-α-
hydrazino-β-hydroxyesters 4. Full assignments of 4 were made based on NMR spectra, 
and only anti N-Boc-α-hydrazino-β-hydroxyesters 4 were provided as detectable 
diastereomers according to 1H NMR spectroscopy.  
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3.2.2. Anti 2-hydrazino 1, 3-diol (5) 
    As a highly chemoselective reducing agent, NaBH4 is widely used in the reduction of 
aldehydes and ketones, but the reduction of esters by NaBH4 directly shows no or less 
reactivity under ambient conditions. Many effects have been reported on adding additives 
to enhance the reactivity of NaBH4 towards esters. For example, Lewis acids such as 
aluminum chloride (Brown and Rao 1956, Yamakawa, Masaki et al. 1991), zinc 
bromohydride (Narasimhan, Madhavan et al. 1995), iodine (Kanth and Periasamy 1991), 
and zinc chloride (Yamakawa, Masaki et al. 1991) could serve as additives to increase the 
reactivity of NaBH4 towards esters. In the presence of a large excess of NaBH4, the 
reduction of aliphatic and aromatic esters has also been accomplished. In 1963, Brown 
and his colleagues reported the reduction of saturated esters using a 20 fold excess of 
NaBH4 in methanol (Brown and Rapoport 1963). However, they also found that 
unsaturated esters, in the presence of 10 fold excess of NaBH4, yielded mostly saturated 
alcohol with small amounts of the saturated ester and unsaturated alcohol (Brown and 
Rapoport 1963). Kim et al. investigated reduction of saturated aromatic keto esters to 
diols by 3 equivalents of methanolic NaBH4, and the reactions were completed with 0.5 
to 3 hours (Kim, De Castro et al. 2010). Chaudhuri and his colleagues reacted 4 
equivalents of methanolic NaBH4 with γ-aryl-α, β-unsaturated-γ-ketoesters and obtained 
completely saturated diols (Chaudhuri, Saha et al. 2010).  
    The reduction of ethyl esters in anti N-Boc-α-hydrazino-β-hydroxyesters 4 to anti 2-
hydrazino 1,3-diol 5 was accomplished using a modification of the method of Chaudhuri 
and Kim (Chaudhuri, Saha et al. 2010, Kim, De Castro et al. 2010). In this method 
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developed, ketoesters were reduced effectively to diols using three equivalents of NaBH4 
in MeOH solvent over a short reaction time at room temperature in the absence of any 
additives. A possible mechanism was proposed in which NaBH4 was slowly decomposed 
in methanol to generate trimethoxy borane, which further served as a Lewis acid to form 
a ring intermediate with β-hydroxyesters 4 to activate and promote the reduction of ester 
by sodium alkoxyborohydride species. Scheme 3.4 below shows a possible cyclic 
intermediate formed between anti N-Boc-α-hydrazino-β-hydroxyesters 4 and trimethoxy 
borane in our substrate molecules. 
O
OOH
R
NBoc
BocHN
B(OCH3)3
O
OO
R
NBoc
BocHN
B
OMeMeO
4  
Scheme 3.4. A possible ring intermediate between anti N-Boc-α-hydrazino-β-
hydroxyesters 4 and trimethoxy borane.  
 
    Under Kim’s reaction conditions, only a few percent of compound 4 was reduced to 
1,3-diol 5 by using three equivalents of NaBH4 over three hours as indicated by TLC 
analysis. To increase the conversion of compound 4 to 1,3-diol 5 and avoid the 
hydrogenation of C=C bonds induced by a large excess of NaBH4, we modified the 
reaction conditions. In a typical procedure, three equivalents of NaBH4 was added into 
compound 4 in methanol every 15 min until compound 4 was completely consumed as 
indicated by TLC plate (eluent: CH2Cl2/EtOAc = 5:3). The reaction was usually 
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completed within 3 - 4 h at ambient temperature and the total amount of NaBH4 
consumed was 36-51 equivalents. Excess NaBH4 was destroyed with saturated NH4Cl 
solution. After a simple chromatography on silica gel, a good yield with a range of 80-85% 
was obtained (Table 3.1). A very large excess of NaBH4 was used to reduce N-Boc-α-
hydrazino-β-hydroxyesters compared to Kim’s reaction condition where only 3 
equivalents of NaBH4 was used to reduce saturated aromatic ketoesters. We believe that 
this arises from the cyclic intermediate in Scheme 3.3, which has steric hindrance due to 
the bulky α-hydrazino and aromatic ring functionalities. This steric effect decreases the 
reactivity of the intermediate and reduction rate by NaBH4. The solvent methanol 
competes with the intermediate to consume most of NaBH4. Therefore, the amount of 
NaBH4 needs to be replenished every 15 min to ensure that the unreacted intermediate is 
completely reduced.    
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Table 3.1. Reduction of anti N-Boc-α-hydrazino-β-hydroxyesters 4 by excess NaBH4. 
Reactant Product NaBH4 (equiv.) yield, % d.e. % 
S-3A 
OH
OH
NBoc
HNBoc  
39 88 >99 
S-3E 
OH
OH
NBoc
HNBoc  
45 81 >99 
R-3A 
OH
OH
NBoc
HNBoc  
45 85 >99 
R-3E 
OH
OH
NBoc
HNBoc  
51 80 >99 
anti-3B 
Racemic 
OH
OH
NBoc
HNBoc  
36 83 >99 
anti-3C 
Racemic 
OH
OH
NBoc
HNBoc
Cl
 
45 83 >99 
 
    The structures of the purified products 1,3-diols 5 were verified by NMR spectroscopy. 
The 1H NMR spectra of these intermediates 5 were almost identical in the H-1 to H-5 
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region. The 1H NMR of the purified 3A is shown in Figure 3.6, and, consistent with 
highly restricted bond rotation, very broad, poorly resolved signals are observed. 
Broadened signals at 3.0-5.0 ppm belong to two hydroxyls and the hydrogens attached to 
C-1 to C-3 (integrates for 6H), and these proton signals are not assigned. A broadened 
peak centered at 6.35 ppm is characteristic of N-H which is overlapping with a doublet of 
doublet at 6.21 ppm assigned to H-4. A sharp hydrogen signal of one tert-butoxycarbonyl 
[C(CH3)3] at 1.47 ppm is not identical with the hydrogen signal of the tert-
butoxycarbonyl at 1.42 ppm which is broad, due to hindered rotation.  
 
Figure 3.6. 1H NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-
trideoxy-5-phenyl-D-erythro-pent-4-enitol (5A) in CDCl3. 
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Chiral HPLC was employed to measure possible racemization of reduced 1,3-diol 
product  5, and the result shows no racemization occurs during the reaction process using 
using a large excess of NaBH4.  
 
3.2.3. Non-reductive eliminative cleavage of the hydrazine N-N bonds 
    Many protocols have been recently developed to cleave N-N bonds. Although usually 
successful, these methods have inherent disadvantages and failure to cleave N-N bonds in 
anti N-Boc-α-hydrazino-β-hydroxyesters 4. For example, H2/Pd-C (Girard, Greck et al. 
1996), H2/Raney Ni (Hinman 1957, Denmark, Nicaise et al. 1990, Ghelfi and Parsons 
2000, Raup, Cardinal-David et al. 2010) and BH3·THF (Yamazaki and Kibayashi 1997) 
have been widely used to cleave N-N bonds, however, these conditions are incompatible 
with C=C bonds. Sapountzis et al. treated hydrazine derivatives with Zn/H+ to 
accomplish the reductive cleavage of N-N bonds (Sapountzis and Knochel 2004). 
However, for our substrate, acidic conditions will subsequently cause the deprotection of 
Boc protected group. What’s more, Zhang and his colleague reported a reductive 
cleavage of N-N bonds in hydrazines using aqueous TiCl3 under a broad pH range from 
acidic to basic conditions (Zhang, Tang et al. 2011). However, in our hands, a white 
precipitate formed during the basification of TiCl3 by an aqueous solution NaOH to pH 
10, and failed to cause N-N bond cleavage in anti N-Boc-α-hydrazino-β-hydroxyesters 4. 
The reagent t-BuOK in DMSO and the presence of fluorenyl bromide has also been used 
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in the N-N bonds cleavage; however yields for this reaction are not practical (Gong, 
Bausch et al. 2001, Magnus, Garizi et al. 2009).  
    Other improvements in N-N bonds cleavage protocols have been developed. For 
example, SmI2 has also been used in the reductive cleavage of the N-N bonds in 
hydrazine, where an activated acyl group on one of the nitrogen atoms is required to 
promote the N-N cleavage with SmI2 (Friestad and Ding 2001, Ding and Friestad 2004, 
Errasti, Koundé et al. 2009). Recently, Magnus and his colleagues developed an E1cB 
eliminative cleavage of N-N bonds in diethoxycarbonyl hydrazino derivatives by treating 
the derivatives with methyl bromoacetate in the presence of Cs2CO3 in MeCN solvent at 
50 °C, followed by refluxing to break N-N bonds and generate carbamates (Magnus, 
Garizi et al. 2009). These methods are compatible with alkene functionality. Both of 
these methods could potentially be used for the N-N bond cleavage of compound 5. 
    Comparing the structure of anti 2-[1,2-bis(tert-butoxycarbonyl)]hydrazino 1,3-diol 5 
with the structure of substrates used by Magnus, they have structural similarity except the 
bis(tert-butoxycarbonyl)hydrazino is used instead of diethoxycarbonyl hydrazino. 
Therefore, this dissertation research employed E1cB eliminative N-N bonds cleavage 
protocol to cleave the N-N bonds in compound 5.   
    Before performing the E1cB eliminative N-N bonds cleavage on compound 5, both OH 
groups in compound 5 need to be protected to prevent their alkylation by methyl 
bromoacetate in the presence of Cs2CO3 in MeCN. To prevent the OH alkylation, 
compound 5 was protected as 1, 3-diol ketal 6 with anhydrous acetone using 10 mol % p-
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toluenesulfonic acid at RT (Scheme 3.4). TLC (eluent: CH2Cl2/EtOAc 10:1) was used to 
monitor the completion of protection.  
OH
R1 OH
NBoc
HNBoc
10% TsOH
Acetone, r.t
O
R1
O
NBoc
HNBoc
5 6  
Scheme 3.5. Ketalization of anti 2-di-tert-butoxycarbonyl hydrazino 1, 3-diol ketals (6). 
 
    As shown in Scheme 3.6, anti 2-N-alkylated-di-tert-butoxycarbonyl hydrazino 1,3-diol 
ketals 7 were obtained via alkylation on NH of anti 2-di-tert-butoxycarbonyl hydrazino 
1,3-diol ketals 6 by methyl bromoacetate (2.0 equiv.) in anhydrous MeCN in the presence 
of 2.5 equiv. of Cs2CO3 at 50 °C. After purification by column chromatography on silica 
gel using 10:1 CH2Cl2/EtOAc, 7 were refluxed in anhydrous MeCN with 3 equiv. of 
suspended Cs2CO3 to give carbamates 8 as a white solid with a yield of 83-95%. The 
eliminative pathway is displayed in Scheme 3.7, where carbamates 8 is formed by E1cB 
(Elimination Unimolecular conjugate Base) in which the anion of 7 is formed in base, 
and then undergoes cleavage of N-N bond with a loss of a dehydroglycine derivative.  
Workup is by protonation using saturated aqueous NH4Cl solution. Compound 6 could 
also be refluxed in a suspended solution of 4.0 equiv. of Cs2CO3 and 2.0 equiv. of methyl 
bromoacetate in anhydrous MeCN and give carbamates 8 directly with a high yield of 93% 
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after 24 h. As discussed by Magnus et.al., the presence of water would slow the 
elimination process (Magnus, Garizi et al. 2009).  
  
 
Scheme 3.6. E1cB non-reductive cleavage of N-N bonds into carbamates (8). (a) Cs2CO3 
(2.5 equiv.), BrCH2CO2CH3 (2 equiv.), MeCN, 50 °C; (b) Cs2CO3 (3.0 equiv.), MeCN, 
reflux; (c) Cs2CO3 (4.0 equiv.), BrCH2CO2CH3 (2 equiv.), MeCN, reflux. 
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Scheme 3.7. E1cB elimination of N-N bonds in anti 2-N-alkylated-di-tert-butoxycarbonyl 
hydrazino 1, 3-diol ketals (7) to obtain (8). 
      
 
Figure 3.7. 1H NMR spectrum of (7C) in CDCl3 by a Bruker 600 MHz spectroscopy. 
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    NMR spectra of anti 2-N-alkylated-di-tert-butoxycarbonyl hydrazino 1, 3-diol ketals 7 
were obtained on a 300 MHz Varian Mercury FT-NMR spectrometer. Owing to very 
complicated 1H and 13C NMR spectra, no assignments are made. 1H NMR spectrum of 
7C was collected on a Bruker 600 MHz NMR spectrometer, shown in Figure 3.7. The 
spectrum is enormously complicated in spite being a pure compound as indicated by TLC 
and mass spectrometry. The complexity, and the presence of the relatively high number 
of narrow resonances, indicates that the molecule exist in a number of conformations 
where the barrier to bond rotation is significantly above room temperature. In the 1H 
NMR spectrum of 7C, the signal of the alkene hydrogen attached to C-4 is split to at five 
sets of doublet of doublets in 7C, which means at least six conformations of compound 7 
exist at ambient temperature.  The complexity can be attributed to the steric effect among 
two di-tert-butoxycarbonyl groups, methylacetate group, ketal and aromatic ring 
functionalities. Figure 3.8 shows a temperature study of 1H NMR spectra of 7C in 
DMSO-d6. Olefin and aromatic hydrogen signals coalesce separately with increased 
temperature, which indicate interconversion of the conformations at higher temperatures. 
When heated at 100 °C for over an hour, compound 7 partially decomposed. 
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Figure 3.8. Stacked 1H NMR spectra of olefin and aromatic hydrogen of 7C in DMSO-d6 
at variant temperatures. a) 20 °C; b) 40 °C; c) 60 °C; d) 80 °C; e) 100 °C.  
 
3.2.4. Deprotection of 2-Bocamino-1,3 diol ketals (8) to provide target products. 
    2-Boc-amino-1,3-diol ketals 8 was then refluxed in the presence of 10 mol % of p-
toluenesulfonic acid in 80% EtOH (in H2O) to afford the final N-Boc-protected aromatic 
erythro-sphingosine analogues.  
Chiral HPLC and capillary electrophoresis with anionic β-cyclodextrin as a chiral 
selector are applied on all intermediates and final products to measure the percent 
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enantiomeric excess, diastereomeric excess and racemization. No racemization is 
detected during the addition in each step. Thus, the enantiomers (S, R)-9A, (S, R)-9E, and 
(R, S)-9E (see Table 3.2) of N-Boc-erthyro-sphingosine analogues have been synthesized 
with over 99% optical purity. 
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Table 3.2. Configuration, diastereoisomeric excesses and isolated yields of all 
intermediates making from corresponding racemic, enantiomeric excess and enantiopure 
pure trans-γ, δ-unsaturated β-hydroxyesters. 
 
Intermediates 
Configuration,a    d.e. (%)b and isolated yield (%) 
SP 
analogues 
9 
Overall 
yield 
4 5 6 7 8 
 
Substance 
ee (%) 
 
 
OH O
OC2H5
NBoc
HNBoc  
OH OH
NBoc
HNBoc  
O O
NBoc
HNBoc  
O O
NBoc
N(Boc)CH2CO2CH3  
O O
NHBoc  
OH OH
NHBoc  
 
R-3A, >99 (S, S), >99, 58% 
(S, R), >99,  
85% 
(S, R), >99, 
94% 
(S, R), >99,  
99% 
(S, R), >99,  
85% 
(S, R), >99,  
96% 37% 
R-3E, >99 (S, S), >99, 50% 
(S, R), >99, 
80% 
(S, R), >99, 
94% 
(S, R), >99,  
94% 
(S, R), >99,  
95% 
(S, R), >99,  
94% 32% 
 
OH O
OC2H5
NBoc
HNBoc  
OH OH
NBoc
HNBoc  
O O
NBoc
HNBoc  
O O
NBoc
N(Boc)CH2CO2CH3  
O O
NHBoc  
OH OH
NHBoc  
 
S-3A, 75 (R,R), >99,  58% 
(R,S), >99,  
88% 
(R,S), >99,  
93%  
(R,S), >99, 
94% 
(R,S), >99,  
93% 41% 
 S-3E, >99 (R,R), >99,  60% 
(R,S), >99,  
81% 
(R,S), >99,  
94% 
(R,S), >99,  
95% 
(R,S), >99, 
86% 
(R,S), >99,  
95% 35% 
 
OH O
OC2H5
NBoc
HNBoc  
OH OH
NBoc
HNBoc  
O O
NBoc
HNBoc  
O O
NBoc
N(Boc)CH2CO2CH3  
O O
NHBoc  
OH OH
NHBoc  
 
3B 
racemic 
racemic, anti 
>99,  55% 
racemic, anti 
>99,  83% 
racemic, anti 
>99,  94% 
racemic, anti 
>99,  98% 
racemic, anti 
>99,  87% 
racemic, anti 
>99,  94% 34% 
3C 
racemic 
racemic, anti 
>99,  58% 
racemic, anti 
>99,  83% 
racemic, anti 
>99,  94% 
racemic, anti 
>99,  99% 
racemic, anti 
>99, 83% 
racemic, anti 
>99,  92% 34% 
a. Assignment of Configuration refers to (configuration of β position, configuration of α position) for N-Boc-α-  
    hydrazino-β-hydroxyesters 2; and (configuration of carbon-3, configuration of carbon-2) for compound 3 to 7; 
b. The percent e.e. was measured by chiral HPLC; and the percernt de was measured by both 1H NMR and chiral   
    HPLC; 
 
3.3. Summary of the novel synthetic route. 
Erthyro sphingosine analogues with aromatic groups in the side chain have been made 
using a novel and effective synthetic route. Configuration, diastereoisomeric excesses and 
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isolated yields of all intermediates and final analogues are summarized in Table 3.2. The 
synthetic route starts with trans-γ, δ-unsaturated β-hydroxyesters and includes five or six 
steps, which are (1) diastereospecific electrophilic amination of the trans-γ, δ-unsaturated 
β-hydroxyesters by DBAD to introduce chiral amino group in the form of anti N-Boc-α-
hydrazino-β-hydroxyesters; (2) reduction of N-Boc-α-hydrazino-β-hydroxyesters to N-
Boc-2-hydrazino-1,3-diols by excess amount of NaBH4 in MeOH solution; (3) protection 
of N-Boc-2-hydrazino-1,3-diols catalyzed by 10 mol % of p-toluenesulfonic acid with 
anhydrous acetone to afford N-Boc-2-hydrazino-1,3-diols ketals; (4) E1cB non-
reductively eliminative cleavage of the hydrazino N-N bond of N-Boc-2-hydrazino-1,3-
diols ketals in the presence methyl bromoacetate and  Cs2CO3 to form N-Boc-2-amino-
1,3-diols ketals directly or via an intermediate N-Boc-2-alkylatedhydrazino-1,3-diols 
ketals; (5) deprotection of N-Boc-2-amino-1,3-diols ketals in the presence of 10 mol % of 
p-toluenesulfonic acid in 80% EtOH (in H2O) to afford final erthyro aromatic 
sphingosine analogues. All final products and intermediates were successfully 
characterized by NMR spectroscopy and chiral HPLC. Excellent stereoselectivity with 
more than 99% d.e. was obtained and there was no racemization during the course of the 
synthesis. Either enantiomer of erthyro aromatic sphingosine analogues was achieved 
using the described method. The optical purity of the final aromatic sphingosine 
analogues depends on that of starting materials trans-γ, δ-unsaturated β-hydroxyesters. 
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3.4. General methods 
3.4.1. Materials 
All chemicals were purchased from VWR International, LLC and were of the highest 
purity unless otherwise noted. Lithium diisopropylamine, zinc bromide, Dess-Martin 
periodinane were purchased from Aldrich Chemical Co. (Milwaukee, WI). Ethyl acetate 
was purchased from Alfa Aesar (Ward Hill, MA). Zinc bromide was dried in an oven at 
110 °C for a minimum of 24 h before using. Methylzinc bromide was prepared via the 
reaction of zinc bromide and methylmagnesium bromide according to the published 
procedure (Joly and Bucourt June 1962). THF was freshly distilled from sodium metal 
with benzophenone ketal indicator. Acetone was dried by simple distillation and stored 
over molecular sieves (4Å, 8-12 mesh). Acetonitrile was distilled from CaH2 and stored 
over 4 Å molecular sieves. Aluminum coated silica gel WF254s plates were used to 
monitor reactions products and flash chromatography eluents. Column chromatography 
were performed with silica gel SiliaFlash®P60 (40 - 60 µm, 230 - 400 mesh).  
 
3.4.2. Instruments 
    NMR spectra were obtained on a Varian Mercury FT-NMR spectrometer, operating at 
300 MHz for 1H NMR and 75 MHz for 13C NMR unless other note. Assignments were 
made by 1H, 13C and gCOSY techniques. Chemical shifts were reported in parts per 
million (ppm, δ) relative to tetramethylsilane (TMS, δ 0.00 ppm). 1H NMR splitting 
patterns are designated as singlet (s), doublet (d), triplet (t), doublet of doublets (dd), 
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multiplet (m), broad (br). Coupling constants (J values) are reported in Hertz (Hz). HPLC 
was performed on Agilent 1100 series with isocratic pump and UV-visible detector. A 
Phenomenex® Lux 3 µ cellulose-1 column (50 x 4.60 mm) was used for the chiral 
separation at 23 °C. The mobile phase consisted of hexanes and isopropanol in the ratio 
of 90:10, and flow rate of 0.5 mL/min. 
Abbreviations: THF, tetrahydrofuran; EtOAc, ethyl acetate; MeZnBr, methyl zinc 
bromide; LDA, Lithium diisopropylamide; DBAD, di-tert-butyl azodicarboxylate; MeOH, 
methanol; MeCN, acetonitrile; KREDs, ketoreductases 
 
3.4.3. Diastereospecific formation of anti N-Boc-α-hydrazino-β-hydroxyesters (4) 
    Under N2, to a solution of trans-γ, δ-unsaturated β-hydroxyesters (3) (1.0 mmol) in 2 
mL anhydrous THF at 0 °C, was added 1.2 equivalent of zinc methyl bromide (1.2 mmol, 
0.4 M in THF). The reaction mixture was stirred for 1 h. After the reaction mixture was 
cooled to -78 °C, 2.0 equivalents of LDA (2.0 mmol, 2M in heptane/THF/ethyl benzene) 
were added dropwise. After 1 h at -78 °C, 2 equivalents of DBAD (2.0 mmol) in 1 mL 
anhydrous THF was added slowly, the reaction mixture continued to stir for another 2 h. 
The reaction mixture was quenched at -78 °C with saturated NH4Cl solution (aq.) (4 mL), 
warmed to room temperature, extracted with Et2O (2 x 10 mL). The combined organic 
layer was dried over anhydrous Na2SO4 and concentrated under vacuum to afford crude 
product. Purification by column chromatography on silica gel using 100% CH2Cl2 to 
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elute unreacted DBAD, then gradient elution using 10:1= CH2Cl2: EtOAc to afford anti 
N-Boc-α-hydrazino-β-hydroxyesters 4. 
3.4.3.1. Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-phenyl-D-
erythro-pent-4-enonate (4A) 
and O
OH O
CH3
NBoc
NHBoc
O
OH O
CH3
NBoc
NHBoc  
White solid; isolated yield: 58%; Diastereomeric excess (d.e.) >99% (anti); (S, S)-4A: [𝛼58923 ]+105° (c = 1.71, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.15 -7.28 (5H), 6.77 (s, 
1H), 6.65 (dd, J = 3, 15.0 Hz, 1H), 6.15 (dd, J = 3.0 Hz, 15.0 Hz, 1H), 5.09-5.37 (br, 1H), 
4.90 (m, 1H), 4.53-4.72 (br, 1H), 4.23 (m, J = 6 Hz, 2H), 1.45 (s, 9H), 1.28 (t, J = 6 Hz, 
3H), 1.26 (s, 9H); 13C NMR (75 MHz, CDCl3) 169.49, 169.31, 156.58, 155.01, 136.97, 
129.76, 128.38, 127.88, 127.41, 126.49, 83.13, 82.36, 82.09, 69.78, 65.57, 63.36, 61.58, 
27.99, 14.26 
3.4.3.2. Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-phenyl-D-
erythro-pent-4-enonate (4B) 
Racemic mixture
O
OH O
CH3
NBoc
NHBoc
O
OH O
CH3
NBoc
NHBoc
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White solid; Isolated yield: 55%; Diastereomeric excess (d.e.) >99% (anti); 1H NMR 
(300 MHz, CDCl3): δ 7.19 (d, J = 9.0 Hz, 2H), 7.08 (d, J = 9.0 Hz, 2H), 6.75 (s, 1H), 
6.63 (d, J = 15.0 Hz, 1H), 6.10 (dd, J = 3.0 Hz, 15.0 Hz, 1H), 5.11-5.38 (br, 1H), 4.90 (m, 
1H), 4.53-4.73 (br, 1H), 4.23 (m, J = 6.0 Hz, 2H), 2.32 (s, 3H), 1.47 (s, 9H), 1.31 (s, 9H), 
1.30 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) 169.53, 169.34, 157.23, 156.55, 
155.03, 137.17, 134.18, 129.85, 129.08, 126.81, 126.40, 83.13, 82.36, 82.10, 69.96, 65.57, 
63.35, 61.55, 28.03, 21.18, 14.26. HRMS (ESI) calcd for C24H36N2O7Na (M+Na)+ 
487.2415, found 487.2419. 
3.4.3.3. Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-(4-chlorophenyl)-2,4,5-
trideoxy-D-erythro-pent-4-enonate (4C). 
Racemic mixture
O
OH O
CH3
NBoc
NHBoc
Cl
O
OH O
CH3
NBoc
NHBoc
Cl
 
White solid; Isolated yield: 58%; Diastereomeric excess (d.e.) >99% (anti); 1H NMR 
(300 MHz, CDCl3): δ 7.20-7.28 (m, 5H), 6.72 (s, 1H), 6.85 (d, J = 15.0 Hz, 1H), 6.15 (dd, 
J = 3.0, 15.0 Hz, 1H), 5.10-5.38 (br, 1H), 4.91 (m, 1H), 4.54-4.70 (br, 1H), 4.21-4.29 (m, 
2H), 1.47 (s, 9H), 1.31 (t, J = 6.0 Hz, 3H) 1.29 (s, 9H); 13C NMR (75 MHz, CDCl3) 
169.46, 169.28, 157.26, 156.59, 155.14, 154.96, 135.54, 132.98, 128.67, 128.57, 128.42, 
127.68, 83.26, 82.51, 82.20, 69.62, 65.51, 63.33, 61.66, 28.02, 14.28. HRMS (ESI) calcd 
for C23H33N2O7ClNa (M+Na)+ 507.1869, found 507.1877. 
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3.4.3.4. Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-(4-butylphenyl)-2,4,5-
trideoxypent-4-enonate (4E) 
 
and
O
OH O
CH3
NBoc
NHBoc
O
OH O
CH3
NBoc
NHBoc  
Slightly yellow solid; Isolated yield: 50% and 60%; Diastereomeric excess (d.e.) >99% 
(anti); (R, R)-4E: [𝛼58923 ]-89° (c = 0.56, CHCl3); (S, S)-4E: [𝛼58923 ]+130° (c = 0.23, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 7.21 (d, J = 9.0 Hz, 2H), 7.08 (d, J = 9.0 Hz, 2H), 6.85 
(dd, J = 3.0, 15.0 Hz, 1H), 6.11 (dd, J = 3.0, 15.0 Hz, 1H), 5.11-5.38 (br, 1H), 4.91 (m, 
1H), 4.50-4.70 (br, 1H), 4.21 (m, J = 6.0 Hz, 2H), 2.58 (t, J = 6.0 Hz, 2H), 1.57 (m, 2H), 
1.47 (s, 9H), 1.36 (m, 2H), 1.33 (t, J = 6.0 Hz, 3H), 1.30 (s, 9H), 0.91 (t, J = 6.0 Hz, 3H); 
13C NMR (75 MHz, CDCl3) 169.55, 169.33, 157.17, 156.51, 155.19, 155.05, 142.27, 
134.38, 129.85, 128.45, 126.78, 126.42, 83.14, 82.36, 82.09, 69.95, 65.60, 63.40, 61.56, 
35.31, 33.38, 28.00, 22.23, 14.26, 13.94. HRMS (ESI) calcd for C27H42N2O7Na (M+Na)+ 
529.2884, found 529.2886. 
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3.4.4. Synthesis of anti 2-di-tert-butoxycarbonyl hydrazino 1, 3-diol (5)  
    Into a solution of anti N-Boc-α-hydrazino-β-hydroxyesters (4) (1 mmol) in 25 mL 
methanol, 3 equivalents of NaBH4 was added every 15 min till the starting material was 
consumed as indicated by TLC. A total 36 - 51 equiv. of NaBH4 was added. Afterwards, 
the reaction was quenched with saturated NH4Cl (aq.) (10 mL); and the reaction mixture 
was concentrated under vacuum, extracted with EtOAc, and the combined extracts were 
washed with brine, dried over anhydrous Na2SO4, and the organic solvent was removed 
by rotovaporization at 60 - 70 °C. Purification by chromatography on silica gel using 5:3 
CH2Cl2/EtOAc as eluent afforded the product. 
3.4.4.1. (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-phenyl-D-
erythro-pent-4-enitol (5A). 
OH OH
NBoc
NHBoc
OH OH
NBoc
NHBoc
and
 
White solid; Isolated yield: 88% and 85%; Diastereomeric excess (d.e.) >99% (anti); (3R, 
2S)-5A: [𝛼58923 ]+10° (c = 0.49, CHCl3); (3S, 2R)-5A: [𝛼58923 ]-18° (c = 1.13, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.24 (m, 5H), 6.60 (d, J = 15.0 Hz, 1H), 6.35 (br, 1H), 6.21 
(br, J = 6.0, 15.0 Hz, 1H), 2.85-4.98 (br, 6H), 1.47 (s, 9H), 1.42 (s, 9H); 13C NMR (75 
MHz, CDCl3) 158.54, 157.83, 155.36, 136.31, 132.26, 129.12, 128.52, 127.86, 126.55, 
82.61, 82.40, 81.88, 71.99, 64.68, 62.35, 59.18, 28.10. HRMS (ESI) calcd for 
C21H32N2O6Na (M+Na)+ 431.2153, found 431.2147. 
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3.4.4.2. (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-(4-
methylphenyl)-D-erythro-pent-4-enitol (5B). 
Racemic mixture
OH OH
NBoc
NHBoc
OH OH
NBoc
NHBoc
 
White solid; Isolated yield: 83%; Diastereomeric excess (d.e.) >99% (anti); 1H NMR 
(300 MHz, CDCl3): δ 7.24 (d, J = 6.0 Hz, 2H), 7.10 (d, J = 6.0 Hz, 2H), 6.58 (d, J = 15.0 
Hz, 1H), 6.36 (br, 1H), 6.18 (dd, J = 6.0, 15.0 Hz, 1H), 3.50-4.70 (br, 5H), 2.50-3.10 (br, 
1H), 2.32 (s, 3H), 1.48 (s, 9H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) 158.51, 157.74, 
155.35, 137.84, 133.38, 132.18, 129.26, 127.86, 126.48, 82.69, 82.46, 81.90, 72.30, 64.62, 
62.52, 59.29, 28.10, 21.20. HRMS (ESI) calcd for C22H34N2O6Na (M+Na)+ 445.2309, 
found 445.2305. 
3.4.4.3. (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-(4-chlorophenyl)-2,4,5-
trideoxy-D-erythro-pent-4-enitol (5C). 
Racemic mixture
OH OH
NBoc
NHBoc
Cl
OH OH
NBoc
NHBoc
Cl
 
White solid; Isolated yield: 83%; Diastereomeric excess (d.e.) >99% (anti); 1H NMR 
(300 MHz, CDCl3): δ 7.25 (s, 4H), 6.55 (d, J = 15.0 Hz, 1H), 6.35 (br, 1H), 6.20 (dd, J = 
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6.0, 15.0 Hz, 1H), 2.85-4.90 (br, 6H), 1.47 (s, 9H), 1.41 (s, 9H); 13C NMR (75 MHz, 
CDCl3) 158.41, 157.83, 155.40, 135.08, 133.33, 130.59, 129.94, 128.88, 127.74, 82.54, 
82.01, 71.81, 64.53, 62.50, 59.31, 28.09. HRMS (ESI) calcd for C21H31N2O6ClNa 
(M+Na)+ 465.1763, found 465.1764. 
3.4.4.5. (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-(4-butylphenyl)-1,2,4-
trideoxypent-1-enitol (5E). 
OH OH
NBoc
NHBoc
OH OH
NBoc
NHBoc
and
 
White solid; Isolated yield: 81% and 80%; Diastereomeric excess (d.e.) >99% (anti); (3R, 
2S)-5E: [𝛼58923 ]+83° (c = 0.24, CHCl3); (3S, 2R)-5E: [𝛼58923 ]-35° (c = 0.29, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.26 (d, J = 9 Hz, 2H), 7.12 (d, J = 9 Hz, 2H), 6.58 (d, J = 
15.0 Hz, 1H), 6.34 (br, 1H), 6.17 (dd, J = 6.0, 15.0 Hz, 1H), 3.35-5.00 (br, 5H), 2.59 (t, J 
= 6.0 Hz, 2H), 2.0 (s, 1H), 1.58 (m, 2H), 1.48 (s, 9H), 1.45 (s, 9H), 1.34 (m, 2H), 0.92 (t, 
J = 6.0 Hz, 3H); 13CNMR (75 MHz, CDCl3) 158.46, 157.74, 155.36, 142.99, 133.60, 
132.31, 128.65, 127.90, 126.50, 82.71, 82.49, 81.93, 72.39, 64.55, 62.55, 59.28, 35.36, 
33.55, 28.11, 22.31, 13.94. HRMS (ESI) calcd for C25H40N2O6Na (M+Na)+ 487.2779, 
found 487.2792. 
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3.4.5. Synthesis of anti 2-di-tert-butoxycarbonyl hydrazino 1, 3-diol ketal (6)  
    Under N2, the mixture of anti 2-di-tert-butoxycarbonyl hydrazino 1,3-diol (5) (0.15 
mmol) and 10% molar equivalent of p-toluene sulfonic acid monohydrate (0.015 mmol) 
in 5.0 mL of anhydrous acetone was stirred at room temperature till the reaction was 
completed as monitored by TLC plate (eluent: CH2Cl2: EtOAc = 5:3) (24h). The reaction 
mixture was quenched with 5% NaHCO3 and extracted by CH2Cl2. The combined 
organic layers were dried over anhydrous Na2SO4, and removed under vacuum. The 
product was purified by flash chromatography on silica gel using 10:1 CH2Cl2/EtOAc as 
eluent. 
3.4.5.1. (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-
methylethylidene)-1-phenylpent-1-enitol (6A). 
O
BocN
NHBoc
O O
NBoc
NHBoc
O
and
 
Slightly yellow solid; isolated yield: 93% and 94%; (3R, 2S)-6A: [𝛼58923 ]+44° (c = 0.45, 
CHCl3); (3S, 2R)-6A: [𝛼58923 ]-40° (c = 0.75, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.37 
(d, J = 6 Hz, 2H), 7.20 – 7.32 (m, 3H), 6.66 (d, J = 15.0 Hz, 1H), 6.00-6.35 (br, 2H), 4.56 
(m, 1H), 3.70-4.28 (br, 1H), 4.02 (br, 2H), 1.55 (s, 3H), 1.48 (s, 9H), 1.45 (s, 3H), 1.37 (s, 
9H); 13C NMR (75 MHz, CDCl3) 156.59, 155.79, 154.64, 154.28, 136.38, 136.22, 133.32, 
128.45, 127.93, 127.27, 126.74, 126.61, 98.61, 82.25, 81.84, 81.65, 72.02, 71.40, 60.90, 
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60.47, 56.25, 53.36, 29.00, 28.12, 28.02, 19.60, 19.44. HRMS (ESI) calcd for 
C24H36N2O6Na (M+Na)+ 471.2466, found 471.2470. 
3.4.5.2. (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-
methylethylidene)-1-(4-methylphenyl)pent-1-enitol (6B). 
Racemic mixture
O O
NBoc
NHBoc
O O
NBoc
NHBoc
 
White solid; isolated yield: 94%. 1H NMR (300 MHz, CDCl3): δ 7.25 (d, 2H), 7.08 (d, J 
= 6 Hz, 3H), 6.62 (d, J = 15.0 Hz, 1H), 5.86-6.30 (br, 2H), 4.53 (br, 1H), 3.75-4.26 (br, 
1H), 4.00 (br, 2H), 2.31 (s, 3H), 1.54 (s, 3H), 1.47 (s, 9H), 1.43 (s, 3H), 1.37 (s, 9H); 13C 
NMR (75 MHz, CDCl3) 156.60, 155.77, 154.63, 154.28, 137.81, 133.57, 133.35, 129.16, 
126.67, 126.53, 126.14, 125.53, 98.58, 82.22, 81.84, 81.62, 72.19, 71.57, 60.92, 60.50, 
56.34, 53.44, 29.03, 28.12, 28.02, 21.22, 19.58, 19.43. HRMS (ESI) calcd for 
C25H38N2O6Na (M+Na)+ 485.2622, found 485.2632. 
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3.4.5.3. (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-(4-chlorophenyl)-2,4,5-
trideoxy-1,3-O-(1-methylethylidene)-D-erythro-pent-4-enitol (6C). 
Racemic mixture
O O
NBoc
NHBoc
Cl
O O
NBoc
NHBoc
Cl
 
White solid; isolated yield: 94%; 1H NMR (300 MHz, CDCl3): δ 7.30 (d, J = 9.0 Hz, 2H), 
7.26 (d, J = 9.0 Hz, 2H), 6.63 (d, J = 15.0 Hz, 1H), 6.00-6.55(br, 2H), 4.56 (br, 1H), 4.00-
4.39 (br, 1H), 4.01 (br, 2H), 1.54 (s, 3H), 1.48 (s, 9H), 1.44 (s, 3H), 1.36 (s, 9H); 
13CNMR (75 MHz, CDCl3) 156.65, 155.80, 154.63, 154.28, 134.90, 133.45, 132.33, 
131.71, 128.64, 128.60, 127.93, 127.76, 98.61, 82.19, 81.81, 81.65, 71.84, 71.12, 80.78, 
60.39, 56.35, 53.31, 28.93, 28.11, 28.01, 19.43. HRMS (ESI) calcd for C24H35N2O6ClNa 
(M+Na)+ 505.2076, found 505.2068. 
3.4.5.4. (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-(4-butylphenyl)-1,2,4-
trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (6E). 
O
BocN
NHBoc
O O
NBoc
NHBoc
O
and
 
Slightly yellow oil; isolated yield: 94%; (3R, 2S)-6E: [𝛼58923 ]+67° (c = 0.30, CHCl3); (3S, 
2R)-6E: [𝛼58923 ]-56° (c = 0.61, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.28 (d, J = 6 Hz, 
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2H), 7.10 (d, J = 6.0 Hz, 2H), 6.63 (d, J = 15.0 Hz, 3H), 5.85-6.11 (br, 2H), 4.55 (m, 1H), 
3.75-4.26 (br, 1H), 4.01 (br, 2H), 2.58 (t, J = 6.0 Hz, 2H), 1.58 (m, 2H), 1.55 (s, 3H), 
1.48 (s, 9H), 1.46 (s, 3H), 1.39 (s, 9H), 1.32 (m, 2H), 0.92 (t, J = 6.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) 156.58, 155.82, 154.64, 154.27, 142.92, 134.14, 133.57, 128.22, 
126.66, 126.54, 126.17, 125.62, 98.60, 82.27, 81.86, 81.65, 71.62, 60.95, 60.54, 56.28, 
53.55, 35.55, 33.49, 29.03, 28.11, 28.01, 22.29, 19.44, 13.94. HRMS (ESI) calcd for 
C28H44N2O6Na (M+Na)+ 527.3092, found 527.3088. 
 
Synthesis of anti 2-BocAmino 1, 3-diol ketal (8) via anti 2-alkylhydrazino 1, 3-diol 
ketal (7) 
3.4.6. Synthesis anti 2-alkylhydrazino 1, 3-diol ketal (7) 
    Into a suspension solution of Anti 2-di-tert-butoxycarbonyl hydrazino 1, 3-diol ketal (6) 
(0.242 mmol) and Cs2CO3 (0.61 mmol) in 2.5 mL CH3CN under N2, was added methyl 
bromoacetate (0.484 mmol) in 0.5 mL CH3CN. The reaction mixture was heated at 50 °C 
for 3-8 h as indicated by TLC plate (eluent: 10:1 CH2Cl2/EtOAc). The reaction was 
quenched with saturated NH4Cl (aq.), extracted with EtOAc. The combined extracts were 
washed with brine, and dried over anhydrous Na2SO4, and the solvent was removed 
under vacuum. The Anti 2-alkylhydrazino 1, 3-diol ketal (7) was purified by flash 
chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent as white solid.  
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3.4.6.1. (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-2-oxoethyl)hydrazino]-1,2,4-
trideoxy-3,5-O-(1-methylethylidene)-1-phenyl-D-erythro-pent—enitol (7A). 
O
BocN
H3COOCH2CN
O
Boc  
White solid; isolated yield: >99%; (3S, 2R)-7A: [𝛼58923 ]-63° (c = 1.76, CHCl3); 1H NMR 
(300 MHz, CDCl3): δ 7.23-7.26 (m, 5H), 6.50-6.62 (m, 1H), 6.05-6.26 (m, 1H), 3.31-5.36 
(m, 9H), 1.34-1.68 (m, 24H); 13C NMR (75 MHz, CDCl3) 170.18, 169.78, 169.71, 169.36, 
169.29, 156.51, 155.87, 155.21, 154.58, 154.12, 153.86, 153.71, 153.54, 153.25, 153.07, 
136.30, 136.28, 136.13, 136.03, 136.00, 135.97, 135.92, 134.97, 134.78, 134.64, 134.58, 
133.68, 133.37, 133.32, 128.56, 128.52, 128.45, 128.24, 128.11, 128.05, 127.91, 127.88, 
127.60, 127.45, 127.27, 126.91, 126.78, 126.75, 126.54, 126.43, 126.40, 126.37, 98.78, 
98.73, 98.71, 98.62, 98.54, 82.74, 82.66, 82.56, 82.45, 82.41, 82.30, 82.20, 81.79, 81.70, 
81.53, 81.46, 72.48, 72.23, 71.86, 71.35, 70.57, 70.48, 68.07, 62.80, 60.53, 60.32, 60.16, 
59.59, 59.29, 56.77, 56.35, 56.18, 56.00, 55.55, 55.35, 54.83, 54.62, 54.07, 53.42, 53.35, 
52.40, 52.32, 52.22, 52.19, 51.96, 51.86, 29.33, 29.30, 29.04, 29.00, 28.58, 28.54, 28.52, 
28.19, 28.17, 28.14, 28.05, 28.00, 27.96, 27.90, 20.29, 20.21, 19.92, 19.89, 19.36, 19.28. 
HRMS (ESI) calcd for C27H40N2O8Na (M+Na)+ 543.2677, found 543.2689. 
160 
 
3.4.6.2. (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-2oxoethyl)hydrazino]-1,2,4-
trideoxy-3,5-O-(1-methylethylidene)-1-(4-methylphenyl)pent-1-enitol (7B). 
Racemic mixture
O
NBoc
H3COOCH2CN
O
Boc
O
NBoc
H3COOCH2CN
O
Boc
 
White solid; isolated yield: 98%; 1H NMR (600 MHz, CDCl3): δ 7.23-7.26 (m, J = 3.0, 
6.0 Hz, 1H), 7.18-7.21 (m, J = 6.0 Hz, 1H), 7.10 (dd, J = 3.0, 6.0 Hz, 2H), 6.49-6.58 (m, 
1H), 6.01-6.19 (m, 1H), 3.33-5.31 (m, 9H), 2.33 (s, 3H), 1.35-1.68 (m, 24H); 13C NMR 
(150 MHz, CDCl3) 170.22, 169.74, 169.42, 156.53, 155.90, 154.59, 154.13, 153.87, 
153.55, 153.07, 138.20, 138.05, 138.04, 135.19, 134.84, 133.82, 133.54, 133.31, 133.15, 
129.27, 129.24, 129.21, 129.16, 126.77, 126.73, 126.69, 126.50, 126.38, 126.33, 126.31, 
126.28, 126.01, 125.69, 98.78, 98.70, 98.63, 98.53, 82.74, 82.55, 82.43, 82.39, 82.19, 
81.79, 81.89, 81.50, 81.42, 72.51, 72.37, 71.92, 70.75, 7.65, 62.84, 60.56, 06.37, 59.30, 
56.15, 55.53, 55.52, 54.80, 54.59, 54.06, 53.36, 52.43, 52.33, 52.02, 29.34, 29.30, 29.07, 
29.02, 28.65, 28.54, 28.17, 28.12, 28.07, 28.00, 27.96, 27.90, 21.25, 19.91, 19.88, 19.34, 
19.25. HRMS (ESI) calcd for C28H42N2O8Na (M+Na)+ 557.2833, found 557.2852. 
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3.4.6.3. (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-2oxoethyl)hydrazino]- 1-(4-
chlorophenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (7C). 
Racemic mixture
O
NBoc
H3COOCH2CN
O
Boc
Cl
O
NBoc
H3COOCH2CN
O
Boc
Cl
 
White solid; isolated yield: >99%; 1H NMR (300 MHz, CDCl3): δ 7.26 (m, 4H), 6.46-
6.59 (m, 1H), 6.05-6.25 (m, 1H), 3.28-5.32 (m, 9H), 1.35-1.67 (m, 24); 13C NMR (75 
MHz, CDCl3) 170.13, 169.72, 169.67, 169.33, 169.25, 156.45, 155.80, 155.42, 155.17, 
155.11, 154.54, 154.43, 154.18, 154.10, 154.02, 153.82, 153.72, 153.53, 153.23, 153.05, 
134.94, 134.84, 134.68, 134.53, 133.88, 133.78, 133.68, 133.48, 133.30, 133.05, 133.00, 
132.92, 132.23, 131.62, 131.66, 128.86, 128.81, 128.78, 128.70, 128.67, 128.60, 128.34, 
128.23, 128.03, 127.96, 127.92, 127.69, 127.64, 127.60, 127.55, 98.80, 98.77, 98.72, 
98.64, 98.60, 98.56, 82.83, 82.77, 82.71, 82.60, 82.52, 82.48, 82.43, 82.29, 81.84, 81.73, 
81.61, 81.55, 72.44, 72.02, 71.78, 71.62, 71.05, 70.91, 70.32, 62.66, 62.31, 60.87, 60.50, 
60.44, 60.20, 60.04, 59.61, 59.27, 56.82, 56.35, 56.16, 56.03, 55.55, 55.37, 54.87, 54.73, 
54.00, 53.45, 53.34, 52.42, 52.33, 52.25, 52.21, 52.00, 51.97, 51.88, 29.27, 28.99, 28.96, 
28.61, 28.52, 28.45, 28.17, 28.15, 28.11,29.04, 27.97, 27.95, 27.89, 20.27, 20.11, 19.88, 
19.83, 19.34, 19.27. HRMS (ESI) calcd for C27H39N2O8ClNa (M+Na)+ 577.2287, found 
577.2299. 
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3.4.6.4. (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-2-oxoethyl)hydrazino]-1-(4-
butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (7E). 
O
BocN
H3COOCH2CN
O
Boc
O
BocN
H3COOCH2CN
O
Boc
and
 
White solid, isolated yield: 95% and 94%; (3R, 2S)-7E: [𝛼58923 ]+83° (c = 0.24, CHCl3); 
(3S, 2R)-7E: [𝛼58923 ]-65° (c = 0.77, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.22 (m, 2H), 
7.11 (m, 2H), 6.47-6.59 (m, 1H), 5.99-6.20 (m, 1H), 3.32-5.30 (m, 9H), 2.58 (t, J = 6.0 
Hz, 2H), 1.26-1.68 (m, 28H), 0.92 (dt, J = 3.0, 6.0Hz, 3H); 13C NMR (75 MHz, CDCl3) 
170.19, 169.83, 169.80, 169.71, 169.37, 169.33, 156.52, 155.89, 155.24, 154.58, 154.13, 
153.86, 153.54, 153.06, 143.23, 143.07, 143.04, 142.85, 135.15, 134.98, 134.86, 134.80, 
133.75, 133.68, 133.54, 133.48, 133.41, 133.38, 128.61, 128.57, 128.55, 128.49, 126.93, 
126.81, 126.72, 126.68, 126.49, 126.35, 126.31, 125.82, 98.76, 98.70, 98.68, 98.60, 98.51, 
82.72, 82.54, 82.51, 82.42, 82.38, 82.17, 81.77, 81.69, 81.49, 81.41, 72.48, 72.34, 71.88, 
71.55, 70.70, 70.58, 63.03, 62.87, 60.58, 60.38, 60.21, 59.57, 59.27, 56.76, 56.34, 56.18, 
55.53, 55.32, 54.82, 54.60, 54.09, 53.37, 52.39, 52.31, 52.21, 52.15, 51.97, 51.87, 35.37, 
33.50, 33.49, 33.46, 29.34, 29.30, 20.05, 29.01, 28.54, 28.19, 28.17, 28.13, 28.06, 28.00, 
27.96, 29.90, 22.37, 22.34, 22.30, 22.29, 19.92, 19.89, 19.35, 19.26, 13.94. HRMS (ESI) 
calcd for C31H48N2O8Na (M+Na)+ 599.3303, found 599.3309. 
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3.4.7. Synthesis of anti 2-BocAmino 1, 3-diol ketal (8) 
    Into a suspension solution of (7) (0.22 mmol) in 5.0 mL CH3CN under N2, was added 
and 3 equivalents of Cs2CO3 (0.66 mmol), and the reaction mixture was refluxed for over 
20 h till the starting material was consumed as indicated by TLC plate (Eluent: 10:1 
CH2Cl2/EtOAc). The reaction was quenched with saturated NH4Cl (aq.), extracted with 
EtOAc. The combined extracts were washed with brine, and dried over anhydrous 
Na2SO4, and the solvent was removed under vacuum. The product (8) was purified by 
flash chromatography on silica gel using 10:1 CH2Cl2/EtOAc eluent as white solid.  
3.4.7.1. (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-
1-phenylpent-1-enitol (8A). 
O
NHBoc
O O
NHBoc
O
and
 
White solid; isolated yield: 85%; (3R, 2S)-8A: [𝛼58923 ]+21° (c = 0.24, CHCl3); (3S, 2R)-8A: [𝛼58923 ]-25° (c = 0.79, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.38 (m, 2H), 7.20-7.32 (m, 
3H), 6.65 (d, J = 15.0 Hz, 1H), 6.18 (dd, J = 6.0, 15.0 Hz, 1H), 4.43 (d, J = 9.0 Hz, 1H), 
4.27 (br, 1H), 4.00 (dd, J = 6.0 Hz, 1H), 3.72 (m, 1H), 3.61 (m, 1H), 1.53 (s, 3H), 1.46 (s, 
3H), 1.35 (s, 9H); 13C NMR (75 MHz, CDCl3) 155.11, 136.34, 133.58, 128.44, 127.89, 
126.71, 126.59, 98.81, 79.81, 74.65, 62.96, 49.11, 28.73, 28.21, 19.60. HRMS (ESI) 
calcd for C19H27NO4Na (M+Na)+ 356.1832, found 356.1841. 
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3.4.7.2. (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-
1-(4-methylphenyl)pent-1-enitol (8B). 
Racemic mixture
O
NHBoc
O O
NHBoc
O
 
White solid; isolated yield: 87%; 1H NMR (300 MHz, CDCl3): δ 7.28 (d, J = 6.0 Hz, 2H), 
7.10 (d, J = 6.0 Hz, 2H), 6.62 (d, J = 15.0 Hz, 1H), 6.11 (dd, J = 6.0, 15.0 Hz, 1H), 4.41 
(d, J = 9.0 Hz, 1H), 4.25 (br, 1H), 4.00 (dd, J = 6.0 Hz, 1H), 3.71 (m, 1H), 3.63 (m, 1H), 
2.32 (s, 3H), 1.53 (s, 3H), 1.46 (s, 3H), 1.35 (s, 9H); 13C NMR (75 MHz, CDCl3) 155.12, 
137.76, 133.70, 133.53, 129.18, 126.63, 125.47, 98.79, 97.76, 74.71, 63.01, 49.11, 28.76, 
28.23, 21.23, 19.60. HRMS (ESI) calcd for C20H29NO4Na (M+Na)+ 370.1989, found 
370.1993. 
3.4.7.3. (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-methylphenyl)-1,2,4-trideoxy-3,5-O-
(1-methylethylidene)pent-1-enitol (8C). 
Racemic mixture
O
NHBoc
O O
NHBoc
O
Cl Cl
 
White solid; isolated yield: 83%; 1H NMR (300 MHz, CDCl3): δ 7.28 (ddd, J = 3.0, 6.0 
Hz, 4H), 6.66 (d, J = 15.0 Hz, 1H), 6.16 (dd, J = 6.0, 15.0 Hz, 1H), 4.51 (br, 1H), 4.24 (br, 
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1H), 3.97 (dd, J = 6.0 Hz, 1H), 3.66 (m, 2H), 1.52 (s, 3H), 1.46 (s, 3H), 1.35 (s, 9H); 13C 
NMR (75 MHz, CDCl3) 155.13, 134.93, 133.48, 131.99, 128.63, 127.87, 127.38, 98.82, 
79.79, 74.58, 62.88, 48.92, 28.73, 28.22, 19.53. HRMS (ESI) calcd for C19H26NO4ClNa 
(M+Na)+ 390.1443, found 390.1448. 
 
3.4.7.4. (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-butylphenyl)-1,2,4-trideoxy-3,5-O-(1-
methylethylidene)pent-1-enitol (8E). 
O
NHBoc
O O
NHBoc
O
and
 
White solid, isolated yield: 86% and 95%; (3R, 2S)-8E: [𝛼58923 ]+59° (c = 0.17, CHCl3); 
(3S, 2R)-8E: [𝛼58923 ]-61° (c = 0.49, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.30 (d, J = 
6.0 Hz, 2H), 7.11(d, J = 6.0 Hz, 2H), 6.63 (d, J = 15.0 Hz, 1H), 6.12 (dd, J = 6.0, 15.0 Hz, 
1H), 4.37 (br, 1H), 4.25 (br, 1H), 4.02 (dd, J = 6.0 Hz, 1H), 3.71 (m, 1H), 3.59 (m, 1H), 
2.58 (t, J = 6.0 Hz, 2H), 1.58 (m, 2H), 1.53 (s, 3H), 1.46 (s, 3H), 1.35 (s, 9H), 1.32 (m, 
2H), 0.92 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) 155.09, 142.86, 133.74, 128.52, 
126.64, 125.52, 98.81, 79.87, 74.68, 63.04, 49.23, 35.37, 33.50, 28.74, 28.23, 22.31, 
19.64, 13.94. HRMS (ESI) calcd for C23H35NO4Na (M+Na)+ 412.2458, found 412.2468. 
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3.4.8. Direct synthesis of anti 2-BocAmino 1,3-diol ketal (8) 
    Under argon, 2 equivalents of methyl bromoacetate (0.085 mmol) was added into a 
suspension of anti 2-di-tert-butoxycarbonyl hydrazino 1, 3-diol ketal (6) (0.043 mmol) 
and 4 equivalents of Cs2CO3 (0.170 mmol) in 3 mL of anhydrous CH3CN. The reaction 
mixture was stirred at reflux until the starting material was consumed as indicated by 
TLC plate (eluent: 10:1 CH2Cl2/EtOAc) (usually 15-24 h). After completion, the reaction 
was quenched with saturated NH4Cl (aq.) and extracted with EtOAc. The combined 
extracts were washed with brine, and dried over anhydrous Na2SO4, and the solvent was 
removed under vacuum. The product 8 was purified by flash chromatography on silica 
gel using 10:1 CH2Cl2/EtOAc eluent as white solid.  
 
3.4.9. trans-4,5-Unsaturated anti 2-BocAmino 1,3-diol (9) 
    A mixture of anti 2-BocAmino 1, 3-diol ketal (8) (0.1 mmol) and 10 mol% of TsOH 
(0.05 mmol) in 10.0 mL 80% EtOH in H2O was stirred at reflux till the starting material 
was consumed as indicated by TLC plate (Eluent: CH2Cl2: EtOAc = 5:3). After the 
reaction was completed (usually 1h), the reaction was quenched by 4 mL of 5% NaHCO3. 
The mixture was concentrated under vacuum at 60-70 °C, extracted with EtOAc, dried 
over anhydrous Na2SO4. The product was isolated by column chromatography on silica 
gel using 5:3 CH2Cl2/EtOAc as eluent. 
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3.4.9.1. (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-1-phenylpent-1-enitol (9A).  
OH
NHBoc
OHOH
NHBoc
OH
and
 
White solid; isolated yield: 96%; (3R, 2S)-9A: [𝛼58923 ] -9° (c = 0.57, CHCl3), lit. -
19.4°;(Moreno, Murruzzu et al. 2011) (3S, 2R)-9A: [𝛼58923 ]+13° (c = 2.40, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.21-7.39 (m, 5H), 6.68 (d, J = 15.0 Hz, 1H), 6.26 (dd, J = 
6.0, 15.0 Hz, 1H), 5.42 (d, J = 6.0 Hz, 1H), 4.53 (t, J = 6.0 Hz, 1H), 3.97 (dd, J = 3.0, 
12.0 Hz, 1H), 3.76 (dd, J = 3.0, 12.0 Hz, 1H), 3.72 (br, 1H), 3.05 (br, 2H), 1.42 (s, 9H); 
13C NMR (75 MHz, CDCl3) 156.26, 136.33, 131.78, 128.59, 128.54, 127.86, 126.55, 
79.99, 74.60, 62.54, 55.44, 28.34. HRMS (ESI) calcd for C16H23NO4Na (M+Na)+ 
316.1519, found 316.1524. 
3.4.9.2. (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-1-(4-methylphenyl)pent-1-
enitol (9B). 
Racemic mixture
OH
NHBoc
OHOH
NHBoc
OH
 
White solid; isolated yield: 94%; 1H NMR (300 MHz, CDCl3): δ 7.26 (d, J = 6.0 Hz, 2H), 
7.11 (d, J = 6.0 Hz, 2H), 6.63 (d, J = 15.0 Hz, 1H), 6.20 (dd, J = 6.0, 15.0 Hz, 1H), 5.41 
(d, J = 6.0 Hz, 1H), 4.51 (dd, J = 3.0, 6.0 Hz, 1H), 3.97 (dt, J = 3.0, 12.0 Hz, 1H), 3.75 
(dt, J = 3.0, 12.0 Hz, 1H), 3.72 (m, 1H), 3.31 (d, J =  3.0 Hz, 1H), 3.00 (s, 1H), 2.33 (s, 
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3H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3) 156.27, 137.75, 133.54, 131.76, 129.30, 
127.44, 126.48, 79.95, 74.71, 62.57, 55.49, 28.36, 21.21. HRMS (ESI) calcd for 
C17H25NO4Na (M+Na)+ 330.1676, found 330.1671.  
 
3.4.9.3. (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-chlorophenyl)-1,2,4-trideoxypent-1-
enitol (9C). 
Racemic mixture
OH
NHBoc
OHOH
NHBoc
OH
Cl Cl
 
White solid, isolated yield: 92%; 1H NMR (300 MHz, CDCl3): δ 7.27 (m, 4H), 6.65 (d, J 
= 15.0 Hz, 1H), 6.25 (dd, J = 6.0, 15.0 Hz, 1H), 5.38 (d, J = 9.0 Hz, 1H), 4.53 (dd, J = 3.0, 
6.0 Hz, 1H), 3.98 (dt, J = 3.0, 12.0 Hz, 1H), 3.78 (dt, J = 3.0, 12.0 Hz, 1H), 3.72 (m, 1H), 
3.24 (d, J = 3.0 Hz, 1H), 2.77 (s, 1H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3) 156.21, 
134.84, 133.53, 130.53, 129.27, 128.78, 127.76, 80.06, 74.58, 62.54, 55.36, 28.35. 
HRMS (ESI) calcd for C16H22NO4ClNa (M+Na)+ 350.1130, found 350.1124. 
3.4.9.4. (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-butylphenyl)-1,2,4-trideoxypent-1-
enitol (9E). 
OH
NHBoc
OH OH
NHBoc
OH
and
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White solid; isolated yield: 95% and 94%%; (3R, 2S)-9E: [𝛼58923 ]-15° (c = 0.67, CHCl3); 
(3S, 2R)-9E: [𝛼58923 ]+10° (c = 0.97, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.29 (d,  J = 
9.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.67 (d, J = 15.0 Hz, 1H), 6.21 (dd, J = 6.0, 15.0 
Hz, 1H), 5.36 (d, J = 9.0 Hz, 1H), 4.54 (t, J = 3.0 Hz, 1H), 3.99 (dd, J = 3.0, 12.0 Hz, 1H), 
3.76 (dt, J = 3.0, 12.0 Hz, 1H), 3.71 (m, 1H), 2.84 (br,  2H), 2.59 (t, J = 6.0 Hz, 2H), 
1.54-1.65 (m, 2H), 1.44 (s, 9H), 1.29-1.41 (m, 2H), 0.92 (t, J = 6.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) 156.21, 142.91, 133.68, 131.80, 128.68, 127.40, 126.47, 79.93, 74.91, 
62.65, 55.42, 35.36, 33.55, 28.34, 22.31, 13.93. HRMS (ESI) calcd for C20H31NO4Na 
(M+Na)+ 372.2145, found 372.2156. 
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Appendix B, Supplementary for Chapter 3 
 
Figure B3.1. 1H NMR spectrum of Ethyl (4E)-2-[1,2-bis(tert-
butoxycarbonyl)hydrazino]-2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enonate (4A) at 
25 °C in CDCl3. 
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Figure B3.2. 13C NMR spectrum of Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) 
hydrazino]-2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enonate (4A) at 25 °C in CDCl3. 
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Figure B3.3. 1H NMR spectrum of Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino] 
-2,4,5-trideoxy-5-(4-methylphenyl)-D-erythro-pent-4-enonate (4B) at 25 °C in CDCl3. 
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Figure B3.4. 13C NMR spectrum of Ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) hydrazino] 
-2,4,5-trideoxy-5-(4-methylphenyl)-D-erythro-pent-4-enonate (4B) at 25 °C in CDCl3. 
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Figure B3.5. 1H NMR spectrum of ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino] 
-5-(4-chlorophenyl)-2,4,5-trideoxy-D-erythro-pent-4-enonate (4C) at 25 °C in CDCl3. 
182 
 
 
Figure B3.6. 13C NMR spectrum of ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) hydrazino] 
-5-(4-chlorophenyl)-2,4,5-trideoxy-D-erythro-pent-4-enonate (4C) at 25 °C in CDCl3. 
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Figure B3.7. 1H NMR spectrum of ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) hydrazino] 
-5-(4-butylphenyl)-2,4,5-trideoxypent-4-enonate (4E) at 25 °C in CDCl3. 
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Figure B3.8. 13C NMR spectrum of ethyl (4E)-2-[1,2-bis(tert-butoxycarbonyl) 
hydrazino]-5-(4-butylphenyl)-2,4,5-trideoxypent-4-enonate (4E) at 25 °C in CDCl3. 
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Figure B3.9. 1H NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enitol (5A) at 25 °C in CDCl3. 
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Figure B3.10. 13C NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
2,4,5-trideoxy-5-phenyl-D-erythro-pent-4-enitol (5A) at 25 °C in CDCl3. 
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Figure B3.11. 1H NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
2,4,5-trideoxy-5-(4-methylphenyl)-D-erythro-pent-4-enitol (5B) at 25 °C in CDCl3. 
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Figure B3.12. 13C NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
2,4,5-trideoxy-5-(4-methylphenyl)-D-erythro-pent-4-enitol (5B) at 25 °C in CDCl3. 
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Figure B3.13. 1H NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-
(4-chlorophenyl)-2,4,5-trideoxy-D-erythro-pent-4-enitol (5C) in CDCl3. 
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Figure B3.14. 13C NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-
(4-chlorophenyl)-2,4,5-trideoxy-D-erythro-pent-4-enitol (5C) in CDCl3. 
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Figure B3.15. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-
(4-butylphenyl)-1,2,4-trideoxypent-1-enitol (5E) in CDCl3. 
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Figure B3.15. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-
(4-butylphenyl)-1,2,4-trideoxypent-1-enitol (5E) in CDCl3. 
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Figure B3.17. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-phenylpent-1-enitol (6A) in CDCl3. 
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Figure B3.18. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-phenylpent-1-enitol (6A) in CDCl3. 
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Figure B3.19. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-(4-methylphenyl)pent-1-enitol (6B) in 
CDCl3. 
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Figure B3.20. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-
1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-(4-methylphenyl)pent-1-enitol (6B) in 
CDCl3. 
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Figure B3.20. 1H NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-
(4-chlorophenyl)-2,4,5-trideoxy-1,3-O-(1-methylethylidene)-D-erythro-pent-4-enitol (6C) 
in CDCl3. 
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Figure B3.22. 13C NMR spectrum of (4E)-2-[1,2-bis(tert-butoxycarbonyl)hydrazino]-5-
(4-chlorophenyl)-2,4,5-trideoxy-1,3-O-(1-methylethylidene)-D-erythro-pent-4-enitol (6C) 
in CDCl3. 
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Figure B3.23. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-
(4-butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (6E) in CDCl3. 
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Figure B3.24. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)hydrazino]-1-
(4-butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (6E) in CDCl3. 
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Figure B3.25. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2-oxoethyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-phenyl-D-erythro-
pent-enitol (7A) in CDCl3. 
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Figure B3.26. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2-oxoethyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-phenyl-D-erythro-
pent-enitol (7A) in CDCl3. 
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Figure B3.27. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2oxoethyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-(4-
methylphenyl)pent-1-enitol (7B) in CDCl3. 
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Figure B3.28. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2oxoethyl)hydrazino]-1,2,4-trideoxy-3,5-O-(1-methylethylidene)-1-(4-methylphenyl) 
pent-1-enitol (7B) in CDCl3. 
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Figure B3.29. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2oxoethyl)hydrazino]- 1-(4-chlorophenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene) 
pent-1-enitol (7C) in CDCl3 on a 600 MHz Bruker  spectroscopy in CDCl3. 
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Figure B3.30. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2oxoethyl)hydrazino]- 1-(4-chlorophenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene) 
pent-1-enitol (7C) in CDCl3 on a 600 MHz Bruker  spectroscopy in CDCl3. 
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Figure B3.31. 1H NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2-oxoethyl)hydrazino]-1-(4-butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-
1-enitol (7E) in CDCl3. 
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Figure B3.32. 13C NMR spectrum of (1E)-4-[1,2-bis(tert-butoxycarbonyl)-2-(2-methoxy-
2-oxoethyl)hydrazino]-1-(4-butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene) 
pent-1-enitol (7E) in CDCl3. 
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Figure B3.33. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-
3,5-O-(1-methylethylidene)-1-phenylpent-1-enitol (8A) in CDCl3. 
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Figure B3.34. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-
trideoxy-3,5-O-(1-methylethylidene)-1-phenylpent-1-enitol (8A) in CDCl3. 
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Figure B3.35. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-
3,5-O-(1-methylethylidene)-1-(4-methylphenyl)pent-1-enitol (8B) in CDCl3. 
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Figure B3.36. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-
trideoxy-3,5-O-(1-methylethylidene)-1-(4-methylphenyl)pent-1-enitol (8B) in CDCl3. 
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Figure B3.37. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
methylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (8C) in CDCl3. 
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Figure B3.38. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
methylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (8C) in CDCl3. 
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Figure B3.39. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (8E) in CDCl3. 
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Figure B3.40. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
butylphenyl)-1,2,4-trideoxy-3,5-O-(1-methylethylidene)pent-1-enitol (8E) in CDCl3. 
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Figure B3.41. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-
1-phenylpent-1-enitol (9A) in CDCl3. 
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Figure B3.42. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-
trideoxy-1-phenylpent-1-enitol (9A) in CDCl3. 
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Figure B3.43. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-trideoxy-
1-(4-methylphenyl)pent-1-enitol (9B) in CDCl3. 
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Figure B3.44. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1,2,4-
trideoxy-1-(4-methylphenyl)pent-1-enitol (9B) in CDCl3. 
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Figure B3.45. 1H NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
chlorophenyl)-1,2,4-trideoxypent-1-enitol (9C) in CDCl3. 
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Figure B3.46. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
chlorophenyl)-1,2,4-trideoxypent-1-enitol (9C) in CDCl3. 
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Figure B3.47. 1H NMR spectrum (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
butylphenyl)-1,2,4-trideoxypent-1-enitol (9E) in CDCl3. 
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Figure B3.48. 13C NMR spectrum of (1E)-4-[(tert-butoxycarbonyl)amino]-1-(4-
butylphenyl)-1,2,4-trideoxypent-1-enitol (9E) in CDCl3. 
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Figure B3.49. Chiral HPLC chromatograph of 9A. Top: (3R, 2S)-9A made from S-3A; 
Bottom: (3S, 2R)-9A made from R-3A. HPLC column: Phenomenex® Lux 3µ cellulose-1 
column (50 x 4.60 mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure B3.50. Chiral HPLC chromatograph of 8B and 9B; Top: 8B made from 3B; 
Bottom: 9B made from 3B. HPLC column: Phenomenex® Lux 3µ cellulose-1 column 
(50 x 4.60 mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure B3.51. Chiral HPLC chromatograph of 8C and 9C; Top: 8C made from 3C; 
Bottom: 9C made from 3C. HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 
x 4.60 mm); mobile phase: hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure B3.52. Chiral HPLC chromatograph of 8E; Top: mixture of (3R, 2S)-8E and (3S, 
2R)-8E; Middle:  (3R, 2S)-8E made from S-3E; Bottom: (3S, 2R)-6B made from R-3E. 
HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 mm); mobile phase: 
hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Figure B3.53. Chiral HPLC chromatograph of 9E; Top: mixture of (3R, 2S)-9E and (3S, 
2R)-9E; Middle:  (3R, 2S)-9E made from S-3E; Bottom: (3S, 2R)-9E made from R-3E. 
HPLC column: Phenomenex® Lux 3µ cellulose-1 column (50 x 4.60 mm); mobile phase: 
hexane: isopropanol = 9:1; Flow rate: 0.5 ml/min. 
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Chapter 4 
Conclusion 
 
4.1. Overview 
    The primary focus of this dissertation was to develop a new synthetic route to 
sphingosine analogues.  A considerable effort was made to synthesize intermediate chiral 
trans-γ, δ-unsaturated β-hydroxy esters in high enantiopurity. We found that the reduction 
of the corresponding β-keto esters by commercially available ketoreductases was far 
superior to chemical methods for providing these critical enantiopure intermediates. The 
chiral trans-γ, δ-unsaturated β-hydroxy esters could then be conveniently α-aminated 
diastereospecifically using zinc chelation and Michael reaction with azodicarboxylate to 
produce α-hydrazino intermediates.  The N-N bond was then effectively cleaved using 
known nonreductive E1cB elimination to preserve the double bond stereochemistry. Thus, 
a family of aromatic sphingosine analogues can be synthesized in high purity by the new 
synthetic route.  
    
4.2. Conclusions on KREDs induced reduction of aryl γ, δ-unsaturated-β-ketoesters. 
Saturated β-hydroxy esters have been asymmetrically prepared by many traditional 
methods and some biological methods. However, no literature was found to describe the 
asymmetrical formation of aryl trans-γ, δ-unsaturated β-hydroxyesters with high 
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enantioselectivity.  In this research, an efficient enzymatic method was developed 
systematically utilizing isolated NAD(P)H dependent ketoreductases for the direct and 
stereoselective reduction of γ, δ-unsaturated β-keto esters.  
For each γ, δ-unsaturated β-ketoesters, at least one enzyme could catalyze the 
formation of the corresponding (S)-enantiomer of γ, δ-unsaturated β-hydroxyesters and 
several enzymes could afford the corresponding (R)-enantiomer, both in excellent optical 
purity (>99%) and with good to excellent conversion for at least one ketoreductase. For 
several γ, δ-unsaturated β-ketoesters, the reactions were scaled (100-200 mg) with a 
chosen enzyme under the same reaction condition. The isolated yields are very close to 
the conversion of micro reactions monitored by 1H NMR spectroscopy and with same 
optical purity (>99%).  
Traditional chemical methods including Mukaiyama aldol condensation and Me-CBS-
Borane catalyst reduction were also performed for formation of aryl γ, δ-unsaturated β-
hydroxyester. Mukaiyama aldol condensation between trans-cinnamaldehyde and silyl 
ketene acetal afforded methyl (3S, 4E)-3-hydroxy-5-phenylpent-4-enoate with 80% yield 
and only 75% e.e.. Me-CBS-Borane catalyzed reduction of ethyl (4E)-3-oxo-5-
phenylpent-4-enoate to ethyl (3S, 4E)-3-hydroxy-5-phenylpent-4-enoate gave 50% yield 
and only 44% e.e.. Thus, the enzymatic route to trans-γ, δ-unsaturated β-hydroxyesters is 
deemed far superior to the chemical methods explored here.  
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4.3. Conclusion of a novel and effective synthesis of erythro aromatic sphingosine 
analogues. 
This research dissertation described a new and effective synthetic route to synthesize a 
family of sphingosine analogues. The synthetic route started with trans-γ, δ-unsaturated 
β-hydroxyesters. The synthetic route includes five or six steps. The key steps of this 
synthesis are (1) diastereospecific electrophilic amination of the trans-γ, δ-unsaturated β-
hydroxyesters by DBAD to introduce chiral amino group and generate anti N-Boc-α-
hydrazino-β-hydroxyesters and (2) E1cB non-reductively eliminative cleavage of the 
hydrazino N-N bond of N-Boc-2-hydrazino-1,3-diols ketals in the presence methyl 
bromoacetate and Cs2CO3.  
In the diastereospecific electrophilic amination of the trans-γ, δ-unsaturated β-
hydroxyesters, highly diastereospecificity is obtained for the anti-product and no syn 
product is detected. Zinc chelation appears to be necessary for the high 
diastereoselectivity, owing to the rigid zinc enolate form of trans-γ, δ-unsaturated β-
hydroxyesters which facilitate the Michael addition of DBAD from the less sterically 
hindered side. The yields are 50% and the unreacted trans-γ, δ-unsaturated β-
hydroxyesters can be recovered. Optimization needs to be carried out to increase the yield 
of this step.       
E1cB non-reductively eliminative cleavage can be accomplished in two steps by 
separating intermediates N-Boc-2-alkylatedhydrazino-1,3-diols ketals and further 
cleaving N-N bonds under reflux. These two steps for N-N cleavage provide a combined 
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yield of 82-89%. Alternatively, E1cB non-reductively eliminative cleavage could also be 
performed without isolating intermediates with a higher overall yield. This one-step 
pathway is preferred because it is faster and provides higher overall yield.   
In summary, excellent stereochemistry with more than 99% d.e. was obtained using the 
above described methodology, and no loss of stereochemistry is detected over the entire 
synthetic pathway. In this way, this methodology provides an improvement over more 
traditional approaches of sphingosine synthesis using serine-based strategies. The optical 
purity of final aromatic sphingosine analogues is dependent on that of the starting trans-γ, 
δ-unsaturated β-hydroxyesters. When starting with enantiopure γ, δ-unsaturated β-
hydroxyesters, excellent e.e. and d.e. (>99 e.e. and >99 d.e.) were obtained in the final 
analogues. Using the described synthetic approach, either enantiomer of erthyro aromatic 
sphingosine analogues could be obtained, with 32-41% overall yield.  
 
4.4. Final remarks 
Analogues of this nature may prove useful as novel and specific inhibitors, which can 
be used potential drug candidates.  
The novel synthetic approach described in this dissertation offers an opportunity to 
introduce variable substituents into sphingosine backbone, which to some extent will 
affect the ability of sphingosine analogues to act as agonists or antagonists. Further 
studies could focus on the convenient incorporation of a substituent, for example a 
methyl group, onto the C-2 position, which is in close proximity to the phosphorylation 
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site in the SP to S1P transformation. Incorporation of a substituent at the C-2 position is 
desirable because it may block phosphorylation and render the molecule as a competitive 
inhibitor. What is more, incorporation of structural variations into Carbon 1, 2, 4 and 5 
positions of sphingosine backbone can also be explored in the future.  
In the future, saturation transfer difference (STD) NMR can also be applied to study 
the interaction between aromatic sphingosine analogues and enzymes in sphingolipid 
metabolism pathway. This ligand based NMR method is applicable for screening 
aromatic sphingosine analogues and identifying the moieties for binding, which as a 
result will help us to improve the modification of sphingosine analogues based drug 
discovery process. 
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Appendix C 
 Atropisomers of Serotonin Dimer3 
C.1 Abstract 
This dissertation also describes a preparative scale synthesis of a dimer of serotonin (5-
HT). DHBT or 5,5’-dihydroxy-4,4’-bitryptamine is prepared in good yield using 
methanol in the presence of copper (II) chloride and air at room temperature. Exclusion 
of air resulted in no DHBT. Neither 5-HT hydrochloride nor N-BOC-protected 5-HT 
yielded DHBT under identical reaction conditions, evidence that the primary amino 
group of 5-HT plays a critical role in the dimerization reaction. Computational studies 
using the HF/6-31G** method reveal that DHBT exhibits highly restricted rotation about 
the 4, 4’-biaryl carbon-carbon bond, consistent with the existence of enantiomeric 
atropisomers of DHBT. The atropisomers can be resolved by chiral capillary 
electrophoresis. Atropisomerism needs to be considered as a source of chirality when 
evaluating possible neurodegenerative roles of DHBT in biological systems. 
Contributions: Sitara Chauhan contributed to the preliminary analysis of DHBT using 
capillary electrophoresis. Christopher Iceman contributed to Computational simulations 
of DHBT. 
 
3 Zhipeng Dai, Sitara Chauhan, Christopher Iceman and Thomas K. Green. (Manuscript in preparation) 
                                                          
238 
 
C.2. Introduction 
    5-Hydroxytryptamine (5-HT, serotonin, Figure C1a) occurs naturally in central and 
peripheral nervous system, where it plays a key role in regulation of body temperature, 
appetite, alcoholism, drug abuse, sleep and emotional states, as well as in cognition 
including memory and learning (Heath and Hen 1995, Lesch, Bengel et al. 1996, Walther, 
Peter et al. 2003, Sambeth, Riedel et al. 2009). Previous studies have indicated that 5-HT 
forms higher order structures in a faulty oxidative environment that could deplete 
serotonin levels and cause certain types of mental disorders including depression (Wrona 
and Dryhurst 1990), schizophrenia (Woolley and Shaw 1954) and Alzheimer’s disease 
(Wrona and Dryhurst 1998, Brownrigg, Theisen et al. 2011). Studies on 5-HT oxidation 
products have suggested that 5-HT dimer, 5,5’-dihydroxy-4,4’-bitryptamine (DHBT, 
Figure C1b) is potentially neurotoxic and contributes to neurodegenerative diseases 
(Eriksen, Martin et al. 1960, Wrona, Goyal et al. 1992, Huether, Fettkotter et al. 1997, 
Jones, Underwood et al. 2007). Following an early report by Eriksen’s group on a non-
enzymatic oxidation of 5-HT by using inorganic CuSO4 oxidant (Eriksen, Martin et al. 
1960), Wrona and Dryhurst proposed an electrochemical oxidative pathway of 5-HT to 
DHBT by coupling of phenoxy radicals (Wrona and Dryhurst 1987). They further 
reported that DHBT is the major nitrogen-centered radicals to induce the generation of  
C(4)-C(4’) and N(1)-C(4’) dimers in the course of this initial autoxidation product of 5-
HT at physiological pH and temperature (Wrona and Dryhurst 1990, Wrona, Goyal et al. 
1992). Jones and his colleagues studied the formation of DHBT induced by low 
concentration of Cu2+ ion (1 mmol/L). They showed that DHBT had only a minor toxic 
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effect on the neuronal cell model PC12, suggesting that reactive oxygen species are 
primarily responsible for the observed toxic effect (Jones, Underwood et al. 2007). 
Heuther et al. showed that 5-HT is oxidized to DHBT in the presence of peroxidase and 
hydrogen peroxide (Huether, Reimer et al. 1990). The major product was analytically 
isolated and analyzed by mass spectrometry.      
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Figure C1. a. Schematic of 5-hydroxytryptamine (Serotonin) showing numbering 
scheme used in this work; b. DHBT; c. Boc-protected 5-HT; d. 5-Hydroxyindole 
 
    Apart from the foregoing studies on the formation and neurotoxicity of DHBT, no 
further work has appeared on preparative scale synthesis of DHBT. We report here the 
convenient synthesis of DHBT using copper (II) chloride in methanol in the presence of 
air. We find that both air (molecular oxygen) and the primary amino function of 5-HT are 
essential for good yield. Consistent with computational results, DHBT is found to exhibit 
atropisomerism, a type of axial stereoisomerism which results from sterically hindered 
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rotation about a bond axis. The atropisomers can be separated by chiral capillary 
electrophoresis. 
 
C.3. Results and Discussion 
C.3.1. Synthesis and NMR studies of DHBT 
DHBT was obtained by the approach shown in Scheme C1. In situ 1H NMR 
spectroscopy studies were used to establish the optimum amount of copper (II) chloride 
and added base. A typical result is shown in Figure C2, where the 1H NMR spectra of 5-
HT prior to reaction without added Cu2+ (bottom), after reaction for 1 h (middle), and 
purified DHBT (top) in methanol-d4 are presented. The H-7 resonance intensity of 5-HT 
(d, 7.2 ppm) decreases as the H-7/H-7’ resonance (d, 7.4 ppm) of DHBT appears, the H-6 
resonance of 5-HT (dd, 6.7 ppm) decreases as the H-6/H-6’ resonance of DHBT appears 
(d, 6.9 ppm), and the upfield resonances H-1’ and H-2’ of 5-HT (t, 3.0 and t, 3.2 ppm) 
decrease with the appearance of a complex, broad multiplet in the region of 2.2 - 2.5 ppm. 
These results are similar to those reported by Jones et al. (Jones, Underwood et al. 2007)   
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Figure C2. 1H NMR spectra of 5-HT neutralized by 1.0 equivalent of NaOH then reacted 
with 1.25 equivalents of CuCl2·2H2O in methanol- d4 on a Varian 300 MHz NMR 
spectroscopy. Bottom spectrum: 5-HT; Middle spectrum: Reaction of 5-HT after 1 h. 
Top spectrum: purified DBHT. 
 
    No significant difference between 0.625 and 1.25 equivalents of Cu2+ on yield of 
DHBT was observed, but 1.8 and 2.5 equivalents resulted in significantly lower NMR 
yields. Thus preparative scale synthesis of DHBT was accomplished in the presence of 
1.25 molar equivalents of copper (II) chloride dihydrate in methanol, which provided the 
highest isolated yield. The respective DHBT dihydrochloride salt was readily purified by 
Sephadex LH-20 column chromatography (pH 2) in 45% yield. 
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a. 1.0 eqv. of NaOH
b. 1.25 eqv. of CuCl2·2H2O
r.m. 2.5 hours, open to the air
 
Scheme C1. Cu (II) induced oxidative coupling reaction of 5-HT. 
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    When addition of base was omitted, no DHBT was isolated.  Indeed, addition of one 
equivalent of base caused an immediate reaction to occur with formation of a black 
suspension, and led eventually to the color change of the reaction mixture to reddish. This 
finding led us to consider that the primary amino group was indispensable for the Cu2+-
induced oxidative formation of DHBT. To study this finding systematically, we varied 
the amount of base to neutralize 5-HT⋅HCl before adding copper (II) chloride dihydrate 
(Figure C3), and then measured the NMR yield after one hour. Addition of 1.0 and 1.5 
equivalent base gave similar NMR yields, but the highest isolated DHBT yield was 
obtained when 5-HT⋅HCl was neutralized with 1.0 equivalent of base. 
 
Figure C3. Effect of various amounts of base added on the conversion of 5-HT to DHBT 
after 1 hour of reaction time as monitored by 1H NMR spectroscopy. 
 
    To further investigate the influence of the primary amino function, BOC-protected 5-
HT (Figure C1c) and 5-hydroxyindole (Figure C1d), which lack the primary amino 
function, were evaluated under the same reaction conditions shown in Scheme C1. In situ 
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1H NMR spectroscopy in methanol-d4 did not reveal formation of dimer for either 
substrate, but rather the disappearance of some resonances was observed from an 
otherwise unchanging spectrum. The results are interpreted as hydrogen/deuterium 
exchange of H-4 of Boc-protected 5-HT (complete in 1.5 h) and both H-3 and H-4 of 5-
hydroxyindole (complete in <5 min and 1 h, respectively) in the presence of Cu2+ ion 
(Figure C4 and C5). Exchange did not take place in the absence of Cu2+ ion. These 
results indicate that, while aryl H-D exchange is promoted by Cu2+, the aminoethyl group 
(-CH2CH2NH2) is essential to the Cu2+-induced oxidative coupling of 5-HT under the 
conditions studied.   
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Figure C4. 1H NMR spectra of Boc-protected 5-HT in the presence of 1.25 equivalents 
of CuCl2·2H2O in methanol-d4 on a Varian 300 MHz NMR spectroscopy. 
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Figure C5. 1H NMR spectra of 5-Hydroxyindole in the presence of 1.25 equivalents of 
CuCl2·2H2O in methanol-d4 on a Varian 300 MHz NMR spectroscopy. 
 
    Copper-mediated or –catalyzed oxidative couplings have been extensively studied for 
the synthesis of biaryl compounds.  Cupric-amine complexes in particular have been 
studied as attractive oxidants for the coupling reaction, for instance the oxidative 
coupling of phenols (Feringa and Wynberg 1977) and naphthols (Feringa and Wynberg 
1978, Smrčina, Lorenc et al. 1991). In the oxidative coupling of 5-HT, the primary amino 
function is critical for achieving high yield of DHBT. The amino group may coordinate 
to Cu2+ to form Cu2+-5-HT complexes, which contributes to the black colored suspension 
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mentioned above, and facilitates the oxidative coupling of two 5-HT molecules within the 
coordination sphere of Cu2+.     
    In the presence of air, DHBT could be observed with in situ 1H NMR spectroscopy 
using either methanol-d4 or D2O as solvent. When the reaction was performed under 
anaerobic conditions, no DHBT formed.  Oxygen may serve to reoxidize Cu(I) to Cu(II), 
thus allowing for a catalytic cycle (Noji, Nakajima et al. 1994, Hassan, Sévignon et al. 
2002).    
 
C.3.2. Atropisomers of DHBT 
    Many biaryl compounds similar in structure to DHBT (Figure C1b) are known to 
exhibit atropisomerism. Atropisomerism is a type of stereoisomerism, which results from 
steric hindrance rotation along a bond axis (Christie and Kenner 1922, Oki 1983, 
Bringmann, Mortimer et al. 2005, Clayden, Moran et al. 2009). Often atropisomers can 
be thermally interconverted via an intramolecular dynamic process without bond 
breaking (LaPlante, Fader et al. 2011), depending on the activation energy for bond 
rotation. The rotational barrier is directly related to the half-time of the interconversion 
between atropisomers (Roussel, Vanthuyne et al. 2008). Atropisomers can be analytically 
isolated when the half-time of inter-conversion is at least 1000 s (Oki 1983). The 
computational rotational energy barrier serves as a guideline to determine whether 
atropisomers should be isolated as a racemic mixture or as a single compound. There is 
good agreement shown between computed and experimental determined rotational 
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barriers (Tobler, Lammerhofer et al. 2001, Clayden, Moran et al. 2009, LaPlante, 
Edwards et al. 2011).     
    Computational simulations of the DHBT transformation from one stereoisomer to the 
other are depicted in Figure C6. We find that the rotation of the molecule through the 
dihedral angle C4-C5-C5’-C4’ shown in Figure C7 is highly hindered with the smallest 
barrier to rotation of 350 kJ/mol occurring through interactions of the hydroxyl and ethyl 
amine groups of the 5-HT dimer, while an even larger barrier to rotation of >600 kJ/mol 
evolves through interactions of the two ethyl amine groups.  The two enantiomers are 
clearly thermally inaccessible to each other.   
 
Figure C6. Computational simulations of DHBT where the dihedral C4-C5-C5’-C4’ was 
restrained. Two separate calculations of DHBT were initiated in each isomeric form and a 
progression of dihedral angles (48 steps of 10 degrees) was explored using a relaxed 
potential energy surface (RPES) scan rotating between the two stereoisomers.    
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Figure C7. Atropisomers of DHBT attributed to slow rotation about 4-4’ carbon-carbon 
bond. 
 
    Thus, DHBT is predicted as a pair of enantiomeric atropisomers with chirality arising 
from hindered rotation about the biaryl C4-C4’ bond (Figure C7). Consistent with this 
prediction, the chiral separation of DHBT enantiomeric atropisomers was successfully 
acheived by capillary electrophoresis with sodium taurodeoxycholate (STDC) as chiral 
selector (Figure C8). After a systematic study, a buffer system composing of 80 mM 
STDC in 20.0 mM Tris at pH=8.0 was adopted to generate nearly baseline resolution for 
DHBT enantiomeric atropisomers. This technique could be used for monitoring 
conversion of 5-HT to DHBT during the course of the reaction.   
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Figure C8. Electropherogram for 5-HT and DHBT atropisomers. 50.0 μm i.d., bare fused 
silica capillary, 32.5 cm total length, 24.0 cm to detector; detection 214 nm; Injection: 
50.0 mBar/1s; BGE: 80 mM taurodeoxycholate in 20.0 mM Tris, pH=8.0; normal 
polarity, 10 kV. Sample was injected during the course of the reaction.  
 
 
    The NMR spectrum also supports the existence of atropisomers of DHBT. The four 
hydrogens of the ethylamino group are diastereotopic by virtue of the chiral axis and 
reveal distinct, baseline-resolved resonances in the 600 MHz 1H NMR spectrum as 
shown in Figure C9. Spin simulation of the spectrum yields the chemical shifts and 
couplings constants, J, for each resonance, as described in the Figure C9. The chemical 
shifts of the DHBT methylene resonances are significantly upfield shifted (2.15-2.60 ppm) 
compared to 5-HT methylene resonances (2.85 -3.00 ppm). The upfield shift is probably 
attributed to the positioning of the DHBT methylene hydrogens in the shielding cone of 
the adjacent aromatic ring system (see Figure C7). 
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Figure C6. 600 MHz 1H NMR spectrum of upfield region of 5, 5’-dihydroxy-4, 4’-
bitryptamine (DHBT) in D2O (lower spectrum) and simulated spectrum using chemical 
shifts (δ) and coupling constants (J).  The hydrogens are assigned to the –CH2CH2NH2 
group and are diastereotopic due to the chiral axis. Chemical shifts are 2.21 (H-a), 2.37 
(H-b), 2.50 (H-c) and 2.57 (H-d).   Coupling constants, J, in Hz are 2Jab= 14.8, 3Jac=6.8, 
3Jad=6.8, 3Jbc=7.8, 3Jbd=6.8, 2Jcd=12.8. H-a and H-b are geminal and H-c and H-d are 
geminal. 
 
C.4. Summary of atropisomers of DHBT 
    We have demonstrated a preparative procedure for DHBT in methanol induced by 
Cu2+ under oxygen. The coupling condition is simple and the work-up is straightforward.  
The primary amino function of 5-HT is essential for a good yield under the experimental 
conditions. We hypothesize that Cu2+ ion coordinates to a 5-HT through the amino 
function, and that coupling occurs in the coordination sphere of the metal. The existence 
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of atropisomers of DHBT was supported by 1H NMR spectroscopy. And DHBT 
atropisomers are also resolved using chiral capillary electrophoresis.   
 
C.5. Experimental  
C.5.1. Materials 
Sigma-Aldrich Chemical Company supplied all chemicals unless otherwise noted. 
Water was purified with a Millipore Milli-Q ultrapure water purification system with an 
18 MΏ-cm resistivity. 
 
C.5.2. NMR Spectroscopy  
    1H and 13C NMR spectra were recorded with a Varian 300 MHz and Bruker 600 MHz 
instrument. Chemical shifts are reported in ppm relative to TMS as internal standard. A 
typical in situ 1H NMR reaction is as follows; 4.5 mg (21.2 µmol, 1.0 eq.) of 5-HT·HCl 
was dissolved in 0.75 mL of methanol-d4 in an NMR tube and neutralized by various 
amount of NaOH solution (5M in H2O). The NMR tube was placed in the 300 MHz 
NMR spectrometer at 23 oC and the 1H NMR spectrum of 5-HT prior to the reaction was 
obtained. 4.5 mg (26.4 µmol, 1.25 eq.) of CuCl2·2H2O was then added into 5-HT solution 
in the NMR tube and the in situ 1H NMR spectra were recorded over time.    
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C.5.3. Chiral Capillary Electrophoresis  
Capillary electrophoresis was performed with an Agilent 3D Capillary Electrophoresis 
System using bare fused silica capillary (purchased from Polymicro Technologies, L.L.C.) 
(50 μm i.d., 32.5 cm total length, 24.0 cm to detector) under normal polarity (10 kV), and 
detection was by UV absorbance at 214 nm. Prior to first use, the capillary was primed 
for 2 min with 1 M NaOH solution and then for 2 min with 0.1 M NaOH solution. For 
each use, the capillary was preconditioned for 1 min using background electrolyte (BGE).  
BGE was 80 mM sodium taurodeoxycholate as chiral selector in 20 mM tris buffer. 
Samples (diluted 10 fold into 90:10 v/v milli-Q water/acetone solvent) were injected into 
the capillary under 50.0 mbar pressures for 3 seconds. At the end of each run, the 
capillary was post-conditioned with 0.1 M NaOH solution for 1 min and then with Milli-
Q water for 1 min.   
 
C.5.4. Synthesis and Purification  
C.5.4.1. 5,5’-dihydroxy-4, 4’-bitryptamine (DHBT)·2HCl  
    To a stirred solution of serotonin hydrochloride (60mg, 0.282 mmol) in 5.0 mL 
methanol at room temperature, a solution of 5.0 M NaOH (56.4 µL, 0.282 mmol) was 
added. After 5 min, CuCl2·2H2O (60 mg, 0.352 mmol) in 5.0 mL methanol was added 
dropwise, and the mixture was reacted for 2.5 hours at ambient temperature without 
stirring but with swirling every 15 min. The mixture was vacuum filtered, and the solvent 
was evaporated off under vacuum flow. Purification was accomplished by Sephadex LH-
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20 column chromatography (Column: 15 x 2.5 cm; mobile phase: H2O: methanol (9:1, 
v/v), pH = 2.0 adjusted by 1 M HCl) at a flow of 10 mL·h-1. The eluent was monitored 
with capillary electrophoresis at 214 nm using taurodeoxycholic acid as chiral selector. 
Eluent was removed by nitrogen flow to obtain a red solid. Isolated yield: 45mol %. 1H 
NMR (300 MHz, D2O) δ 7.50 (H-7, d, J = 9.0 Hz, 2H), 7.22 (H-2, s, 2H), 6.99 (H-6, d, J 
= 9.0 Hz, 2H), 2.00-2.65 (m, 8H). 13C NMR (75 MHz, D2O) δ 146.8, 131.8, 126.4, 126.1, 
112.6, 112.3, 111.7, 109.3, 39.6, 23.3. For mass spectral analysis, the product was 
recovered from D2O. HRMS (ESI): calcd for C20H22DN4O2+ (M-HCl-Cl)+ 352.1883 
found 352.1876, calcd for C20H21D2N4O2+ (M-HCl-Cl)+ 353.1945 found 353.1938. 
(Figure C10 and C11). 
 
Figure C7. 1H NMR spectrum of 5, 5’-dihydroxy-4, 4’-bitryptamine (DHBT) in D2O; 
D2O was depressed.  
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Figure C8. 13C NMR spectrum of 5, 5’-dihydroxy-4, 4’-bitryptamine (DHBT) in D2O. 
 
C.5.4.2. Boc-protected 5-HT 
    To magnetically stirred suspension of 5-HT⋅HCl (425 mg, 2.0 mmol) in 6.0 ml H2O 
and 2.0 ml THF, was added 1.0 equivalent of NaOH solution. Di-tert-butyl dicarbonate 
(480 mg, 2.2 mmol) was added at room temperature. After 6 h, the reaction mixture was 
concentrated under vacuum, and extracted by EtOAc (2 x 15 ml); the combined organic 
layers were dried over anhydrous Na2SO4 and removed by rotovaporization. Isolated 
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yield: 94%. 1H NMR (300 MHz, CDCl3) δ 8.20 (OH, br s, 1H), 7.13 (H-7, d, J = 9.0 Hz, 
1H), 6.98 (H-4, dd, J = 3.0 Hz, 1H), 6.88 (H-2, br s, 1H), 6.79 (H-6, dd, J = 9.0, 3.0 Hz, 
1H), 6.57 (N-H, br s, 1H), 4.76 (NH-COO, br s, 1H), 3.38 (CH2, t, J = 6.0 Hz, 2H), 2.79 
(CH2, t, J = 6.0, 2H), 1.43 (Me3, s, 9H); 13CNMR (75 MHz, CDCl3) 156.35, 149.76, 
131.48, 127.93, 123.16, 112.05, 111.99, 111.87, 103.22, 79.50, 40.65, 28.44, 25.76. 
(Figure C12 and C13) 
 
Figure C9. 1H NMR spectrum of Boc-protected 5-HT. 
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Figure C10. 13C NMR spectrum of Boc-protected 5-HT.  
 
C.6. Calculations 
We completed calculations on the DHBT using the Gaussian03 computational suite 
(Gaussian 03). Molecular geometries were optimized at the HF level of theory with the 3-
21g basis set.  Two separate calculations of DHBT were initiated in each isomeric form 
and a progression of dihedral angles (48 steps of 10 degrees) was explored using a 
relaxed potential energy surface (RPES) scan rotating between the two 
stereoisomers.  For the RPES scans the basis was increased to 6-31g(d,p) in order to 
better capture interactions between the polar amine and hydroxyl groups. 
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C.7. Conclusion on atropisomers of DHBT 
5-HT dimer, 5,5’-dihydroxy-4,4’-bitryptamine (DHBT), is potentially neurotoxic and 
contributes to neurodegenerative diseases. However, no further work has appeared on 
preparative scale synthesis of DHBT. This dissertation described a preparative scale 
synthesis of DHBT and studied the atropisomerism of DHBT, which is a type of 
stereoisomerism and results from sterically hindered rotation about a bond axis. The 
reaction was performed in methanol induced by Cu2+ under oxygen and monitored with 
1H NMR in Methol-d4 and D2O or capillary electrophoresis at 214 nm using 
taurodeoxycholic acid as chiral selector. After the reaction was completed, DHBT was 
purified by Sephadex LH-20 column chromatography and characterized by NMR and 
HRMS. The primary amino function of 5-HT is essential for good yield under the 
experimental conditions. A hypothesis is proposed in which Cu2+ ion coordinates to a 5-
HT through the amino function, and that coupling occurs in the coordination sphere of 
the metal. HRMS shows the hydrogen exchange between D2O and hydrogen of DHBT. 
Isolated DHBT atropisomers were also resolved using chiral capillary electrophoresis, 
which is consistent with 1H NMR spectrum and computational simulation.  
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